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Abstract       
  
   The   serotonin   (5-­‐‑HT)   transporter   (SERT)   and   the   kappa   opioid   receptor  
(KOPr)  are  important  brain  proteins.  Currently,  it  is  known  that  KOPr  modulates  5-­‐‑
HT   concentrations   but   the   biochemical  mechanisms   responsible   remain   enigmatic.  
The  5-­‐‑HT  and  KOPr  relationship  is  thought  to  involve  SERT  because  both  SERT  and  
KOPr  co-­‐‑localise  in  the  dorsal  raphe  nucleus  (DRN),  a  brain  region  involved  in  drug  
addiction,   affective   disorders,   and   stress   homeostasis.   Thus,   elucidating   the   KOPr  
and   SERT   relationship   will   clarify   biomedical   targets   for   these   disorders.   To  
investigate   this   relationship   the   effect   of   KOPr   activation   on   SERT   function   was  
examined   in  HEK-­‐‑293  cells  co-­‐‑expressing  myc-­‐‑rKOPr  and  eGFP-­‐‑tagged  hSERT.  We  
found  the  KOPr  agonists  U50,488H,  Salvinorin  A  (Sal  A)  and  DS-­‐‑3-­‐‑240  had  no  acute  
(5  min)  effect  on  SERT  function  as  measured  by  rotating  disc  electrode  voltammetry  
(RDEV)  incubated  with  1’-­‐‑diethyl-­‐‑2,2’-­‐‑cyanine  iodide  (D-­‐‑22;  1.5  mM)  and  by  confocal  
microscopy.   Interestingly,   SERT   function   significantly   decreased   with   chronic   (30  
min)  exposure  to  U50,488H  (**p<0.01)  and  Sal  A  (**p<0.01)  as  measured  with  a  novel  
high-­‐‑throughput  assay;   this  decrease  was  also  attenuated  with  5  min  pre-­‐‑treatment  
of   the   SERT   inhibitor,   fluoxitene   (***p<0.001).   Furthermore,   this   novel   high-­‐‑
throughput  assay  also  replicated  our  laboratories  recent  finding  that  chronic  (30  min)  
exposure  to  U50,488H  (**p<0.01)  and  Sal  A  (**p<0.01)  significantly  increase  dopamine  
transporter   (DAT)   function   in   HEK-­‐‑293   cells   co-­‐‑expressing   myc-­‐‑rKOPr   and   eYFP-­‐‑
tagged  DAT.  Collectively,   these   findings  suggest   in   this  cell  model   that  chronic   (30  














“If  the  brain  were  so  simple  that  we  could  understand  it,  we  would  be  so  simple  that  we  
couldn’t”    
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Chapter  1:  Introduction    
  
  
1.1     General  Introduction    
The   serotonin   (5-­‐‑HT)   transporter   (SERT)   and   the   kappa   opioid   receptor  
(KOPr)   are   proteins   involved   in   normal   brain   function   and   their   dysfunction  
contributes   to   the   etiology   of   brain   diseases.   Preclinical   evidence   suggests   the  
biochemical   effects   of   opioids   are   mediated,   at   least   in   part,   by   the   serotonergic  
system   (Filip   et   al.,   2004;   Tao   and   Auerbach,   2005;   Yoshioka   et   al.,   1993).   KOPr  
expresses  in  numberous  brain  regions  and  although  the  KOPr  and  5-­‐‑HT  relationship  
remains   largely   undefined   it   is   known   that   KOPr   activation   in   the   dorsal   raphe  
nucleus  (DRN)  or  nucleus  accumbens  (NAc;  ventral  striatum)  decreases  extracellular  
5-­‐‑HT   concentrations   in   the   respective   region   (Tao   and   Auerbach,   2002;   Tao   and  
Auerbach,   2005;   Tao   et   al.,   2007;   Werling   et   al.,   1989).   In   addition,   KOPr   can   also  
modulate   5-­‐‑HT   neurotransmission   in   the   hypothalamus,   hippocampus   and   dorsal  
striatum   (Str)   (Yilmaz   et   al.,   2006).  Recently,   Land   et   al.   (2009)   illustated   that  KOPr  
and  SERT  co-­‐‑localise  in  the  rat  DRN  and  therefore,  it  is  hypothesized  that  this  KOPr  
and   5-­‐‑HT   relationship   is   mediated   by   SERT.   The   DRN   is   a   brain   region   that  
contributes   to   the   etiology   of   drug   addiction,   affective   disorders,   and   stress  
homeostasis.  Therefore,  eludidating  this  enigmatic  KOPr  and  SERT  relationship  will  
clarify   biomedical   research   targets   to   contribute   overall   with   understanding   our  
neurobiology.    
  
Classical  KOPr   agonists   attenuate   psychostimulant   and   alcohol   drug-­‐‑taking  
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and  drug-­‐‑seeking  in  preclinical  models  of  addiction  and  is  thought  to  occurs  by  DA  
signalling   (Land  et   al.,   2009;  Morani,  2010;  2012;  Schenk  et   al.,   2000;  Zakarova  et   al.,  
2008).   Interestingly,   chronic   cocaine   increases   KOPr   density   when   the   dopamine  
transporter   (DAT)   is   inhibited   with   either   GBR   12909   or   RTI-­‐‑117   (Schenk   and  
Patridge,   2001),   which   suggests   KOPr   modulation   occurs   through   another   DA  
signalling   independent   mechanism   (Collin   et   al.,   2001;   2002).   Dual   activation   of  
KOPr,  other  than  DAT,  highlights  SERT  as  a  primary  candidate  to  modulate  KOPr.  
Co-­‐‑localisation  and  behavioural  studies   illustrate  and  suggest  that  KOPr  modulates  
SERT   in   vitro   (Morani,   unpublished;   Simonson,   unpublished   data)   and   in   vivo  
(Morani,   2010;   2012;   Zakarova   et   al.,   2008);   however,   the   nature   of   this   KOPr   and  
SERT   relationship   remains   unknown.   Collectively,   there   is   rational   to   suggest   a  
relationship  between  KOPr  and  SERT  exhists  and  characterisation  of  this  KOPr  and  
SERT  interaction  has  potential  to  elucidate  key  targets  for  future  biomedical  research,  
which  may  facilitate  the  development  of  more  effective  treatments.  
  
Previously,  acute  (15  min)  incubation  of  the  classic  KOPr  agonists,    (Trans-­‐‑(±)-­‐‑
3,4-­‐‑dichloro-­‐‑N-­‐‑methyl-­‐‑N-­‐‑(2-­‐‑[1-­‐‑pyrrolidinyl]-­‐‑cyclohexyl)   benzeneacetamide  
methanesulfonate   (U50,488H;   500   nM),   and   the   structurally   novel   KOPr   agonists,  
Salvinorin  A  (Sal  A;  500  nM)  and  DS-­‐‑1-­‐‑216  (500  nM),  decreases  SERT  function  in  rat  
striatal   tissue   as   measured   by   rotating   disc   electrode   voltammetry   (RDEV)  
(Simonson,   unpublished   data).   In   addition,   decreases   in   SERT   function   were   also  
observed  with  chronic  (30  min)  incubation  of  U50,488H  (10  µμM)  measured  with  4-­‐‑(4-­‐‑
(dimethylamino)-­‐‑styryl)-­‐‑N-­‐‑methylpyridinium   (ASP+)   uptake   assay   measured   by  
confocal   microscopy   (Morani,   unpublished   data).   In   this   study,   the   interaction  
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between  KOPr  and  SERT  function   is   investigated  by  activating  KOPr  with  agonists  
and  measuring  SERT  function.  This   is  elucidated   in  HEK-­‐‑293  cells  expressing  myc-­‐‑
rKOPr  and  eGFP-­‐‑tagged  SERT  with  acute  (5  min)  incubation  with  the  KOPr  agonists  
U50,488H,  Sal  A  and  DS-­‐‑3-­‐‑240  measured  by  confocal  microscopy  (10  µμM)    and  RDEV  
(500  nM),  as  well  as  chronic   incubation  (30  min)  with  the  KOPr  agonists  U50,488H,  
Sal  A  (10  µμM)  as  measured  by  a  novel  high-­‐‑throughput  assay.    
  
1.2     Serotonin    
   5-­‐‑HT   is   synthesised   from   tryptophan   into   5-­‐‑hydroxytryptophan   (5-­‐‑HTP)   by  
the  enzyme   tryptophan-­‐‑5-­‐‑hydroxylase   (Figure  1.1).   5-­‐‑HTP   is   then  converted   into  5-­‐‑
HT   by   the   enzyme   5-­‐‑hydroxytryptophan   decarboxylase   and   then   packaged   and  
stored   in   vesicles   within   the   presynaptic   serotonergic   neurons   to   prevent  
degradation   by   enzymes,   such   as   monoamine   oxidase   (MAO)   (Jorgensen,   2007;  
Nichols   and  Nichols,   2008).   5-­‐‑HT   is   released  when   an   action   potential   propagates  
along   the  presynaptic  neuron   in   the   form  of  an  electrical   impulse   to  depolarise   the  
nerve   terminal   to   produce   an   influx   of   Ca2+   that   fuses   5-­‐‑HT   vesicles   to   the   cell  
membrane  and  5-­‐‑HT   is   subsequently   released   into   the   synaptic   cleft.   5-­‐‑HT  diffuses  
across  the  synapse  to  continue  the  5-­‐‑HT  signal  by  binding  to  postsynaptic  receptors.  
These  receptors  trigger  second  messenger  molecules  that  activate  effector  molecules  
that  amplify  the  5-­‐‑HT  signal  (Hoffman  et  al.,  1998;  Nichols  and  Nichols,  2008).  After  
binding,   5-­‐‑HT   detatches   from   the   post-­‐‑synaptic   5-­‐‑HT   receptor   and   continues   to  
diffuse  within  the  synapse  where  it  can  either  bind  to  SERT,  MAO-­‐‑A  and  B,  or  glial  
cells  receptors.  SERT  terminates  the  signal  by  re-­‐‑transporting  the  5-­‐‑HT  molecule  back  
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into  the  presynaptic  cell   for  recycling  or  degradation,  MAO  A  and  B  degrade  5-­‐‑HT  
into   its  metabolite   5-­‐‑hydroxyindoleacetic   acid   and  glial   cell   receptors   can   also   take  
up  5-­‐‑HT  to  terminate  the  5-­‐‑HT  signal.  
  
     
Fig.  1.1.  5-­‐‑HT  synthesis.  Tryptophan  is  metabolised  to  5-­‐‑hydroxytryptophan  (5-­‐‑HTP)  by  
the  enzyme  tryptophan-­‐‑5-­‐‑hydroxylase  (also  known  as  L-­‐‑tryptophan-­‐‑5-­‐‑monooxygenase).  5-­‐‑
HTP  is  then  metabolised  to  5-­‐‑HT  by  the  enzyme  5-­‐‑hydroxytryptophan  decarboxylase.  
Serotonin  (5-­‐‑HT)  is  then  metabolised  by  monoamine  oxidase  A  and  B,  which  deaminates  5-­‐‑
HT  into  its  metabolite  5-­‐‑hydroxyindoleacetic  acid  (5-­‐‑HIAA).  (Diagram  modified  from  





5-­‐‑HT   is   synthesised   within   the   median   raphe   nuclei   and   DRN   of   the  
brainstem   in   the   midbrain   region.   The   lower   raphe   nuclei   axons   terminate   at   the  
cerebellum   and   spinal   cord,   and   higher   raphe   nuclei   axons   spread   throughout   the  
central   and   peripheral   nervous   systems.   Neurons   that   utilise   5-­‐‑HT   are   found  
throughout   the   brain   (Figure   1.2),   which   facilitates   5-­‐‑HT   to   interact   with   other  
neurotransmitter  systems  (Hoyer  et  al.,  2002).    
  
Fig.  1.2.  A  schematic  diagram  of  the  brain  with  DA  and  5-­‐‑HT  reward  pathways.  The  
dopaminergic  cell  bodies  originate  in  the  VTA  and  SNg  with  the  mesolimbic  pathway  projects  
from  the  VTA  to  the  NAc,  the  mesocortical  pathway  projects  from  the  VTA  to  the  PFC  and  
the   nigrostriatal   pathway   projects   from   the   SNg   to   the   Str.   The   serotonergic   cell   bodies  
originate  in  the  raphe  nuclei  and  innervate  the  VTA  to  feed  into  the  PFC,  NAc,  Str,  amygdala  
and   hippocampus.   5-­‐‑HT-­‐‑   serotonin,   DA-­‐‑   dopamine,   NAc-­‐‑   nucleus   accumbems   (ventral  
striatum),   PFC-­‐‑   prefrontal   cortex,   SNg-­‐‑   substantia   nigra,   Str-­‐‑   (dorsal)   striatum,   VTA-­‐‑  




Serotonergic  regulation  is  vital  to  maintain  brain  function  for  optimal  mental  
health  and  well-­‐‑being.  5-­‐‑HT  dysfunction   is  known  to  be  one  of   the  primary   factors  
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contributing   to   the   development   and   progression   of   neurological   abnormalities.  
Brain   disorders   such   as   major   depression   (Owens   and   Nemeroff,   1994),   anxiety  
(Suranyi-­‐‑Cadotte  et   al.,   1990),  bipolar  disorder      (Bellivier  et   al.,   1997;  Velayudhan  et  
al.,   1999),   suicide   (Arango   et   al.,   2002;   Purcelle,   2003),   impulsive   behaviour   (Lesch,  
2000;   Kreek   et   al.,   2005),   aggression   (Oquendo   et   al.,   2001),   obsessive   compulsive  
disorder   (Kalueff   and   LaPorte,   2010),   psychostimulant   addiction   (Baumann   and  
Rothman,  1998;  Heinz  et  al.,  2001),  stress  response,  appetite,  and  sleep  (Lotrich  et  al.,  
2004)   have   been   linked   to   5-­‐‑HT   dysfunction.   The   co-­‐‑morbidity   of   these   disorders  
highlights   5-­‐‑HT   as   a   superior   candidate   to   investigate   further   to   understand   the  
biological   basis   of   drug   addiction,   affective   disorders   and   stress   homeostasis.   In  
particluar,   SERT   is   known   to   contribute   significantly   to   these   disorders   because   it  
plays   a   crutial   role   in   5-­‐‑HT   reuptake,   synthesis,   and   release.   This   makes   SERT   a  
prime  candidate  when  investigating  5-­‐‑HT  synergy.  
  
1.2.1     Serotonin  Signalling  
5-­‐‑HT  molecules   bind   to   the   5-­‐‑HT   receptors   and   5-­‐‑HT   autoreceptors   on   the  
postsynaptic   and   presynaptic   neuronal   membrane,   respectively.   Currently,   seven  
types  of  5-­‐‑HT  receptors  with  at  least  15  different  subtypes  have  been  identified  and  
cloned  and  they  are  known  as  5-­‐‑HT1A,  5-­‐‑HT1B,  5-­‐‑HT1D,  5-­‐‑HT1E,  5-­‐‑HT1F,  5-­‐‑HT2A,  
5-­‐‑HT2B,   5-­‐‑HT2C,   5-­‐‑HT3A,   5-­‐‑HT3B,   5-­‐‑HT4,   5-­‐‑HT5A,   5-­‐‑HT5B,   5-­‐‑HT6   and   5-­‐‑HT7  
(Jorgensen,  2007;  Nichols  and  Nichols,  2008).    
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All   5-­‐‑HT   receptors   are   G-­‐‑protein   coupled   receptors   (GPCRs),   with   the  
exception   of   5-­‐‑HT3A   and   3B,   which   are   ionotropic   and   found   within   the  
gastrointestinal   track   and   link   into   the   enteric   nervous   system   (Hoyer   et   al.,   2002;  
Jones   et   al.,   2010;   O'ʹshea   et   al.,   1998).   GPCR’s   are   the   largest   family   of   signaling  
receptors  and  become  activated  by  a  vast  array  of  extracellular   ligands.  GPCRs  are  
seven-­‐‑pass   transmembrane   receptor   proteins   with   a   slower,   longer-­‐‑lasting   and  
diverse  mode  of  action  to  allow  specific  control  of  numerous  intracellular  signalling  
pathways  (Krupnick  and  Benovic,  1998).  5-­‐‑HT  receptors  couple  to  different  types  of  
G-­‐‑proteins.   These   G-­‐‑proteins   dissociate   from   the   GPCR   and   relay   the   signal   to  
second   messenger   molecules   that   interact   with   effector   molecules   to   amplify   and  
thus,   stimulate   downstream   biochemical   signal   transduction   pathways   in   the  
cytoplasm   of   the   cell   (Marinissen   and   Gutkind,   2001).   Specifically,   activation   of  
stimulatory   G-­‐‑proteins   (Gs)   leads   to   the   stimulation   and   activation   of   an   enzyme  
called  adenylate  cyclase  (AC)  which  converts  adenosine  triphosphate  (ATP)  into  the  
intracellular   second   messenger,   cyclic   adenosine   monophosphate   (cAMP).   cAMP  
subsequently   interacts   with   important   target   effector   signaling   proteins,   such   as  
Protein   Kinase   A   (PKA).   Gs-­‐‑protein   effector   molecules   regulate   Ca2+   influx   and  
membrane  excitability  and  PKA  phosphorylates  specific  target  proteins  that  increase  
gene   expression   (Nichols   and   Nichols,   2008).   Activation   of   5-­‐‑HT   receptors   also  
couples   to   inhibitory   G-­‐‑proteins   (Gi)   to   inhibit   and   decrease   AC   concentrations,  
which  then  reduces  cAMP  levels  and  thus,  decreases  PKA  activity  and  downstream  
gene   expression.   Activation   of   Gi   produces   membrane   hyper-­‐‑polarisation   that  
decreases   the   rate   of   neuronal   firing   but   activation   of   Gs   proteins   can   also   cleave  
8	  	  
membrane   phosphoinositides   to   form   of   diacylglycerol   (DAG)   and   inositol  
phosphates,   such   as   inositol   triphosphate   (IP3)   (Nichols   and   Nichols,   2008).   IP3  
stimulates   intracellular   Ca2+   membrane   channels   to   additionally   increase   second  
messengers,   effector  molecules   and   thus,   intracellular   signal   transduction   (Nichols  
and  Nichols,  2008).    
  
5-­‐‑HT  homeostasis  requires  an  intricate  balance  between  receptor  activation  of  
Gs   and   Gi.   Disruption   to   this   system   alters   second  messenger   concentrations   that  
affects  the  activation  of  effector  molecules  by  phosphorylation,  such  as  PKC,  cGMP,  
p38MAPK   and   PKA,   which   are   all   involved   in   SERT   modulation   (for   a  
comprehensive  review  see  Ramamoorthy,  Shippenberg  and  Jayanthi,  2011).    
  
1.2.2     5-­‐‑HT  in  Reward  
5-­‐‑HT   is   involved   in   mood   and   sleep   but   also   plays   an   important   role   in  
reward.  Natural  reward   is  a  neuroadaptation   to  ensure  survival  by  reinforcing  and  
motivating   behaviours   such   as   eating,   sleeping   and   sexual   reproduction   (Gawin,  
1991;   Koob   et   al.,   1998).   Reward,   reinforcement,   and   motivation   all   produce  
subjective   feelings   of   pleasure   and  wellbeing.  DA  predominantly   regulates   reward  
through   three  main  DA   pathways   (Figure   1.2).   The  DA   pathways   originate   in   the  
brain  stem  in  two  main  regions,  the  ventral  tegmental  area  (VTA)  and  the  substantia  
nigra   (SNg).   The   mesolimbic   pathway   projects   from   the   VTA   to   the   nucleus  
accumbens  (NAc;  ventral  striatum),  the  mesocortical  pathway  projects  from  the  VTA  
to  the  prefrontal  cortex  (PFC)  and  the  nigrostriatal  pathway  projects  from  the  SNg  to  
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the  Str  (Robinson  and  Berridge,  2000).  Each  of  these  brain  regions  plays  a  unique  role  
in   reward,   reinforcement   and   motivation.   The   NAc   is   the   reward   centre   because  
preclinical   and   clinical   studies   illustrate   DA   release   here   during   motivational  
behaviour   (Koob  and  Volkow,  2010;  Robinson  and  Berridge,  2000).   Interestingly,   in  
the   NAc   the   mesolimbic   system   significantly   modulates   structural   and   functional  
gamma-­‐‑aminobutyric  acid  (GABA)  medium  spiny  neurons  (see  fig  1.4;  Diana,  2011).  
The   PFC   is   the  motivation   relay   station   and   is   responsible   for   executive   functions  
such   as   consequence   of   actions,   goal   setting   and   predicting   outcomes   (Koob   and  
Volkow,   2010;   Robinson   and   Berridge,   2000).   The   Str   is   involved   in  motor   control  
and  creating  response  to  behaviours  as  a  way  of   learning  (Koob  and  Volkow,  2010;  
Robinson  and  Berridge,  2000)  and  thus,  plays  a  vital  role  in  reinforcement  (Everitt  et  
al.,   2008).   Collectively,   these   DA   pathways   control   the   regulation   of   reward,  
reinforcement,  attention,  motivation,  mood  and  emotions  (Kuhar,  2010).  
  
The  DA  reward  pathways  also  synergistically  interacts  and  overlaps  with  the  
serotonergic   system.  5-­‐‑HT  synthesis  and  release  occurs   in  5-­‐‑HT  cell  bodies   that  are  
found  within   the   raphe   nuclei   cluster   of   neurons   in   the   brain   stem.   5-­‐‑HT   neurons  
project  from  the  DRN  and  medial  raphe  nuclei  to  innervate  the  VTA  and  terminate  at  
the  PFC,  NAc,  Str,  amygdala  and  hippocampus.  These  projections  play  an  important  
role  in  reward,  reinforcement,  attention,  motivation,  mood,  emotions,  perception  and  




1.3     Serotonin  Transporter  
   SERT   is   an   essential   protein   for   brain   development,   neural   plasticity,  
synaptogenesis,   cell   proliferation,   drug   addiction,   emotional   disorders,   and  
dysfunctional  stress  response  (Kalueff  and  LaPorte,  2010).  Numberous  documents  of  
SERT   expression   in   psychopathology   cases   indicate   the   importance   of   SERT  
expression   in   brain   dysfunction   but   also   in   maintaining   normal   brain   function  
(Murphy   et   al.,   2004).   The  primary   function   of   SERT   is   to  mediate   the   recycling   of  
synaptic  5-­‐‑HT  to  effectively  terminate  and  regulate  overall  5-­‐‑HT  neurotransmission.  
Where  5-­‐‑HT  neurotransmission  is  mediated  by  more  than  15  different  types  of  cell-­‐‑
surface   receptors   (Glennon   &   Dukat,   1995)   it   seems   that   one   single   gene  
(Ramamoorthy  et  al.,  1993)  encoding  for  SERT  appears  to  be  responsible  for  majority  
of  the  extracellular  5-­‐‑HT  clearance  (Blakely  et  al.,  1991;  Hoffman  et  al.,  1991;  Lesch  et  
al.,  1993).  
  
1.3.1     SERT  Gene  
The   human   SERT   gene   is   located   on   chromosome   17q11.2   and   consists   of  
378,000   base   pairs   spanning   13   exons   (Ramamoorthy   et   al.,   1993).   SERT   exists   in  
homo-­‐‑multimeric  complexes  and  contains  potential  phosphorylation  sites  for  several  
kinases   (Ramamoorthy   et   al.,   1993;   Schmid   et   al.,   2001).   SERT   belongs   to   the   SLC6  
gene   family   that   also   includes  DAT,   the   norepinephrine   transporter   (NET),  GABA  
and  glycine  transporters.  However,  the  growing  body  of  SERT  literature  emphasises  
the  need  for  more  cellular  and  molecular  preclinical  models  to  fully  understand  the  
mechanisms   and   emphasise   the   clinical   importance   of   SERT   (Kalueff   and   LaPorte,  
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2010).  SERT  animal  research  utilises  knockout  models,  gene  regulation  and  silencing  
models,   as  well   as   epigenetic   regulation   (Molteni   et   al.,   2010).   But   there   remains   a  
paucity   of   cell   models   that   investigate   SERT   function   and   expression   and   SERT’s  
relationship  with  other  neurotransmitter  systems  (Kalueff  and  LaPorte,  2010).  Since  
the   SERT   gene  was   identified  many   polymorphisms   have   been   discovered   as  well  
their   corresponding   neurobiological   and   behavioural   effects.   SERT   polymorphisms  
are  associated  with  a  wide  range  of  diseases  and  disorders  such  as,  attention  deficit  
hyperactivity  disorder  (ADHD)  (Faraone  et  al.,  1998),  major  depression  (Owens  and  
Nemeroff,  1994),  anxiety   (Suranyi-­‐‑Cadotte  et  al.,  1990),  bipolar  disorder   (Bellivier  et  
al.,   1997;   Velayudhan   et   al.,   1999),   suicide   (Arango   et   al.,   2002;   Purcelle,   2003),  
impulsive   behaviour   (Lesch,   2000;   Kreek   et   al.,   2005),   aggression   (Oquendo   et   al.,  
2001),   obsessive   compulsive   disorder   (Kalueff   and  LaPorte,   2010),   psychostimulant  
addiction   (Baumann   and   Rothman,   1998;   Heinz   et   al.,   2001)   and   substance   abuse  
(Gainetdinov  and  Caron,  2003).    
  
   In  particular,  the  SERT  linked  promoter  region  (5-­‐‑HTTLPR)  has  been  
implicated   as   a   potential   risk   factor   for   many   pathophysiological   diseases   and  
disorders  but  majority  of   the  previous  studies   remain  considerably  under  powered  
(Murphy  et  al.,  2013).  The  5-­‐‑HTTLPR  is  a  degenerate  repeat  polymorphic  region  on  
the   SLC6A4   gene.   This   genetic   mutation   is   the   most   thoroughly   researched  
polymorphism   in   the   SERT   literature   with   well   over   300   psychiatric,  
pharmacogenetic,  genetics  and  medical  papers  by  2006   (Wendland   et   al.,   2006)  and  
over  100  neuroscience  genetics  reports  published  in  the  first  part  of  2012  (Murphy  et  
al.,   2013).  Many   of   these   reports   suggest   5-­‐‑HTTLPR   to   have   two  main   alleles,   the  
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‘short’  (“S”)  and  ‘long’  (“L”)  (Murphy  et  al.,  2013;  Wendland  et  al.,  2006).  These  two  
variants  have  been  suggested  to  result  in  different  SERT  mRNA  transcription  levels;  
specifically,   the   “S”   variant   is   suggested   to   reduce   basal   transcription   levels   to  
decrease   SERT   mRNA   levels   (Lesch   et   al.,   1996).   A   decrease   in   SERT   levels   also  
corresponds  to  a  reported  decrease  in  response  to  SERT  acting  compounds,  such  as  
selective   5-­‐‑HT   reuptake   inhibitors  or   also  known  as   SSRIs   (Purselle   and  Nemeroff,  
2003).  SSRIs  are  commonly  used  as  anti-­‐‑depressants,  and  pharmacotherapies,  such  as  
fluoxetine   (Prozac
TM
),   citalopram   (Celexa
TM
),   paroxetine   (Paxil
TM
)   and   sertraline  
(Zoloft
TM
).  SSRIs  act  as  SERT  antagonists,  or  blockers,  by  inhibiting  SERT  function  to  
prevent   5-­‐‑HT   re-­‐‑uptake,   which   increases   the   5-­‐‑HT   synaptic   concentration.  
Accordingly,   SSRIs   were  more   sensitive   to   “L”   variants   because   these   individuals  
have   more   SERT   avaliable   to   inhibit   (Purselle   and   Nemeroff,   2003).   However,  
Purselle  and  Nemeroff’s  (2003)  experimental  analysis  was  conducted  in  post  mortem  
brain   tissue   (and   platelets)   of   suicide   victims   and   50%   of   the   previous   studies  
investigating  SERT  binding   in  postmortem  studies  did  not   identify   the   same  SERT  
binding  and  SERT  genotype  correlation.    
  
The  classification  of  only  two  alleles  does  raise  serious  research  methodology  
issues  because   less   than  half   (44%)  of   the  100  neuroscience  genetics   reports   in  2012  
investigating  this  promoter  polymorphism  5-­‐‑HTTLPR  (simple  long  “L”  versus  short  
“S”  allele  classifications)  neglect  to  include  other  5-­‐‑HTTLPR  variants  and  related  that  
have   been   shown   to   alter   the   functional   effects   of   these   so   called   “L”   versus   “S”  
variants   (Murphy  et  al.,  2013).  Thus,   interpretation  of  5-­‐‑HTTLPR  studies,  and  SERT  
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single  nucleotide  polymorphisms  must  be  interpreted  with  extreme  caution,  and  all  
limitations   should   be   stated.   Despite   discrepancies   in   SERT   polymorphisms   and  
behaviour  in  the  literature,  stringent  methodology  must  be  performed  to  reduce  bias,  
chance  and  confounding   in  order   to   reveal   a   true   correlation   (Murphy   et   al.,   2013).  
Nevertheless,   it   is   accepted   that   SERT   is   important   in   behavior,   so   SERT   genetic  
polymorphisms   must   continue   to   be   researched   so   the   subsequent   biological   and  
behavioural   effects   can   fully   recognised.   Perhaps   Purselle   and   Nemeroff’s   (2003)  
omission  of  two  nearby  polymorphisms,  rs25531  and  rs25532  that  substantially  alter  
5-­‐‑HTTLPR   allele   frequencies   and   functionality   or   not   reporting   ethnicity   of   the  
subjects   genotyped   produced   bias,   chance   and   confounding   (Murphy   et   al.,   2013)  
that   would   account   for   these   discrepancies.   Until   a   well-­‐‑conducted   double   blind  
randomized   control   trial   is   carried   out   the   definitive   answer   to   this   contradicting  
literature  remains  the  topic  of  speculation.    
  
Interestingly,  other  scientific  disciplines  are  contributing  to   the   idea   that   the  
5-­‐‑HTTLPR    “L”  vs.  “S”  alelles  account  for  different  behaviours.  For  example,  social  
sciences  are  investigating  the  5-­‐‑HTTLPR  allele  frequency  across  populations  because  
the  genetic  differences  vary  considerably  and  have  been  hypothesized  to  account  for  
cultural  differences.  Social  sciences  are  attempting  to  correlate  their  genetic  findings  
with   the   cultural   patterns   to   explain   differences   between   cultures.   Social   sciences  
illustrate   a   higher   frequency   of   the   “L”   allele   is   found   in   Europe  whereas   a   lower  
frequency  of  “L”  is  found  in  Asia  (Eisenberg  and  Hayes,  2011).  However,  substantial  
oversights  and  omissions   since  2006  are  continuing   to  be  published   (Murphy   et   al.,  
2013),   and   thus,   research   into   5-­‐‑HTTLPR   polymorphism   genotypes   and   related  
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behaviours   should  be   interpreted  with  great   caution,   especially  when   correlating   a  
few  single  nucleotide  polymorphisms  to  population  wide  behaviours.    
  
1.3.2     SERT  Protein    
   The   SERT   protein   contains   630   amino   acid   residues   and  
hydrophobicity   analysis   suggests   the   presence   of   12   hydrophobic   transmembrane  
domains   with   cytoplasmic   NH2   and   COOH   termini   (Ramamoorthy   et   al.,   2011).    
Transmembranes   three   and   four   are   separated   by   a   large,   hydrophilic   loop   that  
contains   two   canonical   sites   for   N-­‐‑linked   glycosylation   (Lesch   et   al.,   1993;  
Ramamoorthy  et  al.,  1993).  SERT  is  found  in  the  peri  and  extrasynaptic  regions  of  the  
presynaptic   serotonergic   neurons   and   it   regulates   synaptic   5-­‐‑HT   concentrations  
through  reuptake  into  the  presynaptic  neuron  that  feedbacks  the  information  to  the  
5-­‐‑HT   system,   which   modulates   overall   5-­‐‑HT   synthesis   and   release   (Blakely   et   al.,  
1994;  Rudnick,  2006;  Zahniser  and  Doolen,  2001).  SERT  belongs  to  the  SLC6  sodium  
(Na+)  ion  and  chloride  (Cl-­‐‑)  dependent  plasma  membrane  transporters  family.  These  
transporters   exploit   the   Na+   gradient   across   the   neuron   membrane   to   drive  
secondary  active  transport  of   the  neurotransmitter  from  the  synaptic  cleft  back  into  
the  presynaptic  compartment.  This  is  the  most  rapid  and  economical  way  to  remove  
and   recycle   synaptic   neurotransmitters   (Murphy   et   al.,   2004;   Sitte   and   Freissmuth,  
2010).  SERT  requires  one  Na+  ion,  one  Cl-­‐‑  ion  and  one  5-­‐‑HT  molecule  to  facilitate  5-­‐‑
HT  transport  across  SERT  (for  a  review  see  Torres  et  al.,  2003).  Upon  5-­‐‑HT  binding,  
SERT   undergoes   conformational   changes   to   form   an   external   barrier   that   allows  
SERT  to  open  the  5-­‐‑HT  active  site  into  the  cytoplasmic  space  so  5-­‐‑HT  can  detach  and  
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be   recycled.   The   subsequent   absence   of   5-­‐‑HT,   as   well   as   Na+   and   Cl-­‐‑,   reconforms  
SERT  back  into  the  original  synaptic  cleft  facing  position  (for  a  review  see  Murphy  et  
al.,  2004).    
  
SERT   is   a   phosphoprotein  with   a  multitude   of   presynaptic   receptor-­‐‑second  
messenger-­‐‑kinase   and   phosphatase   linked   pathway   networks.   These   networks  
regulate   SERT   to   alter   the   protein   conformation   and   dynamically   control   the  
transporter   expression,   activity,   trafficking   and   degradation   (Kalueff   and   LaPorte,  
2010;  Muller  et  al.,  2007;  Rammamoorthy  et  al.,  2011;  Torres  et  al.,  2003).  Kinase  and  
phosphatase  pathways  play  a  pivotal  role  in  the  regulation  of  SERT  activity  as  they  
are  either  constitutively  operational  or  activated  by  extracellular  signals  (Holley  et  al.,  
2013;  Ramamoorthy  et  al.,  2011).    
  
SERT   function   rapidly   decreases   in   response   to   acute   depletion   of  
intracellular   Ca2+,   inhibition   of   calmodulin,   Ca
2+
  /calmodulin-­‐‑dependent   protein  
kinases   II   (CaMKII),   Src-­‐‑kinase,   p38-­‐‑Mitogen   activated  protein   kinase   (p38  MAPK)  
and  activation  of  PKC   (Ramamoorthy   et   al.,   2011).  Additionally,  data   also   suggests  
that   cytokines   can  affect  SERT  activity   through  p38  MAPK-­‐‑dependent  mechanisms  
in  some  cell   lines  and  mice  neurons  (Zhu  et  al.,  2006).  Conversely,  SERT  function  is  
increased  by  an  increase  in  intracellular  Ca2+  as  well  as  activation  of  NOS/cGMP  and  
MAPK   pathways   (PKA).   However,   the   three   major   protein   kinases   that   are  
responsible   for   SERT’s   phosphorylation   state   and   SERT  membrane   expression   are  
PKC   (Qian   et   al.,   1997)   and  p38  MAPK   (Samuvel   et   al.,  2005)  which  decrease  SERT  
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function,  and  PKA  (Ramamoorthy  et  al.,  1997)  which  increases  SERT  function.    
  
SERT  function  is  regulated  by  trafficking  between  the  plasma  membrane  and  
intracellular   compartments   through   a   series   of   post-­‐‑translational   modifications,  
however,   the  exact   functional  mechanisms  and  specific   residues  responsible   for   the  
regulation   of   SERT   is   not   completely   understood   (Rammamoorthy   et   al.,   2011)  
Thoroughly   understanding   the   pathways   involved   in   modulating   SERT   function,  
particularly   decreasing,   allow   us   to   better   understand   the   role   of   transporter  
phosphorylation  and  thus,  the  regulation  of  5-­‐‑HT  neurotransmission  (Ramamoorthy  
et  al.,  2011).    
    
1.3.3     ASP+  Uptake  as  a  SERT  Uptake  Identification  Technique  
  
ASP+   is   a   fluorescent   analogue   of   the   neurotoxic   substrate   1-­‐‑methyl-­‐‑4-­‐‑
phenylpyridinium  (MPP+)   (Schwartz  et  al.,  2003).  ASP+  has  previously  been  used  as  
an   identification   tool   to   visualise   and   quantify   monoamine   transporter   function  
(Schwartz   et   al.,   2003).   Visualising   the  monoamine   transporter   function   is   possible  
because   ASP+   fluoresces   a   bright   red   colour   when   it   contacts   the   cell   membrane  
phospholipids   that   are   present   in   the   integral   transporter   protein.   ASP+‘s   red  
fluorescence   provides   a   timely   illustration   of   monoamine   transporter   binding,  
uptake   and   accumulation   within   live   cultured   cells   using   confocal   microscopy  
(Schwartz  et  al.,  2003).  This  advanced  technique  is  unique  and  the  first  of  its  kind  that  
allows   temporal   and  visual   identification   between  monoamine   transporter   binding  
and  uptake.  This   technique  was   initially   established  with  NET  using   cultured   cells  
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expressing  eGFP-­‐‑hNET  and  it  was  subsequently  demonstrated  that  ASP+  uptake  by  
NET   is   Na+,   Cl-­‐‑,   cocaine,   and   temperature   dependent   (Schwartz   et   al.,   2003).   ASP+  
uptake  has  further  been  performed  in  cultured  neurons  and  in  cells  transfected  with  
DAT  (Bolan  et  al.,  2007;  Oz  et  al.,  2010;  Zapata  et  al.,  2007)  to  determine  function  and  
regulation,  and  more  recently  with  SERT  (Schwartz  et  al.,  2003).  SERT  uptake  is  now  
known  to  be  sensitive  to  changes  in  Na+,  Cl-­‐‑,  temperature,  cocaine,  fluoxitene  and  is  
dependent  upon  p38  MAPK  activation  (Oz  et  al.,  2010).  Interestingly,  the  low  affinity  
transporter   organic   cation   transporter   3   (OCT3)   also   uptakes   ASP+   (Mayer   et   al.,  
2012).  However,   there   remains   a   paucity   of   avaliable   literature   on   the   low   affinity  
transporters   and   the   uptake   of   ASP+,   especially   compared   with   the   uptake   of   the  
monoamine  transporters.    
  
1.3.4     SERT  in  Drug  Addiction  
Drug   addiction   is   characterised   as   a   chronic   and   relapsing   disease   with  
reduced  pleasure  from  natural  rewards  along  with  the  compulsive  drug-­‐‑seeking  and  
drug  taking  behaviour  despite  severe  health,  social  and  economic  implications  (Cami  
and  Farre,  2003;  Jaffe,  1990;  Kalivas  et  al.,  2005;  Kelley,  2004;  Koob  and  Le  Moal,  2001;  
Nestler,   1992;   Wise,   1996).   Genetic   polymorphism   on   5-­‐‑HT   genes   (transpoter,  
receptors   or   autoreceptors)   can   create   dysfunction   within   the   5-­‐‑HT   system.   It   is  
hypothesised  by  Kalueff  and  LaPorte  (2010)  that  individuals  with  an  abnormal  5-­‐‑HT  
system   also   have   an   abnormal   reward   system,   and   with   the   appropriate  
environmental   conditions   this   can   results   in   a   predisposition   to   drug-­‐‑taking   and  
drug-­‐‑seeking   behaviours.   Specifically,   SERT   genetic   variations   are   suggested   to  
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contribute  to  individual  differences  in  response  to  drugs  of  abuse  (Ramamoorthy  et  
al.,   1993).   For   example,   the   association   between   SERT   genetic   polymorphism  
variation   have   shown   a   predisposition   for   alcoholism   (Feinn   et   al.,   2005),   cigarette  
smoking   (Kremer   et   al.,   2005),   psychostimulant   (Carroll   et   al.,   1990a;   Carroll   et   al.,  
1990b)   and   heroin   (Gerra   et   al.,   2004)   dependence.   This   is   particularly   interesting  
because  DA  is  largely  been  believed  to  be  responsible  for  drug  addiction  but  recent  
research   suggests   the   involvement   of   SERT.   Suddenly,   the   synergy   of   the   major  
neurobiological   systems   becomes   very   interesting   and   more   fasinating   than  
previously  thought.  
  
Classically,   the   transition   from   drug   use   to   abuse   is   explained   by   the  
“dopamine   hypothesis”   (Prisinzano,   2005)   and   thus,   DA   has   been   the   subject   of  
research   for   pharmacological   targets   of   addiction.   However,   recent   research  
illustrates  the  5-­‐‑HT  system  to  be  heavily  involved  in  reward  and  related  phenotypes  
(Kalueff   and   LaPorte,   2010),   which   highlights   SSRI   use   as   a   prime  
pharmacotharapeutic   treatment   for   drug   addiction.   Cocaine   self   administration   is  
decreased   with   the   pre-­‐‑treatment   of   a   SSRI   (Carroll   et   al.,   1990b)   or   by   a   low   L-­‐‑
tryptophan   (the  precursor  of  5-­‐‑HT)  diet   (Carroll  et  al.,  1990a).  Additionally,  alcohol  
addiction   treatment   with   SSRIs   is   common   because   of   the   established   association  
between  alcoholism  and  affective  (mood)  disorders  (Smith,  2012).  Thus,  the  role  of  5-­‐‑
HT  in  reward,  affective  disorders,  dysfunctional  stress  responses  and  the  prescribing  
of  SSRIs  for  alcohol  dependence,  highlights  the  role  of  SERT  in  drug  addiction.    
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The  DA  and  5-­‐‑HT  neurotransmitter  systems  synergistically  exist  in  the  brain  
and   it   is   commonly   believed   that   they   interact   together   in   the   CNS.  Although   the  
specific  mechanisms  remain  to  be  elucidated,  it  is  known  that  DA  levels  are  directly  
modulated  by  5-­‐‑HT   through   specific   5-­‐‑HT   receptors   (5-­‐‑HT1A,   2A  and  2C)   that   are  
localised   on   DA   neuronal   cells   (Barnes   and   Sharp,   1999;   Bubar   and   Cunningham,  
2006;  Higgins  and  Fletcher,  2003;  Hoyer  et  al.,  2002).  Also,  DA  can  act  indirectly  on  5-­‐‑
HT   through   GABA-­‐‑mediated   inhibitory   (Eberle-­‐‑Wang   et   al.,   1998;   Stanford   and  
Lacey,  1996),  or  glutamate-­‐‑mediated  excitatory  mechanisms  (Di  Matteo  et  al.,  2008).  
In  addition,  the  5-­‐‑HT:DA  ratio  plays  a  crucial  role  in  determining  the  abuse  liability  
of  psychostimulants  (Baumann  et  al.,  2011;  Negus  et  al.,  2007;  Wee  et  al.,  2005).  Table  
1.1   compares   DA,   5-­‐‑HT   and   some   psychostimulants   to   highlight   the   ability   of  
different  molecules   triggering   both  monoamine   systems.   The   lasting   physiological  
reduction   of   DA   and   5-­‐‑HT   after   drug   dependence   has   lead   to   the   hypothesis   that  
restoring   monoamine   acitvity   to   pre-­‐‑drug   levels   may   yield   significant   clinical  
improvements   in   treatment   (Diana,   2011).   Thus,   5-­‐‑HT   regulates   DA   and   KOPr  
pathways  and  other  systems,  so  perhaps  a  5-­‐‑HT  dysfunction  is  enough  to  create  an  
overall   imbalance.   If   this   is   true,   as   suggested   by   the   current   literature,   then   SERT  
function  is  particularly  relevant  in  drug  addiction  (Ramamoorthy  et  al.,  2011).  
  
Drugs  of  abuse  act,  directly  or  indirectly,  to  increase  synaptic  DA  levels  that  
lead   to   the   increase  activation  of  DA  receptors   (Koob  and  Volkow,  2010;  Missale  et  
al.,   1998).  This  modulation  of  DA   is  hypothesised   to  be  predominantly   involved   in  
addiction   (Prisinzano,   2005).   Pharmacological   agents,   along   with   genetic  
manipulation,      facilitates   researchers   to  modulate   DA   receptors   to  motivate   drug-­‐‑  
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taking   and   drug-­‐‑seeking   in   animal   models.   These   methods   add   to   the   current  
knowledge   of  motivation   and   reward   (Nestler,   2005).  Recent   studies   illustrate   that  
DA   neurons   in   alcohol,   opiate,   cannabinoid,   and   other   drug-­‐‑dependent   rats   have  
reduced  electrophysiological  activity,  particularly  in  the  NAc  (Diana,  2011).  Human  
human   imaging   studies   of   cocaine,   heroin,   and   alcohol-­‐‑dependent   subjects   show  
reduced  DA  receptors  and  a  decrease  in  the  release  of  endogenous  DA  into  the  NAc  
(Diana,   2011).   This   offers   proof   that   the   brain   is   “DA-­‐‑impoverished”   in   not   just  
animal   models   after   chronic   drug   abuse   too   (Diana,   2011).   Collectively,   these  
findings  illustrate  that  drug  exposure  deeply  affects  DA  neurotransmission  to  reduce  
natural   reinforcement,   reward   and   motivation,   which   decreases   the   pleasurable  
effects  of  drugs  and  also  effects  other  biochemical  systems.    
  
Table  1.1.  The  effects  of  monoamines  and  psychostimulants  on  the  serotonin  (5-­‐‑HT)  


















Dopamine   >10,000   6489   86.9   38.3  
Serotonin   44.4   16.7   >10,000   2703  
                        
(+)amphetamine   1765   3830   24.78   34  
(+)methamphetamine   736   2137   24.5   114  
Cocaine   >10,000   304   >10,000   478  
(±)MDMA   56.6   238   376   1572  
Modified  from  Rothman  and  Baumann,  2003.  
  
  DAT   is   an   integral   membrane   protein   that   transports   DA   back   into   the  
presynaptic  DA  neurons.  DAT  expressed  in  high  concentrations  in  the  Str  and  NAc  
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where  it  has  been  shown  to  be  involved  in  reward  (Boja  and  Kuhar,  1989).  Drugs  of  
abuse,  such  as  cocaine,  can  target  DAT,  which  prevents  DA  re-­‐‑uptake  and  causes  an  
increase   in   synaptic   DA,   that   increases   synaptic   DA   to   amplify   the   DA   receptor  
signalling  (Mash  et  al.,  2002).  Amphetamine  acts  as  a  DAT  agonist,   is   taken  up  into  
the   presynaptic   neuron,   and   also   reverses   DAT   function   to   release   DA   into   the  
synapse  (Kahlig  et  al.,  2005).    
     
KOPr  agonists  are  known  to  attenuate  drug-­‐‑seeking  behaviour  in  preclinical  
and  clinical  models  of  psychostimulant  addiction  and    may  hold  the  key  to  designing  
better   therapeutic  compounds   to   treat  addiction.  Classical  KOPr  agonism  decreases  
cocaine  conditioned  place  preference  (Shippenberg  and  Rea,  1997;  Zhang  et  al.,  2004),  
locomotor   activity   (Heidbreder   et   al.,   1993;   Zhang   et   al.,   2004),   and   attenuates   the  
reinstatement   of   extinguished  drug-­‐‑taking  behaviour   and  behavioural   sensitization  
(Schenk   et   al.,   1999,   2000,   2001).   This   is   because  KOPr   increases  DAT   function   and  
thus,   decreases   DA   neurotransmission   (Collins   et   al.,   2001   ;   Shippenberg,   2007;  
Simonson,  unpublished  data;  Svignos  et  al.,  2001;  Thompson  et  al.,  2000;  Zhang  et  al.,  
2004).  For  example,   the  KOPr  agonists,  dynorphin  A  and  R-­‐‑84760,  blocked  cocaine-­‐‑
induced  increases  in  striatal  DA  levels  (Zhang  et  al.,  2004).  Repeated  treatment  with  
the   traditional   KOPr   agonist   U69,593   alters   D2   receptor   density   (Izenwasser   et   al.,  
1999)  and  function,   (Acri  et  al.,  2001)  as  well  as  attenuating  the   locomotor  effects  of  
cocaine   in   rats   (Heidbreder   et   al.,   1998).   The   oral   administration   of   cyclazocine,   a  
mixed   KOPr   agonist   and   mu   opioid   antagonist,   reduced   self-­‐‑administration   of  
cocaine  in  rats  (Glick  et  al.,  1998).  Drugs  activating  the  KOPr  have  also  been  shown  to  
reduce   compulsive   drug   seeking   to   alcohol   and   opiates   (Shippenberg   et   al.,   2001;    
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Chefer  et  al.,  2000;  Thompson  et  al.,  2000;  Mitchell  et  al.,  2005)  and  prevent  alterations  
in  brain   function   that  occur   as   a   consequence  of   repeated  drug  use   (Chavkin   et   al.,  
2004;  Chefer  et  al.,  2005;  Mitchell  et  al.,  2005).  Collectively,  these  findings  indicate  the  
KOPr   opioid   receptor   /   dynorphin   system   is   critically   involved   in   mediating   the  
acute   and   chronic   effects   of   psychostimulants,   and   thus   offers   a   novel  
pharmacological  approach  to  treating  drug  abuse.  
      
Previous  studies  have  trialed  the  classical  KOPr  agonists,  such  as  U50,448H  
and  (5α,  7α,  8β)-­‐‑(+)-­‐‑N-­‐‑methyl-­‐‑N-­‐‑(7-­‐‑(1-­‐‑pyrrolidinly)-­‐‑1-­‐‑oxaspiro(4,5)dec-­‐‑8-­‐‑
yl)benzeneacetamide  (U69,593),  on  cocaine  abusing  humans  and  these  agonists  had  
little  effect  on  drug-­‐‑taking  behaviour  and  side  effects,  such  as  sedation,  depression  
and  dysphoria,  limit  their  therapeutic  use  (Preston  et  al.,  2004;  Walsh  et  al.,  2001).  
Reasons  for  the  low  success  in  humans  are  likely  to  be  the  related  to  the  low  doses  
given  in  the  studies,  and  that  the  KOPr  agonists  selected  did  not  have  high  enough  
affinities  for  the  KOPr.  The  low  affinity  of  classical  KOPr  agonists  for  KOPr  receptors  
has  support  from  preclinical  studies.  Therefore,  KOPr  agonism  has  the  potential  to  
attenuate  drug-­‐‑taking  in  humans  but  the  classical  KOPr  agonists  do  not  show  
promise  as  pharmacotherapies.    
  
In   preclinical   models   the   classical   KOPr   agonists,   such   as   U50,448H   and  
U69,593,   along  with   structural   derivatives,   Sal   A   and  DS-­‐‑3-­‐‑240,   had   anti-­‐‑addictive  
effects   in   rats   self-­‐‑administering   cocaine   (Morani,   2011).   This   study   highlights   that  
structurally   derived   KOPr   agonist   compounds   may   have   clinical  
pharmacotherapeutic   potential,   however   they   just   require   additional   research   into  
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concentration   and   frequency   of   dose.   For   example,   although   traditional   KOPr  
agonists   may   not   be   ideal   for   pharmacotherapies   because   of   side   effects,   novel  
compounds   that   have   reduce   side   effects   may   provide   an   understanding   into   the  
mechanisms   by   which   KOPr   agonists   activley   exhert   their   anti-­‐‑addiction   effects.  
Investigating   these   anti-­‐‑addiction   effects   is   important   for   us   to   understand   the  
mechanisms   of   how   drugs   of   abuse   up-­‐‑regulate   the   KOPr/dynorphin   system,   and  
how   this   effects   the   additional   biochemical   systems   that   are   also   involved   in  
addiction,   reward   and   motivation.   However,   it   is   likely   that   an   increase   of   KOPr  
densities   after   cocaine   exposure   is   not   related   just   to   DAT   inhibition   because  
selective  DAT  inhibitors  do  not  increase  KOPr’s  (Collins  et  al.,  2002).  Thus,  this  KOPr  
agonist  increase  after  drug  exposure  is  thought  to  occur  through  a  DA  independent  
manner   (Collins   et   al.,   2001;   Collins   et   al.,   2002).   Evidence   suggests   this   DA  
independent  KOPr  up-­‐‑regulation   is   likely   to  be  modulated  by  SERT,  either  directly  
or   indirectly,   as   shown   by   in   vitro   (Morani,   unpublished;   Simonson,   unpublished  
data)   and   in   vivo   research   (Morani,   2010;   2012;   Schenk   et   al.,   2000;   Zakarova   et   al.,  
2008).    
  
1.3.5     SERT  in  Affective  Disorders  
Human  studies  illustrate  that  reducing  5-­‐‑HT  transporter  (SERT)  increases  the  
vulnerability  for  the  most  common  mood  disorders,  anxiety  and  depression  (Amat  et  
al.,  2005;  Olivier  et  al.,  2008).  Interestingly,  the  serotonin  transporter  linked  promotor  
region   (5-­‐‑HTTLPR)   variations   have   been   associated   with   changes   in   the   brain  
structures   associated   with   executive   functioning   and   emotional   conditioning.   For  
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example,   a   study  by  Pezawas   et   al.   (2005)   found   less  grey  matter   in   the  perigenual  
anterior   cingulated   cortex   and   the   amygdala   for   the   ‘S’   variant   of   the   5-­‐‑HT   linked  
promotor  gene  region  compared  to  the  ‘L’  variant  of  the  5-­‐‑HT  linked  promotor  gene  
region  variants.  However,  genetic  polymorphisms  must  be  interpreted  with  caution  
as   a   2008   meta-­‐‑analysis   found   no   significant   overall   association   between   the   5-­‐‑
HTTLPR   polymorphisms   and   reduced   grey   matter   volume   in   autistic   individuals  
(Huang  and  Santangelo,  2008).  Nevertheless,  a  landmark  study  by  Caspi  et  al.  (2003)  
hypothesised   the  gene   and   environment   interaction  between   the   ‘S’   allele   of   the   5-­‐‑
HTTLPR   and   stressful   life   events   and   major   depression   (Caspi   et   al.,   2003;  
Nierenberg,   2009;   Uher   and  McGuffin,   2008).   Unfortunatly,   methodological   errors  
highlight   a   flaw   in   the   research   and   a   proposed   interaction   remains   to   be  
conclusively  confirmed  (Risch  et  al.,  2009).  These  5-­‐‑HTTLPR  inconsistencies  remains  
a  caveat  of  SERT  research.  For  example,  14  different  allelic  variations  were  found  in  a  
population  of  200  Japanese  and  Caucasian  subjects  and  they  found  no  correlation  to  
emotional   dysfunction   (Nakamura   et   al.,   2000),   highlighting   that   a   gene   and  
environment   interaction   between   the   5-­‐‑HTTLPR   variant,   stressful   life   events   and  
major   depression   may   be   a   case   of   correlation   misinterpreted   as   causation.  
Nevertheless,   the   collective   of   literature   agrees   that   5-­‐‑HT   and   SERT   are   both  
involved   in   mood   disorders   (Nestler   et   al.,   2002)   but   the   involvement   of   the   5-­‐‑





1.3.6     SERT  in  Stress     
Stress  is  a  complex  experience  with  both  aversive  and  motivating  properties  
(Bruchas  et  al.,  2010).  Continuous  exposure  to  stressful  experiences  (chronic  stress)  is  
well  known  to   increase  the  relapse  of  drug  abuse  and  drug-­‐‑seeking  behaviour,   it   is  
also  well  known  to  induce  despair  and  thus,  escalate  the  risk  of  mood  disorders  such  
as   depression,   and   stress   can   also   adversely   impact   health   (Bruchas   at   al.,   2010).  
Specifically,  early  and/or  late  life  adversity  (chronic  stress)  is  suggested  to  exaggerate  
vulnerabilities   in   individuals  with   a   predisposition   to   these   specific   brain   diseases  
and  disorders   (Adamec   et   al.,   2006;   Bethea   et   al.,   2005;  Caspi   et   al.,   2003;   Lee   et   al.,  
2005).   For   example,   preclinical   studies   investigating   early   life   stress   in   the   form   of  
decreased  maternal  licking  and  grooming  in  rat  pups  and  experimenter  manipulated  
stress  by  pups  and  dam  separation  noticed  increases  the  likelihood  of  alcohol  abuse  
later  in  life  (Kuhar,  2006;  2008;  Moffett  et  al.,  2006).  In  addition,  late  life  adversity  in  
primates   in   the   form   of   a   social   hierarchical   dominance   also   increases   drug   self  
administration   (Kreek   et   al.,   2007).   Life   stress   also   reinstates   human   drug   addicts  
(Hyman  et  al.,  2006;  Koob  and  Volkow,  2010)  although  the  correlation  between  stress  
and   drug   addiction   remains   to   be   fully   elucidated   by   clinical   studies   (Land   et   al.,  
2010).  There  is  a  growing  body  of  evidence  demonstrating  that  stress  is  linked  with  
mood   (Calabrese   et   al.,   2009;   Duman   and   Monteggia,   2006)   For   example,   stress  
decreases   the   expression   of   brain-­‐‑derived   neurotrophic   factor   (BDNF)   in   limbic  
structures   that   control  mood  and   that  antidepressant   treatment   (SSRI’s)   reverses  or  
blocks  the  effects  of  stress  (Calabrese  et  al.,  2009;  Duman  and  Monteggia,  2006).  This  
indicates   a   relationship   between   stress   and   mood,   as   well   as   stress   and   SERT.  
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Furthermore,  Tjurmina  et  al.  (2004)  indicate  that  a  lifelong  SERT  deficiency  results  in  
complex  alterations   in  adrenomedullary  response  to  stress.   In  a   landmark  study  by  
Caspi  et  al.  (2003)  a  relationship  between  SERT  reuptake,  stress  and  depression  was  
proposed.  They  suggest  that  life  stressors  and  certain  5-­‐‑HTTLPR  genetic  variants  can  
predispose   individuals   to  depression   (Caspi  et  al.,  2003).  This   finding  has  also  been  
replicated   in   other   studies   (Karg	   et   al.,   2011;   Kendler   et   al.,   2005)   but   remains  
controversial   (Risch   et   al.,   2009).  Nevertheless,   the   correlation   between   a   gene   and  
environment  interaction  between  SERT,  stressful  life  events,  and  brain  diseases  and  
disorders   remains   inconclusive.   Bruchas   et   al.   (2007)   and   Land   et   al.   (2008)  
demonstrate   that   stress   (cortisol)   and   cortocotrophin   releasing   factor   (CRF)   cause  
KOPr  activation   in   several  key  brain   structures  associated  with   stress,   reward,   and  
pathologies  such  as  addiction  and  depression.  However,  the  process  by  which  KOPr  
acts  in  these  structures  to  modulate  affect  is  a  critical  question  (Bruchas  and  Chavkin,  
2010).  KOPr  action  in  the  mesolimbic  DA  circuit  is  well  characterized,  however  other  
monoamines   and   neuropeptide   systems   are   also   likely   to   be   involved   in   KOPr-­‐‑
mediated  behaviors.   Because  both   the  kappa-­‐‑opioid  system,  and  thus  KOPr’s,  and  
SERT  are  both   implicated   in  drug  addiction,  mood  disorders  and  stress   response  a  
relationship  appears  appropriate.  A  relationship  between  these   two  proteins   (KOPr  
and   SERT)   would   strengthen   the   argument   that   dysfunctional   SERT   or   KOPr  
proteins   are   both   involved   in   the   predisposition   of   these   diseases   and   disorders  




1.4     The  κ-­‐‑opioid  Receptor  
   KOPr   is   a   pertussis   toxin   (PTX)   sensitive,   (Avidor-­‐‑Reiss   et   al.,   1995)   7-­‐‑
transmembrane  GPCR  that  exerts  its  effects  on  the  CNS  and  intestines  (Eguchi,  2004).  
Specifically,  within  the  brain  KOPr’s  are  found  in  high  concentration  in  the  NAc,  Str,  
PFC,  amygdala,  caudate  putamen,  endoperiform  nucleus  and  in  claustrum  and  low  
levels   found   in   the   VTA   and   SNg   (Mansour   et   al.,   1995;   Quirion   et   al.,   1987).  
Presently,   only   one   KOPr   receptor   type   (KOPr-­‐‑1)   has   been   cloned,   although  
pharmacological  data  suggest  the  existence  of  three  KOPr  receptor  subtypes  (KOPr-­‐‑
1,   KOPr-­‐‑2,   KOPr-­‐‑3)   (Horan   et   al.,   1993;   Heyliger   et   al.,   1999);   yet,   a   clear  
demonstration  of  KOPr  heterogeneity  remains  to  be  fully  elucidated.  
  
   A  substantial  proportion  of  the  literature  that  investigates  the  opioid  receptor  
and  5-­‐‑HT  concentration  relationship  was  dedicated  to  the  mu-­‐‑opioid  receptor  (Tao  et  
al.,   2005).   Currently,   few   studies   have   investigated   the   relationship   between  KOPr  
and   5-­‐‑HT   (Yilmaz   et   al.,   2006)   with   even   fewer   into   KOPr   and   SERT.   This   is  
interesting  because  KOPr  activation  in  the  DRN  or  NAc  decreases  extracellular  5-­‐‑HT  
concentrations  in  the  respective  region  (Tao  and  Auerbach,  2002;  Tao  and  Auerbach,  
2005;  Tao  et  al.,  2007;  Werling  et  al.,  1989).  In  addition,  KOPr  modulates  serotonergic  
neurotransmission  in  the  hypothalamus,  hippocampus  and  striatum  (Yilmaz,  2006).  
Thus,   to   date   it   is   believed   that   mu-­‐‑Opioids   disinhibit   and   kappa-­‐‑opioids   inhibit  
serotonin  efflux  in  the  DRN  (Yilmaz,  2006).  
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KOPr   activation  by   the   endogenous   ligand  dynorphin,   PTX   or   by   synthetic  
agonists,  such  as  U50,488H  and  U69,593,  leads  to  a  conformational  change  of  the  G-­‐‑
protein   coupled   receptor   heterotimer   that   comprises   of   Gαi,   Gβ   and   Gγ   subunits  
(Connor   and   Christie,   1999).   This   activates   the   intracellular   Gαi   protein   trimer   to  
replace  GDP  with  GTP,  dissociating   the  Gαi-­‐‑GTP   subunit   (Eguchi,   2004).  The  Gαi-­‐‑
GTP  subunit  subsequently  inhibits  the  enzyme  adenylate  cyclase  (AC),  which  leads    
to  a  decrease  in  cyclic  adenosine  monophoshate  (cAMP)  and  subsequently  a  decrease  
in  protein  kinase  A  (PKA)  phosphorylation  activity  (Avidor-­‐‑Reiss  et  al.,  1995;  Watts  
and  Neve,   2005).  Meanwhile,  Gβγ   binds   directly   to   the   potassium   (Kir3.1)   channel,  
increasing   the   efflux   of   potassium,   and   binding   to   the   N,   L   and   P/Q   type   Ca2+  
channels  to  decrease  the  influx  of  calcium  via  these  voltage  gated  channels  (Rusin  et  
al.,  1997).  This  leads  to  hyperpolarisation  of  the  KOPr  neuron,  maintaining  its  resting  
state  potential  and  decreasing  neuronal  excitability   (Figure  1.3)   (Avidor-­‐‑Reiss  et  al.,  
1995;   Bruchas   and   Chavkin,   2010;  Watts   and  Neve,   2005).   Activation   of   KOPr   can  
trigger   any   one   of   the   three   main   mitogen   activated   protein   kinase   (MAPK)   cell  
signalling   pathways:   the   c-­‐‑Jun   N-­‐‑terminal   kinase   (JNK),   p38   MAPK   and  
extracellular-­‐‑signalled   regulated   kinase   1/2   (ERK1/2)   (for   a   review   see   Bruchas   &  
Chavkin,  2010).    
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Fig.  1.3.  KOPr  signal  transduction  after  acute  and  chronic  activation.  The  binding  of  a  
KOPr   ligand   leads   to   a   conformational   change   in   the  Gαβγ   subunits   of   the   receptor  which  
allows   the   dissociation   of  αi   and   βγ   subunits.   The  Gαi   protein   trimer   replaces  GDP  with  
GTP  that  then  dissiciates  as  a  Gαi-­‐‑GTP  subunit.  The  Gαi-­‐‑GTP  subunit  inhibits  AC  leading  
to  a  decrease  in  cAMP,  and  therefore  a  decrease  in  PKA  activity.  The  Gαi-­‐‑GTP  subunit  also  
activates   ERK1/2   through   a   PI3K,   PKC   and   Ca2+   dependent   signaling.   The   Gβγ   subunit  
increases   the   efflux   of   potassium,   and   decreases   the   influx   of   calcium  via   the   voltage   gated  
channels,   causing   hyperpolarisation,   thus   decreasing   neuronal   excitability.   Long-­‐‑term  
activation   of   KOPr   leads   to   receptor   phosphorylation   and   kinase   activation   via   GRK3-­‐‑
Arrestin   dependent   mechanism.   AC-­‐‑adenylyl   cyclise;   cAMP-­‐‑   cyclic   adenosine  
monophosphate;   Ca2+-­‐‑   calcium   ion;   ERK1/2-­‐‑   extracellular   signal-­‐‑regulated   kinase;  Gαi   -­‐‑  G  
protein  alpha   subunit;  Gβγ-­‐‑  G  protein  beta-­‐‑gamma  subunit;  GDP-­‐‑  Guanosine  diphosphate;  
GRK3-­‐‑   G-­‐‑protein   coupled   receptor   kinase   3;   GTP-­‐‑   Guanosine   triphosphate;   K+-­‐‑   potassium  
ion;   KOPr-­‐‑   kappa   opioid   receptor;   Kir3-­‐‑   G-­‐‑protein   gated   inward   rectifying   K+   channel;   P-­‐‑  
phosphorylation;  p38  –  p38  mitogen  activated  protein  kinase;  PI3K-­‐‑  phosphatidylinositol-­‐‑3-­‐‑
kinase;  PKA-­‐‑  protein  kinase  A;  PKC-­‐‑  protein  kinase  C;  Src-­‐‑  Src  kinase;   zif268-­‐‑  zinc   finger  
protein.  (Adapted  from  (Bruchas  and  Chavkin,  2010).  
  
1.4.1   Dynorphin  
   The  endogenous  KOPr  ligand,  dynorphin,  is  synthesised  from  pro-­‐‑dynorphin  
by  the  enzyme  proprotein  convertase  2  (Marinova  et  al.,  2005).  Pro-­‐‑dynorphin  can  be  
cleaved   into   several   types   of   active   dynorphin:   big   dynorphin,   dynorphin  A,   B   or  
α/β-­‐‑neo-­‐‑   dynorphin   (Merg   et   al.,   2006).   Dynorphin   A   is   the  most   active   form   and  
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preferentially  activates  KOPr,  followed  by  mu  opioid  receptor  and  then  delta  opioid  
receptor   (Chavkin   et   al.,   1982;   Merg   et   al.,   2006).   Dynorphin   has   been   found  
throughout  the  brain  with  particularly  high  levels  being  detected  in  the  rat  forebrain,  
hypothalamus   and   SNg,   and   in   low   levels   in   the   Str,   NAc,   amygdala   and  
hippocampus  (Goldstein  and  Ghazarossian,  1980;  Weber  et  al.,  1982).  
  
A   large  body  of  evidence   in  animal  models   indicates   that  KOPr’s   (and  their  
endogenous  opioid  peptide   ligands)  modulate  the  effects  of  central  nervous  system  
stimulants   (Shippenberg   et   al.,   2001).   For,   example,   administration   of   cocaine   or  
methamphetamine   upregulates   the   kappa   opioid      receptor   and   preprodynorphin  
mRNA  levels  (Tzaferis  and  McGinty,  2001;  Collins  et  al.,  2002).  Dynorphin  and  KOPr  
are   located   in   the   nigrostriatal   and   mesolimbic-­‐‑mesocortical   DA   pathways,   brain  
regions   involved   in   reward,   reinforcement   and   motivation   (Shippenberg   et   al.,  
2007b).   Thus,   it   was   suggested   that   this   KOPr/dynorphin   system   may   play   an  
important  role  in  modulating  reward  to  both  natural  reinforcers  and  drugs  of  abuse  
(Wee   and   Koob,   2010).   KOPr/dynorphin   system   up-­‐‑regulation   after   chronic   drug  
exposure  can  lead  to  withdrawal  symptoms,  stress  induced  aversion,  stress-­‐‑induced  
relapse,  drug  craving  and  drug-­‐‑seeking  (Shippenberg,  2007).    In  addition,  activation  
by   KOPr   agonists   can   lead   to   a   multitude   of   effects,   including   hypersensitive  
analgesia,   immunomodulation,   hypothermia,   anxiety,   dysphoria,   anhedonia   and  
water  diuresis  (Butelman  et  al.,  2012;  Liu-­‐‑Chen,  2004;  Shippenberg  et  al.,  2007b).  On  
the  other  hand,  inhibition  by  KOPr  antagonists  can  lead  to  anti-­‐‑depressant  and  anti-­‐‑
anxiety  behaviours  (Carlezon  et  al.,  2009).    
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1.4.2     Dynorphin  and  KOPr  Negative  Feedback  Loop  
   KOPr  activation  directly  inhibits  DA  neurons  in  the  midbrain  (Margolis  et  al.,  
2003),   which   modulates   DA   uptake   in   the   NAc   (Thompson   et   al.,   2000).   In   other  
words,   the   KOPr/dynorphin   system   acts   to   modulate   DA   VTA   output   through   a  
negative   feedback   loop   (Van   Bockstaele   and   Pickel,   1995).   This   occurs   because   the  
medium  spiny  GABA  neurons  in  the  NAc  receive  a  DA  input  from  the  DA  neurons  
in   the   VTA   (Figure   1.4).   Once   DA   reaches   these   stimulatory   DA1   receptors   AC  
activity  is  increased,  which  increases  cAMP  and  thus,  activates  CREB  resulting  in  the  
release  of  pro-­‐‑dynorphin  and  then  dynorphin  (Nestler,  2001).  Dynorphin  is  released  
from  the  NAc  and  binds  to  KOPr  receptors  in  the  VTA  acting  to  decrease  the  overall  
DA  tone  and  thus,   the  hedonic  properties.  This  activation  of  KOPr   is  known  as   the  
anti-­‐‑reward   system   and   thus,   KOPr   agonists   are   the   subject   of   anti-­‐‑addiction  
pharmacotherapies.   Overlap   of   the   endogenous   opioid   systems   with   monoamine  
systems   in   the   brain   suggest   that   other   overlapping   systems   may   also   interact  





Fig.  1.4.  KOPr/dynorphin  negative  feedback  loop.  This  negative  feedback  pathway  acts  to  
modulate  DA  release  into  the  NAc.  Briefly,  the  NAc  GABA  medium  spiny  neurons  receive  
the  DA  input  through  the  DA1  receptor.  This  stimulates  AC,  which  increases  cAMP  and  
thus  PKA,  activating  CREB  which  results  in  the  release  of  prodynorpin  then  dynorphin.  
Dynorphin  is  then  released  from  the  GABA  medium  spiny  neurons  in  the  NAc  to  bind  to  
KOPr  on  the  DA  VTA  neurons  to  decrease  DA  increase  and  thus,  hedonic  properties.  NAc-­‐‑  
nucleus  accumbens;  GABA  -­‐‑  gamma  amino  butyric  acid  medium  spiny  neuron;  VTA  -­‐‑  
ventral  tegmental  area;  CREB  -­‐‑  cAMP  response  element  binding  protein;  DA-­‐‑  dopamine;  
D1-­‐‑  DA  1  receptor;  Gs-­‐‑  Stimulatory  G-­‐‑protein  coupled  receptors;  KOPr-­‐‑  kappa  opioid  
receptor.  (Adapted  from  Carlezon  et  al.,  2005)  
  
1.4.3     KOPr  and  DA  
  It  has  been  known  and  documented  for  at  nearly  25  years  that  KOPr  has  an  
inhibitory   effect   on   DA   neurons   in   the   rat   brain   (Di   Chiara   and   Imperato,   1988;  
Werling  et  al.,  1988).  These  groundbreaking  studies   illustrates   for   the   first   time  that  
KOPr   agonists   decrease   DA   concentrations   in   the   NAc   and   dorsal   caudate   brain  
regions  of  rats,  as  well  as  observing  decreased  motor  activity  (Kunihara  et  al.,  1993).  
Since   these   landmark   studies   it   has   been   further   confirmed   that   KOPr   activation  
inhibits   previously   stimulated   DA   neurons   in   the   nigrostriatal,   mesolimbic,  
tuberunfundibular   and   tuberohypophysial   systems   (Manzanares   et   al.,   1991)   and  
33	  	  
several  doses  of  KOPr  activation  with  U50,488H  decreased   this  effect,   suggesting  a  
receptor  desensitisation  with  overstimulation  (Schlosser  et  al.,  1995).  This   inhibitory  
DA   effect   induced   by   KOPr   agonists   can   also   be   reversed   with   KOPr   antagonists  
(Manzanares  et  al.,  1991).  Co-­‐‑localisation    of  KOPr’s  and  DAT  was  first  found  in  the  
NAc   (Svingos   et   al.,   2001)   and   KOPr   agonists   were   then   found   to   modulate   DA  
function   through   an   increase   of   DAT   function   (in   the  NAc)   (Morani,   unpublished  
data;   Simonson,   unpublished   data;   Thompson   et   al.,   2000;   Zhang   et   al.,   2004).  
However,  when  the  biochemical  mechanism  behind  this  KOPr  activation  to  increase  
DAT  function  was  investigated  it  was  found  that  DAT  inhibitors  did  not  prevent  the  
NAc  DA   increase   from  baseline.   This   provided   evidence   to   suggest   the   rewarding  
effects   of   opiates   and   their   receptors   may   also   be   occuring   through   a   DA-­‐‑
independent   mechanism.   Indicating   that   another   similar   monoamine   transporters,  
such  as  5-­‐‑HT,  may  be  responsible   for   this  NAc  DA  increase   (Collins  et  al.,  2001).  A  
recent  study  by  Bruchas  et  al.   (2011)  showed  that   the  activation  of  p38  MAP-­‐‑kinase  
was   responsible   for   kappa-­‐‑mediated   effects   on   stress   in   serotonergic   neurons,  
possibly  by   regulating   the   function  of   the  SERT   (Bruchas   et   al.,   2011).  This   leads   to  
the   possibility   that   compounds   that   differentially   activate   signaling   pathways   and  
related   monoamine   transporters,   such   as   SERT,   may   have   varying   effects   on  
addiction,  mood,  depression,  aversion  and  dysphoria.    Therefore,  preclinical  research  
illustrates  that  KOPr  modulates  DAT,  and  also  suggests  KOPr  modulates  SERT  too,  




1.5     Salvinorin  A  and  Derivatives  
   At   present,   the   Mexican   mint   Salvia   divinorum   or   ‘divine   sage’   is   an   un-­‐‑
regulated   hallucinogen   that   has   been   traditionally   used   by   Mazatex   Indians   in  
shamanistic  rituals  to  induce  short,   intense  hallucinations  (Siebert,  1994).  The  active  
ingredient  in  Salvia  divinorum,  salvinorin  A  (Sal  A)  (Fig.  1.5),  has  been  shown  to  be  a  
KOPr  agonist  both  in  vitro  and  in  vivo  (Prisinzano,  2005).  In  fact,  Sal  A  was  found  to  
be  more  similar  to  dynorphin  than  the  classical  KOPr  agonists  U50,488H  (Fig.  1.5)  or  
U69,593   (Chavkin   et   al.,   2004)   that  have  been  previously   shown   to  attenuate   stress,  
and   drug   primed   reinstatement.   This   may   be   because   Sal   A   has   a   unique  
neoclerodane   diterpene   structure   including   no   nitrogen   atoms   (Prisinzano   and  
Rothman,  2008).  Other  novel  neoclerodane  diterpines  (DS-­‐‑3-­‐‑240)  are  also  of   interest  
because  they  show  psychostimulant  pharmacotherapy  potential,  however  they  differ  
from  Sal  A  because  but  they  have  a  different  C2  side  chain  (Morani,  2011).    
  
Classic  KOPr  agonists  have  anti-­‐‑addictive  properties  and  also  show  potential  
in  helping  affective  disorders,  stress  dysfunction  and  pain  response  studies  in  animal  
models  but  unfortunately,   they  also   lead   to  negative  side  effects   such  as  dysphoria  
and  depression,  particularly  with  long-­‐‑term  use  (Negus  et  al.,  1997).  Sal  A  is  unique  
in  that  it  has  no  affinity  for  the  mu  opioid,  delta  opioid,  DA,  or  5-­‐‑HT  receptors,  and  
unlike   all   other   hallucinogens   it   had   no   binding   affinity   for   the   5-­‐‑HT2A   receptor,  
which   is   a   target   for   hallucinogens   such   as   lysergic   acid   diethylamine,  
dimethyltryptamine,   and   ibogaine   (Munro   et   al.,   2005;   Vortherms   and  Roth,   2006).  
Yet,   few   studies   have   reported   behavioural   findings   with   KOPr   agonists   in   non-­‐‑
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primates  (Prisinzano,  2005;  Shippenberg  et  al.,  2007a;  Shippenberg  et  al.,  2007b).  It  has  
been   found   that   the  classic  KOPr  agonist  U50,488H  and  Sal  A  decrease  SERT  5-­‐‑HT  
uptake   in   rat   striatal   tissue   after   acute   (15   min)   exposure   as   shown   using   RDEV  
(Simonson,   unpublished   data)   and   U50,488H   decrease   SERT   5-­‐‑HT   uptake   in   co-­‐‑
transfected  HEK-­‐‑293   cells  with   chronic   (30  min)   exposure  as   shown  using   confocal  
microscopy   (Morani,   unpublished   data).   Collectively,   these   studies   suggest   KOPr  
activation  modulates  SERT  function  in  vitro.  
  
Salvinorin  A         U50,488H  
Fig.  1.5.  KOPr  agonists.  Sal  A  is  a  novel  KOPr  agonist  with  a  unique  structure  that  has  no  
nitrogen,   and  was   found   to  be  more   similar   to  dynorphin   than   the   classical  KOPr  agonists  
U50,488H.  
  
   If   these   compounds  modulate   SERT   function,   they  may  provide   a   platform  
from   which   pharmacotherapeutics   can   originate   to   specifically   target   KOPr   to  
increase  DAT  and  decrease  SERT,  allowing  the  brain  to  resemble  its  innate  biological  
state.  
  
1.6     The  Serotonin  Transporter  and  Kappa-­‐‑Opioid  Receptor    
KOPr  expresses  in  numberous  brain  regions  and  KOPr  activation  in  the  DRN  
or  NAc  decreases  extracellular  5-­‐‑HT  concentrations  in  the  respective  region  (Tao  and  
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Auerbach,  2002;  Tao  and  Auerbach,  2005;  Tao  et  al.,  2007;  Werling  et  al.,  1989).  The  5-­‐‑
HT   and   KOPr   systems   are   involved   in   cocaine   addiction,   affective   disorders,   and  
dysfunctional  stress  responses.  In  addition,  SERT  and  KOPr  co-­‐‑localise  in  the  DRN,  
which   is   a  brain   region   involved   in   the  aetiology  of   these  disorders.  To   investigate  
this  relationship  further  preclinical  models  are  extremely  important.  For  example,  a  
study   by   Ruedi-­‐‑Bettschen   et   al.   (2010)   found   that   fluoxetine,   an   SSRI,   and   a   KOPr  
agonist,   spiradoline,   each   inhibited   cocaine-­‐‑induced   reinstatement   in   squirrel  
monkeys.  Interestingly,  this  effect  was  reversed  for  both  compounds  (fluoxetine  and  
spiradoline)   by   the   5-­‐‑HT1A   agonist,   8-­‐‑OH-­‐‑DPAT,   that   implies   cocaine-­‐‑induced  
reinstatement   involves   5-­‐‑HT   signalling,   which   occurs   via   SERT   and   KOPr.   In  
addition,  KOR  activation   in   the  DRN  or  NAc  decreases  extracellular  5-­‐‑HT   levels   in  
the  respective  brain  region  but  whether  this  effect  is  because  of  direct  5-­‐‑HT  release,  a  
direct  effect  on  SERT  function  or  an  indirect  effect  on  glutamatergic  afferents  to  the  
DRN  was  not  determined  (Tao  and  Auerbach,  2002).  Further,  DRN  5-­‐‑HT  inactivation  
with  the  KOPr  antagonist  norBNI  blocked  stress-­‐‑induced  cocaine  reinstatment  in  rats  
and   any   aversive   response   observed   to   U50,488H   (Land   et   al.,   2009).   Finally,   it   is  
known   that   cocaine   exposure   up-­‐‑regulates   the   KOPr/dynorphin   system   and   this  
increase   is  DAT   independent   because  KOPr’s   did   not   increase  with   selective  DAT  
inhibitors   (Collins   et   al.,   2001).   Thus,   it   was   postulated   that   SERT   may   modulate  
KOPr,   either   directly   or   indirectly   (Collins   et   al.,   2002)   and   thus   a   reciprocal  
relationship   is   likely   to   exhist.   Collectively,   these   preclinical   models   demonstrate  
sufficient  evidence  to  suggest  a  relationship  between  KOPr  and  SERT.  
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A  potential  KOPr  and  SERT  relationship  was  first  documented  by  Schenk  et  
al.   (2000)  when   it  was   illustrated   that   cocaine-­‐‑seeking   in   rats  were   attenuated  with  
the   traditional   KOPr   agonist   U69,593.   This   decrease   in   cocaine-­‐‑seeking   was  
suggested   to  occur  because  kappa-­‐‑opioids  and  cocaine   interact  at   common  sites  on  
the  SERT  protein  (Schenk  et  al.,  2000).  Furthermore,  this  KOPr  and  SERT  hypothesis  
was   further   elaborated   by   Ramamoorthy   et   al.   (2002)   who   illustrated   that   SERT  
activation  by  the  KOPr  agonist,  U69,593,  leads  to  a  decrease  in  5-­‐‑HT  re-­‐‑uptake  in  rat  
NAc   synaptosomes.   Zakharova   et   al.   (2008)   provided   additional   evidence   to   the  
hypothesis   that   KOPr  modulates   SERT,  when   they   illustrated   that   SERT   depletion  
decreases   KOPr   activity.   Additional   recent   findings   from   our   laboratory   also  
complement  this  hypothesis  as  acute  (15  min)  KOPr  agonist  (500  nM;  U50,488H  and  
Sal  A)   exposure   decreases   SERT   function   as  measured  with  RDEV  on   rat   striatum  
tissue   (Simonson,   unpublished   data)   as  well   as   chronic   (30  min)  KOPr   agonist   (10  
µμM;  U50,488H)  exposure  in  co-­‐‑expressing  HEK-­‐‑293  cells  using  confocal  microscopy  
(Morani,   unpublished   data).   Collectively,   an   overview   of   the   current   literature  
strongly  suggests  there  is  an  interaction  between  KOPr  and  5-­‐‑HT,  which  is  indicated  
to   occur   between   KOPr   and   SERT.   Therefore,   the   literature   provides   rationale   to  
further   investigate   this   relationship  by   elucidating   the   effect   of  KOPr  activation  on  
SERT  regulation.  
  
1.7     Significance  and  Hypotheses  
   SERT  and  KOPr  co-­‐‑localise  in  the  DRN  and  NAc  which  is  a  brain  region  vital  
to  the  etiology  of  psychiatric  diseases  and  disorders,  however  a  relationship  remains  
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inconclusive.   Elucidating   the   effect   of   KOPr   activation   on   SERT   function   will  
elucidate   key   molecular   targets   to   facilitate   future   psychiatric   research   and  
pharmacotherapeutic   development   for   more   effective   treatment   of   neurological  
diseases.   It   is   hypothesised   that   both   acute   (5   min)   and   chronic   (30   min)   KOPr  
activation  using  the  classical  KOPr  (U50,488H)  and  novel  KOPr  agonists  (Sal  A,  DS-­‐‑
3-­‐‑240)  will  significantly  decrease  SERT  function  in  vitro   in  HEK-­‐‑293  cells  transiently  
expressing  myc-­‐‑rKOPr  and  eGFP-­‐‑tagged  SERT.  
  
  
1.8     Aims    
   The  aim  of  the  present  study  is:  
1) To  investigate  the  cellular  effect  with  acute  (5  min)  exposure  of  classical  KOPr  
(U50,488H)   and   novel   KOPr   agonists   (Sal   A,   DS-­‐‑3-­‐‑240;   10   µμM)   on   the  
modulation   of   SERT   function   in   vitro   in   HEK-­‐‑293   cells   co-­‐‑expressing   myc-­‐‑
rKOPr  and  eGFP-­‐‑tagged  SERT  using  ASP+  uptake  assay.  
2) To  investigate  the  cellular  effect  with  acute  (5  min)  exposure  of  classical  KOPr  
(U50,488H)   and   novel   KOPr   agonists   (Sal   A,   DS-­‐‑3-­‐‑240;   500   nM)   on  
modulation   of   SERT   function   in   vitro   in   HEK-­‐‑293   cells   co-­‐‑expressing   myc-­‐‑
rKOPr  and  eGFP-­‐‑tagged  SERT  using  rotating  disc  electrode  voltammetry.  
3) To   develop   a   high-­‐‑throughput   screening   assay   to   investigate   the   effect   of  
chronic   (30   min)   KOPr   agonist   (U50,488H,   Sal   A;   10   µμM)   exposure   on  
modulation  of  SERT  function  in  vitro  using  HEK-­‐‑293  cells  co-­‐‑expressing  myc-­‐‑
rKOPr  and  eGFP-­‐‑tagged  SERT.  
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Chapter  2:  General  Methods  
  
2.1     Cell  Culture  
   The   cell   lines   used   in   this   study   were   grown   under   PC2   conditions   in   the  
School   of   Biological   Sciences,   Victoria  University   of  Wellington,  New  Zealand.  All  
cell  culture  work  was  performed  in  a  sterile  Email  Air  Handeling  Class  II  Biological  
safety  cabinet  (AES  Environment  Pty  LTD,  Auburn,  Australia)  with  HEPA  air  filters.  
Before   the   cabinet   was   used   it   was   sterilized   with   Ultraviolet   (UV)   light   (1390  
mW/m2)   for   a  minimum  of   15  min   and  wiped   prior   to   use  with   70%   ethanol.   The  
sterile  plasticware  used  for  all  cell  culture  work  was  purchased  from  BD  Biosciences  
(BD-­‐‑New   Zealand,   Auckland,   New   Zealand)   and   Greiner   Bio   One   (Raylab,  
Auckland,   New   Zealand).   Cells   were   grown   in   a   Heracell   incubator   (Kendro  
Laboratory  Products,  GmbH,  Germany)  under  constant  environmental  conditions  at  
37˚C  with  5%  CO2.  In  this  study  human  embryonic  kidney  cells  (HEK-­‐‑293  cells)  were  
purchased  from  American  Type  Culture  Collection  (ATCC,  Manassas,  VA,  USA)  and  
were  used  between  passage  number  6  and  30.  
  
   Human   embryonic   kidney   (HEK-­‐‑293)   cells   are   an   immortalised   human  
embryonic  cell  line  that  has  been  transformed  with  adenovirus  5.  They  were  cultured  
in   Dulbecco’s   Modified   Eagle’s   Media   (DMEM)   high   glucose   medium   (Gibco,  
Invitrogen,  Auckland,  NZ)   containing  a   final   concentration  of   10%   fetal   calf   serum  
(FCS;   IPC   biological,   Auckland,   NZ),   1%   Penstrep   antibiotic   (Penicillin   G   sodium  
5000   units/mL,   streptomycin   sulphate   5000   units/mL   in   0.85%   saline,   Gibco,  
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Invitrogen)  and  0.1%  L-­‐‑glutamine  (Gibco,  Invitrogen).  Penstrep-­‐‑free  media  was  used  
for   all   transfections   and   comprised   of  DMEM   containing   10%   fetal   calf   serum   and  
0.1%   L-­‐‑glutamine.   For   confocal   microscopy   and   establishment   of   a   stable   cell   line  
expressing  eGFP-­‐‑tagged  hSERT,  HEK-­‐‑293  cells  were  plated  at  a  concentration  of  5  x  
105  cells/mL  in  a  35  mm  glass  bottom  dishes  (Mattec,  Loveland,  Ohio,  USA)  and  for  
RDEV  HEK-­‐‑293   cells  were   plated   at   a   concentration   of   5   x   105   cells/mL   in   60  mm  
plastic   bottom  dishes.   The   96-­‐‑well   plate   assay   and  preliminary  RDEV   experiments  
used  5  x  105  cells/mL  in  100  mm  plastic  bottom  dishes.    
  
2.1.1     Cell  growth    
Cryovials  of   cell   stocks  were   stored   in   liquid  nitrogen   for  experimental  use.  
To   defrost   cells   a   cryovial   of   previously   frozen   cells  was   removed   from   the   liquid  
nitrogen  dewer  and  defrosted  at  37˚C  in  a  water  bath.  They  were  then  immediately  
added   to   5  mL  of   pre-­‐‑warmed   37˚C  media   in   a   15  mL   conical   centrifuge   tube   and  
centrifuged  at  300  g  for  5  min.  The  supernatant  was  aspirated  off  and  cells  were  re-­‐‑
suspended   in  5  mL  of  media,  and   transferred   into  a  75  mL  flask   fitted  with  a   filter  
screw  cap,  placed  in  the   incubator  and  allowed  to  grow.  The  following  day  the  old  
media  was  aspirated  and  fresh  media  was  placed  into  the  flask  to  feed  the  cells  and  
encourage  growth.  Once  the  cells  were  80-­‐‑90%  confluent  they  were  passaged  into  a  
250  mL  flask.  When  this  flask  became  80-­‐‑90%  confluent  the  cells  were  passaged  into  
two  new  250  mL  flasks,  one  flask  was  to  continue  the  cell  line  for  use  in  experiments,  
and  the  other  flask  was  used  to  replace  the  removed  cell  stock.  
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2.1.2     Cell  Passaging  and  Freezing  of  Cell  Lines  
   When  cells  became  80-­‐‑90%  confluent  they  were  ready  to  be  passaged  into  the  
sterile  plasticware  required  for  experiments  or  continued  growth.  The  old  media  was  
aspirated  off  and  cells  were  washed  with  5  mL  of  sterile  1x  phosphate  buffered  saline  
(1x   PBS;   137  mM  NaCl,   2.7  mM  KCl,   8.1  mM  Na2HPO4,   1.5  mM  KH2PO4,   pH   7.4;  
Appendix  1)  and  then  incubated  with  2  mL  of  TrpLE  Express  (Gibco,  Invitrogen)  for  
5  min  or  until  cells  had  detached  from  the  bottom  of  the  flask.  Gentle  agitation  of  the  
flask  helped  to  remove  any  still  adhered  cells  and  when  the  cells  had  detached  they  
were   diluted  with   2  mL   of  DMEM  media,   transferred   into   a   sterile   15  mL   conical  
centrifuge   tube   and   centrifuged   at   300   g   for   5   min.   The   supernatant   was   then  
aspirated  off  and  the  cells  were  re-­‐‑suspended  in  5  mL  of  media.  The  concentration  of  
live   cells  was   then   determined   by   using   a   haemocytometer   and   0.4%   Trypan   blue  
(Sigma).  
  
   Cells  were  frozen  down  when  in  the  log  growth  phase  at  a  concentration  of  1  
x   106   cells/mL   in   the   corresponding   media   containing   10%   dimethyl   sulfoxide  
(DMSO).   Aliquots   of   1   mL   were   frozen   in   cryovials   overnight   at   -­‐‑80˚C   and   then  
transferred  to  the  liquid  nitrogen  dewar  the  following  day  for  long  term  storage.  
  
2.1.3     Cell  Transfection  
   On  the  first  day  (Day  1)  the  cells  were  passaged  into  plates  at  a  density  for  the  
relevant   experiment.  The  day  after  plating   (Day  2)   cells  were   transfected  when  60-­‐‑
80%   confluent   and   in   the   log   growth   phase.   Cells   were   transfected   using  
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Lipofectamine   2000   (Gibco,   Invitrogen,   Auckland,   New   Zealand)   and   Optimem   I  
medium   (Invitrogen).   Transfections   were   carried   out   according   to   manufacturer’s  
instructions.  For  HEK-­‐‑293  cells,  3  µμL  of  Lipofectamine  2000  was  made  up   to  50  µμL  
with  Optimum  I  in  a  tube  and  incubated  at  room  temperature  for  5  min.  In  a  separate  
tube,  myc-­‐‑tagged   rat  κ-­‐‑opioid   receptor  plasmid  DNA   (myc-­‐‑rKOPr,   kindly  donated  
by  L.  Devi;  Table  2.1)  and  enhanced  green   fluorescent  protein-­‐‑tagged  human  SERT  
plasmid  DNA   (eGFP-­‐‑hSERT,   kindly   donated   by   S.   Ramamoorthy;   Table   2.1)   were  
made   up   to   50   µμL  with  Optimem   I,   to   a   final   concentration   of   0.6   µμg/mL   and   0.4  
µμg/mL,  respectively.  After  a  5  min  incubation  tube  1  and  2  tube  were  mixed  together  
and   incubated  at   room   temperature   for   20  min.  Prior   to   transfection   cells  were   fed  
with   1   mL   of   penstrep-­‐‑free   medium   for   every   100   µμL   of   the   transfection   mixture  
added.  Transfected  cells  were  used  48  hours  later  (Day  4).    
  
Table  2.1.  myc-­‐‑rKOPr  and  eGFP-­‐‑hSERT  Plasmid  Information  
Gene     Vector     Resistance     Provided  by    
myc-­‐‑rKOPr     pcDNA3     Ampicillin    
(100  µμg/mL)    
L.  Devi    
(Jordan  and  Devi,  
1999)    
eGFP-­‐‑hSERT     peGFP-­‐‑C1     Kanamycin    
(50  µμg/mL)    
S.  Ramamoorthy  
(Scholze  et  al.,  
2000)  
  
2.2     Plasmid  Preparation  
2.2.1     Luria  Broth  (LB)  and  LB  agar    
LB  broth    (10  g/L  NaCl,  5  g/L  Yeast  extract,  10  g/L  Bactotryptone)  (Appendix  
1)   and   LB   agar   (10   g/L   NaCl,   5   g/L   Yeast   extract,   10   g/L   Yeast   agar,   10   g/L  
Bactotryptone)  (Appendix  1)  were  steralised  by  placing  in  an  autoclave  at  121°C  at  20  
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lb/in2  for  20  min.  Solutions  were  then  left  to  cool  to  37°C  in  a  waterbath  and  then  the  
appropriate   amount   of   the   antibiotic   was   added   to   each   solution   (myc-­‐‑rKOPr:100  
µμg/mL   ampicillin   or   e-­‐‑hSERT:50   µμg/mL   kanamycin).   The   agar   was   then   gently  
placed   into   sterile  100  mm  plastic  plates  and   left   to   set.  Agar  plates  were   stored  at  
4°C  until  needed  but  for  no  longer  than  2  weeks.  
  
2.2.2     Transformation  of  MAX  Efficiency  DH5α™  Competent  cells  
   A  100  µμL  aliquot  of  MAX  Efficiency®  DH5α™  Competent  Cells  (Invitrogen)  
was   thawed  on  wet   ice  and   then  divided   into   two  50  µμL  aliquots   in   ice-­‐‑cold  micro  
centrifuge  tubes.  20  ng  of  plasmid  DNA  (Table  2.1)  was  added  to  one  tube,  the  other  
tube  acted  as  a  negative  control.  Both  aliquots  of  cells  were  incubated  on  ice  for  1  h,  
then  heat  shocked  at  42°C  for  2  min  in  a  heat  block  (Global  Science)  and  then  placed  
on  ice  for  a  further  5  min.  After  cooling,  450  µμL  of  room  temperature  SOC  medium  
(Invitrogen)  was   added   to   each   of   the   tubes,   and   the   tubes  were   placed   in   a   37°C  
Shaker   (Bioline,   Edwards   Instrument   Company,   Australia)   set   at   225   rpm   for   1   h.  
Following  this,  100  µμL  of  each  culture  was  spread  onto  a  LB  agar  plate  containing  the  
appropriate  antibiotic  to  create  a  ‘lawn’  culture.  The  plates  were  incubated  overnight  
in  a  37°C  humid  incubator  (Bioline).  
  
2.2.3     Escherichia  coli  (E.coli)  Cultivation  
   To   cultivate   single   colonies   either:   (1)   A   single   colony   from   a   freshly  
transformed  agar  plate   as  previously  described   above  or   (2)   From  a  plate   streaked  
with   plasmid   transformed   bacteria   from   a   glycerol   stock,   was   picked   off   with   a  
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pippette  tip  and  added  to  2  mL  of  LB  Broth  containing  the  appropriate  concentration  
of   antibiotic.  This  was  only   carried  out   if   there  was  no  growth  of  non-­‐‑transformed  
bacteria  on  the  antibiotic  containing  agar  (negative  control  plate);   if  this  occurred,  a  
new  transformation  was  performed.  The  bacterial  culture  was  then  incubated  for  24  
h   in  a  shaking,  humid  37°  C   incubator   (Bioline).  After  24  h,  200  µμL  of  bacteria  was  
removed  and  added  to  200  mL  of  LB  broth  containing  the  appropriate  antibiotic,  and  
this   culture  was   incubated   for   another   24   h   in   a   shaking,   humid   37°   C   incubator.  
After  24  h  the  plasmid  preparation  was  carried  out.  The  reason  for  2  x  24  h  growth  
phase  was  because  the  bacteria  was  to  produce  the  highest  yield  of  plasmid,  and  this  
was  shown  in  the  past  to  be  the  most  effective  method.  
  
2.2.4     Plasmid  Purification  using  the  Qiagen  HiSpeed  Maxi  Kit  
   Plasmid   DNA   was   purified   from   200   mL   bacterial   culture   following   the  
manufacturer’s  protocol.    
  
   Briefly,  the  200  mL  bacterial  culture  was  centrifuged  at  6,000  g  for  25  min  at  
4°C   in   a   Sorvall   Evolution   RC   centrifuge   (Kendro   Laboratory   Products,   Bath,   UK)  
and  the  supernatant  discarded.  The  bacterial  pellet  was  re-­‐‑suspended  in  10  mL  of  re-­‐‑
suspension   buffer   containing  RNase  A   and   lysis   blue  Qiagen   reagents   (Buffer   P1).  
Following   this   cells  were   lysed  by   transferring   the   resuspended   transformed  E.   coli  
cells   to   a   sterile   50  mL   tube   and   10  mL   of   lysis   buffer   (Buffer   P2)  was   added   and  
mixed   by   inverting   4-­‐‑6   times.   The   solution   was   incubated   for   5   min   at   room  
temperature   then   10  mL   of   chilled   neutralisation   buffer   (Buffer   P3)   was   added   to  
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stop   cell   lysing   and   mixed   by   inverting   the   tube   4-­‐‑6   times.   This   lysate   was   then  
transferred  into  a  QIAfilter  Cartridge  and  incubated  for  10  min  at  room  temperature.  
During   this   time   a   HiSpeed   Maxi   Tip   was   placed   over   a   waste   container   and  
equilibrated  by  the  application  of  10  mL  of  Buffer  QBT  through  the  filter.  The  lysate  
was   then   filtered   through  a  HiSpeed  Maxi  Tip   into  a  waste  container,   trapping   the  
DNA  within   the   tip.   The   tip  was   then  washed  with   60  mL   of  wash   buffer   (Buffer  
QC),   and   then   the   DNA  was   eluted   into   a   sterile   50  mL   tube   using   15  mL   of   the  
elution  buffer   (Buffer  QF).  The  DNA  was  then  precipitated  by   incubation  with  10.5  
mL   of   room   temperature   molecular   grade   isopropanol   (Sigma)   for   5   min.   The  
isopropanol   mixture   was   transferred   into   a   30   mL   syringe   attached   to   a  
QIAprecipitator   Maxi   Module   and   filtered   through   the   precipitator   into   a   waste  
container.   The   DNA   remained   trapped   in   the   precipitation   filter.   The   precipitator  
filter  was  then  rapidly  washed  with  2  mL  of  room  temperature  molecular  grade  70%  
ethanol   (Ajax  Chemicals,  Auckland,  NZ)  through  a  5  mL  syringe.  The  precipitation  
filter  was  then  air  dried  by  quickly  pushing  air  carefully  through  the  syringe  through  
the   filter   twice   then   the   filter   was   dried   on   a   paper   towel   to   prevent   ethanol  
carryover.   The   precipitation   filter   was   then   re-­‐‑attached   to   the   5   mL   syringe   and  
placed  over  a  microcentrifuge  tube,  1000  µμL  of  endotoxin  free  buffer  (Buffer  TE)  was  
pippetted   into   the   5  mL   syringe   and   the   DNA  was   eluted   into   a   1.5  mL   capacity  
microcentrifuge   tube.   The   eluted  DNA  was   then   transferred   back   into   the   syringe  
and   filtered   a   second   time   through   the   precipitator   into   the   same   1.5  mL   capacity  
microcentrifuge  tube.  The  yield  of  DNA  was  determined  using  a  Nanodrop  ND-­‐‑1000  
spectrophotometer  (BioLab,  Auckland,  NZ).  The  Nanodrop  was  initialised  and  then  
blanked   using   1   µμL   of   double   distilled  water.   A   1   µμL   sample   of   eluted  DNA  was  
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placed  onto  the  nanodrop  sensor  and  the  amount  of  DNA  present  was  measured  at  
230   nM.   Yields   of   above   250   ng/µμL  with   an  A260/A280   ratio   of   1.8-­‐‑1.9  were   deemed  
acceptable  and  subsequently  used  for  cell  transfection  protocols.    
  
   If  yields  of  1  mg/mL  or  above  were  purified,  the  2  mL  culture  of  bacteria  was  
frozen   in   500   µμL   aliquots   in   20%   glycerol   at   -­‐‑80°C   for   future   use   so   that  
transformations  were  not  necessary  each  time  the  plasmid  was  needed.  In  this  case,  a  
scraping  from  the  frozen  bacteria  stock  was  streaked  onto  a  LB  agar  plate  containing  
the  appropriate  antibiotic   to  obtain  a  single  colony  that  could  then  be  cultured  in  2  
mL  of  LB  broth  containing  the  appropriate  antibiotic.  
  
2.3       Reagents  
   In  all  experiments  Sal  A  (50  mM  stock  concentration),  DS-­‐‑3-­‐‑240  (50  mM  stock  
concentration)   (Kind   gifts   from   Dr.   Thomas   E.   Prisinzano,   University   of   Kansas),  
U50,488H   (50  mM  stock  concentration),   fluoxetine-­‐‑HCl   (Tocris,  UK)  and  1’-­‐‑diethyl-­‐‑
2,2’-­‐‑cyanine  iodide  (decynium-­‐‑22;  D-­‐‑22)  (Sigma  Aldrich,  St.  Louis,  MO)  were  initially  
suspended  in  100%  DMSO  to  make  stock  concentrations.  [4-­‐‑(dimethylamino)styryl]-­‐‑
1-­‐‑methylpyridinium   (ASP+)   (Sigma   Aldrich)   stock   solution   was   made   in   sterile,  
filtered   KREBS   buffer   (130   mM   NaCl,   1.3   mM   KCl,   2.2   mM   CaCl2,   1.2   mM  
MgSO4.6H20,   1.2   mM   KH2PO4,   10   mM   HEPES,   10   mM   D-­‐‑glucose,   pH   7.4)  
(Appendix  1).  All  drugs  were   further  diluted   into   the  working  concentration  using  
sterile,   filtered   KREBS   (pH   7.4).   Serotonin   hydrochloride   (5-­‐‑HT   HCl)   (Tocris,   UK)  
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Chapter   3:   The   Effect   of   Acute   (5   min)   KOPr   Agonist  
Exposure   on   Modulating   SERT   Function   in   HEK-­‐‑293  
Cells  using  Confocal  Microscopy  
  
3.1     Introduction  
   Cultured  cell  lines  expressing  proteins  of  interest  are  an  extremely  useful  tool  
to  understand  cellular  and  molecular  processes.  Specifically,  cell  models  facilitate  the  
ability  to  manipulate  a  wider  spectrum  than  is  currently  possible  in  animal  models.  
Previously,   SERT   function   has   been   measured   in   tissue   and   cell   models   by  
radioactive  5-­‐‑HT  uptake   (Ramamoorthy  et   al.,   1998;  Owens  et   al.,   2001),  high-­‐‑speed  
chronoamperometry   (Perez   and   Andrews,   2005)   and   fast   scan   cyclic   voltammetry  
(John  and  Jones,  2007;  Hashemi  et  al.,  2009).  However,  recent  developed  temporally-­‐‑
resolved  techniques  enable  a  much  greater  understanding  of  monoamine  transporter  
function.   In   this  study  we  utilise  confocal  microscopy  4-­‐‑(4-­‐‑(dimethylamino)-­‐‑styryl)-­‐‑
N-­‐‑methylpyridinium   (ASP+)   uptake   techniques   to   investigate   the   effect   of   KOPr  
agonists   on   SERT   function   in  HEK-­‐‑293   cells   transiently   transfected  with   enhanced  
green   fluorescent  protein-­‐‑tagged  human  SERT  (eGFP-­‐‑hSERT)  and  myc-­‐‑rKOPr.  This  
sensitive   ASP+   uptake   model   has   multiple   benefits   over   the   other   available  
techniques,   including   visualising   eGFP-­‐‑hSERT   to   quantify   SERT   expression   levels  
using   single-­‐‑cell,   spatially   resolved,   real-­‐‑time   fluorescence  microscopy  analysis   (Oz  
et   al.,   2010).   This   advanced   technique   is   unique   and   the   first   of   its   kind   to   allow  
separation   between   ASP+   binding   and   uptake,   because   rapid   binding   occurs   with  
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micromolar   affinity   and   then   linear   uptake   occurs   for   at   least   10  min   (Figure   3.1),  
which  accumulates  intracellularly  and  binds  irreversibly  to  mitochondria  (Schwartz  
et  al.,  2003).    
  
Fig.  3.1.  Binding  and  uptake  of  ASP+  in  arbitrary  fluorescence  units  (AFU)  in  a  single  
HEK-­‐‑293  cell.  The  initial  rapid  binding  phase  is  followed  by  a  linear  uptake  phase  for  at  least  
10  min  after  ASP+  addition.    
  
   To  date  it  is  known  that  KOPr’s  co-­‐‑localise  with  SERT  in  a  key  brain  region,  
the  DRN,  that   is   involved  in  mood,  stress,   learning  and  memory  (Land  et  al.,  2009).  
Preliminary   data   from   our   laboratory   suggests   that   KOPr’s  modulate   SERT,   either  
directly   or   indirectly,   in   vitro   and   in   vivo   (Morani,   2011;   Simonson,   unpublished  
data).   In   addition,  Thompson   et   al.   (2000)   suggest   that  KOPr’s   act   to  modulate  DA  
function,  which  is  confirmed  with  the  discovery  that  KOPr’s  co-­‐‑localise  with  DAT  in  
the  NAc  (Svingos  et  al.,  2001).  Our  laboratory  has  since  illustrated  that  KOPr  agonists  
increase  the  function  of  DAT  as  a  result  of  change  in  DAT  function  in  the  NAc  and  in  
HEK-­‐‑293  and  N2A  cells  expressing  myc-­‐‑rKOPr  and  eYFP-­‐‑hDAT  proteins  (Simonson,  
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unpublished  data).  Because  both  the  SERT  and  KOPr  systems  are  involved  in  mood  
and   stress   dysfunctions,   co-­‐‑localise   within   the   same   brain   regions,   and   have   been  
suggested  to  interact  there  is  sufficient  rational  for  SERT  regulation  by  KOPr.  In  this  
study  we  utilise  a  cellular   in  vitro  model  that  measures  SERT  function  pre  and  post  
KOPr  activation.  We  use  ASP+  uptake  techniques  in  a  within-­‐‑cell  design  to  determine  
if   SERT   is  modulated   by  KOPr.   This  will   determine   if   acute   (5  min)  KOPr   agonist  
exposure   modulates   SERT   function.   Overall,   this   study   may   aid   to   develop   more  
effective  targets  for  pharmacotherapy  research.  
  
3.1.1     Aim  
In  this  chapter  we  aim  to  use  confocal  microscopy  to  measure  ASP+  uptake  in  
transiently  transfected  (eGFP-­‐‑hSERT  and  myc-­‐‑rKOPr)  HEK-­‐‑293  cells  to  determine  if  
acute  KOPr  activation  modulates  SERT  function.    
  
3.2     Methods    
3.2.1     Acute  ASP+  Uptake  using  Confocal  Microscopy  
HEK-­‐‑293  cells  were  cultured  and  transiently  transfected  with  myc-­‐‑rKOPr  and  
eGFP-­‐‑hSERT  plasmids  as  described   in   the  general  methods  section  (Chapter  2)  and  
used  48  hours  after  transfection  when  the  cells  were  70-­‐‑90%  confluent.    
  
Methods  were  carried  out  as  previously  described  (Bolan  et  al.,  2007;  Oz  et  al.,  
2010a;   Schwartz   et   al.,   2003;   Zapata   et   al.,   2007).   The   fluorescent   monoamine  
transporter   substrate  ASP+   (Tocris,  UK)  was  made  up   into   a   10  mM  stock   solution  
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using  sterile,  filtered  KREBS  buffer  (pH  7.4).  This  stock  solution  was  further  diluted  
to  a  10  µμM  working  solution.  Agonists  were  made  into  a  50  mM  stock  concentration  
in   DMSO   and   then   diluted   in   sterile,   filtered   KREBS   buffer   to   a  working   solution  
concentration  of  1.01  mM  so  that  when  10  µμL  was  added  to  the  dish  of  cells  with  1  
mL   (10  µμM)  ASP+   in  KREBS  buffer   the   final   concentrations  of   the  agonists  were  10  
µμM.  Control  experiments  were  carried  out  using  vehicle  (DMSO)  matched  solutions.    
  
   The  ASP+  and  KOPr  agonists  (U50,488H,  Sal  A  or  DS-­‐‑3-­‐‑240)  were  warmed  to  
37°C  along  with  the  solution  of  KREBS.  An  Olympus  Fluoview  FV1000  confocal  laser  
scanning  biological  microscope  (inverted  model  1X81)  (Olympus,  Tokyo,  Japan)  was  
used   to   monitor   ASP+   uptake   and   binding   of   cells,   using   a   40X   water   immersion  
objective  (NA=0.9).  To  maintain  the  temperature  of  the  cells  at  37˚C  during  confocal  
microscopy,   a  heat-­‐‑plated,   insulated,  double-­‐‑layer  heating   chamber   (INU-­‐‑21LCS-­‐‑F1  
model,  Tokai  Hit  Co.,  Ltd,  Japan)  mounted  on  the  microscope  stage  was  filled  with  
distilled  water  and  allowed  to  warm  to  37˚C.  ASP+  fluorescence  was  measured  with  a  
558   nm   laser   (ASP+   filter:   573   nm   excitation;   590   nm   emission)   at   settings   of   2.0%  
power,   high   voltage   (HV)   600   V,   offset   8%,   and   gain   1%.   eGFP   fluorescence   was  
measured  with  a  473  nm   laser   (eGFP   filter:   472  nm  excitation;  595  nm  emission)  at  
settings  of  0.2%  power,  HV  650  V,  offset  8%,  and  gain  1%.  The  microscope  pinhole  
was  opened  to  500  µμm  to  allow  for  more  light  from  a  greater  z  plane  to  be  detected.  
This  decreases  confocality  and  allows  ASP+  accumulation  to  be  more  representative  
of  uptake  from  the  whole  cell  rather  than  just  a  single  plane.  Images  were  acquired  
using  Olympus  FV10-­‐‑ASW  software.    
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   Acute   ASP+   experiments   were   carried   out   at   room   temperature   in   a   dark  
room   with   limited   light   so   that   fluorescence   was   not   affected.   First,   the   culture  
medium   was   removed   from   the   35   mm   glass   bottom   petridish   by   aspiration   and  
washed  once  with  1  X  PBS  then  replaced  with  sterile,  filtered  KREBS  buffer  at  37˚C.  
Dishes  were  mounted  on  the  microscope  stage,  and  the  microscope  was  focused  onto  
an   appropriate  monolayer   collection  of   cells  using  differential   interference   contrast  
(DIC).  Once  an  appropriate  area  of  cells  was  located,  the  KREBS  buffer  was  removed  
and  the  time  course  started  (120  scans,  every  5  s)  and  then  once  the  first  image  was  
collected   using   the  DIC,   eGFP   and  ASP+   filters,   1  mL   of   10   µμM  ASP+   at   37˚C  was  
added.  300  s  after  ASP+  was  added,  10  µμL  of  the  KOPr  agonist  (U50  488H,  Sal  A  and  
DS-­‐‑3-­‐‑240),   fluoxitene   (1.5  mM),  or   vehicle   control  was   carefully   added   to   the   petri  
dish.  Non-­‐‑expressing  HEK-­‐‑293  cells  served  as  a  negative  control   to  determine  non-­‐‑
specific   ASP+   uptake   by   non-­‐‑SERT   mediated   mechanisms.   The   amount   of   ASP
+  
accumulation   in   cells   not   expressing   GFP-­‐‑hSERT   (non-­‐‑transfected   cells)   was  
compared  with  those  cells  expressing  GFP-­‐‑hSERT  (transfected  cells).    
     
This  method  allowed  the  uptake  of  ASP+  before  the  KOPr  agonist  addition  to  
be   measured,   and   compared   to   ASP+   uptake   after   KOPr   agonist   addition.   This  
allowed   SERT   function   to   be   determined   within   single   cells.   Data   is   presented   as  
percentage  change  of  ASP+  uptake  within  a  single  cell.  Each  condition,  along  side  the  




3.2.2     Data  Analysis  for  Acute  ASP+  Uptake  Studies    
Cells   expressing   eGFP-­‐‑hSERT   were   manually   outlined   using   Fluoview  
FV1000   software,   and   these   regions   of   interest   (ROI)   were   graphed   as   integrated  
pixel  density  over  time  to  show  the  changes  in  ASP+  fluorescence.  The  data  from  the  
ASP+  uptake  graph  of  each  cell  that  fit  the  selection  criteria  was  then  transferred  into  
a  Microsoft  Excel  spreadsheet,  and  graphed   individually.  Cells  without   linear  ASP+  
uptake   were   discarded,   as   this   indicated   that   the   cells   moved   or   drifted   over   the  
period  of   the   experiment   and  would  not  provide  a   representation  of   SERT  uptake.  
The  initial  eGFP  fluorescence  was  also  recorded  so  that  cells  could  be  selected  based  
on   their   eGFP-­‐‑hSERT   expression.   Cells   expressing   less   than   200,000   arbitrary  
fluorescence  units  (AFU)  or  more  then  900,000  AFU  of  eGFP-­‐‑hSERT  were  not  used.  
Cells  with   an   eGFP-­‐‑hSERT   expression   of   less   than   200,000  were   not   used   because  
they  had  low  SERT  expression  as  they  showed  significantly  less  ASP+  uptake  at  300  s,  
did   not   demonstrate   linear   uptake   and   therefore,   were   classed   as   non-­‐‑transfected  
cells  (Figure  3.5)  and  >900,000  AFU  were  overexpressing  eGFP-­‐‑hSERT.  
  
   To   analyse   the   ASP+   uptake   data,   a   linear   trend   line   was   generated   for   a  
period  of  60  s,  1  s  before  KOPr  agonist  addition,  and  compared  to  a  linear  trend  line  
created  for  a  period  of  60  s  after  KOPr  agonist  addiction  during  the  time  of  maximal  
change   in  uptake.  The   change   in  ASP+  uptake  was   then   calculated   as   a  percentage  
change   of   the   slope   difference   ((slope   after   drug   at   maximal   time   of   effect/slope  
before  drug)  x100)  and  graphed  using  Graphpad  Prism  (GraphPad  Software  Inc,  La  
Jolla,  CA,  USA)  (Appendix  2).  Any  cells  that  had  a  linear  uptake  trend  line  of  r2<0.95  
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were  discarded  because  ASP+  uptake  was  not  linear,  and  not  representative  of  SERT  
function.    
  
   GraphPad  Prism  was  used  to  carry  out  one-­‐‑way  ANOVA  followed  by  Tukey  
Post   test   was   performed   on   the   average   percentage   change   of   ASP+   uptake.  
Significance  was  defined  as  p<0.05.    
  
3.3     Results    
3.3.1     ASP+  Uptake  Method  Validation    
  
ASP+  uptake  studies  were  conducted  in  transiently  transfected  HEK-­‐‑293  cells  
shown   to   co-­‐‑express   eGFP-­‐‑hSERT   and   myc-­‐‑rKOPr   in   HEK-­‐‑293   cells   using   a   Cy5-­‐‑
myc-­‐‑rKOPr   antibody   (Simonson,   unpublished   data).   Preliminary   experiments  
confirmed  that  ASP+  binding  was  rapid,  uptake  was  linear  for  10  min  (Figure  3.1)  and  
the  correlation  with  increasing  eGFP-­‐‑hSERT  cell  expression  and  ASP+  accumulation  
at  300  s  was  positive  (r2<0.58;  Figure  3.2).  eGFP  AFU  expression  less  than  200,000  at  0  
s  was  used  as  the  criteria  cut  off  point  for  cell  selection  because  there  is  a  significant  
decrease   in  ASP+  uptake   compared   to  non-­‐‑transfected   cells   (***p<0.001;   Figure   3.3).  
This   is   the   same   significant   decrease   found   between   transfected   cells   versus   non-­‐‑
transfected   cells   (***p<0.001;   Fig.   3.3),   justifying   the   cell   selection   cut   off   point.  
Transfected   cells   versus   fluoxitene   pre-­‐‑treated   (5  min)   cells   also   had   a   decrease   in  
ASP+   accumulation   (**p<0.01;   Figure   3.3).  Collectively,   these   results   so   far   illustrate  
that   ASP+   is   taken   up   through   SERT.   Interestingly,   ASP+   uptake   occurs   in   non-­‐‑
transfected  cells  aswell  as  cells  with  an  eGFP  AFU  at  0  s  of  less  than  200,000  (Figure  
3.3).  This   indicates  ASP+  uptake  through  low  affinity  monoamine  transporters,  such  
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as   extraneuronal   monoamine   transporter   (EMT),   the   plasmalemmal   monoamine  
transporter   (PMAT),   and   the   organic   cation   transporters-­‐‑  OCT1,  OCT2,   and  OCT3.  
For   example,   ASP+   uptake   of   fluorescent   in   HEK-­‐‑293   cells   by   OCT3   was   recently  
shown   in   real-­‐‑time   and   thus,   it   is   likely   that   other   low   affinity   transporters   also  
contribute  ASP+  uptake  (Mayer  et  al.,  2012).  This  idea  is  further  discussed  in  the  final  
discussion  (chapter  6).    
  
Fig.   3.2.   ASP+   uptake   in   arbitrary   fluorescence   units   (AFU)   at   300   s   versus  
eGFP-­‐‑  hSERT   intensity  at  0   s  have  a  positive   correlation   in  HEK-­‐‑293  cells.  
An   increase   in   eGFP-­‐‑hSERT   expression   at   0   s   resulted   in   an   increase   of   ASP+  
accumulation  at  300  s  (r2=0.5791,  p<0.001).  
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Fig.  3.3.  ASP+  accumulation  in  arbitrary  fluorescent  units  (AFU)  at  300  s  in  HEK-­‐‑293  
cells   that   were   non-­‐‑transfected,   transfected,   fluoxitene   pre-­‐‑treated   (5   mins),   and  
eGFP   less   than   200,000   at   0   s.   The   difference   in   ASP+   accumulation   between   non-­‐‑
transfected  cells  and  cells  with  an  eGFP  AFU  at  0  s  of  less  than  200,000  versus  transfected  
cells  was   significantly  different   (***p<0.001).  Non-­‐‑transfected   cells   and   cells  with   an   eGFP  
AFU  at  0  s  of  less  than  200,000  versus  fluoxitene  (1.5  mM)  pre-­‐‑treated  (5  min)  cells  was  also  
significant   (**p<0.01).   Transfected   cells   and   fluoxitene   pre-­‐‑treated   cells   were   also  
significantly  different  (**p<0.01)  (n=50-­‐‑200  cells).  
  
  
3.3.2     Effect  of  Acute  KOPr  Agonist  on  SERT  Function    
   ASP+   uptake   assisted   fluorescence   investigated   the   effect   of   acute   KOPr  
agonists  on  SERT  function.  As  shown  by  one  way  ANOVA  with  Tukey  post  test,   it  
was  found  that  there  was  no  statistical  significance  in  the  difference  of  ASP+  uptake,  
as  a  correlation  of  SERT  function,  between  any  of  the  KOPr  agonists  compared  to  the  
vehicle  matched  control  (***p<0.001)  (Figure  3.6).    
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Fig.   3.4.   Percentage   changes   of   ASP+   after   acute   (5   mins)   KOPr   agonists  
exposure   and   fluoxitene   pre-­‐‑treatement   (5   mins).   There   is   no   difference   in  
percentage  change  of  ASP+  uptake  between  the  DMSO  vehicle  and  any  of  the  KOPr  agonists.  
This   was   confirmed   by   inhibition   of   hSERT   by   the   SSRI,   fluoxitene   (1.5  mM),   for   5  min  
which   significantly   decreased   the  ASP+.  As   shown   by   a   one  way  ANOVA   followed  with   a  
Tukey  post  test  (***p<0.001).    
  
  
To  confirm  that  no  KOPr  agonists  had  a  modulatory  effect  on  SERT  function  
we  used  an  SSRI,  fluoxitene,  as  a  positive  control.  Here,  it  was  shown  that  the  hSERT  
plasmid  in  this  cell  model  was  functional  because  ASP+  accumulation  was  inhibited  
significantly   with   the   addition   of   fluoxitene   (***p<0.001;   Figure   3.6).   This   confirms  
hSERT  is  functional,    working  correctly  in  this  model  and  again  confirming  our  belief  
that  ASP+  uptake  occurs  through  SERT.  Based  on  our  knowledge  that  ASP+  uptake  is  
indicative   of   SERT   function,   these   results   suggest   acute   KOPr   activation   by   the  













































model.  Thus,  in  this  transiently  transfected  HEK-­‐‑293  cell  model,  KOPr  agonists  have  
no  modulatory  effect  on  SERT  function  as  measured  by  confocal  microscopy.    
  
When   an   appropriate   area   of   cells   in   the   dish  was   located   visualining  with  
both  both  the  eGFP-­‐‑  hSERT  (Fig.  3.4  A  and  3.5  A)  and  DIC  image  (Fig.  3.4  B  and  3.5  
B)  the  KREBS  buffer  was  removed  and  the  time  course  started  (120  scans,  every  5  s).  
The  first  image  was  collected  without  any  KREBS  containing  ASP+  solution.  This  was  
because  ASP+  binding  is  so  fast  that  it  was  impossible  to  take  an  image  quick  enough  
with   KREBS   containing   ASP+   solution   without   detecting   any   ASP+   intensity.  
Immediately   after   the   first   image  was   collected,   1  mL   of   10   µμM  ASP+   at   37˚C  was  
added  to  the  cells  before  the  next  image  was  taken.  Exactly  300  s  after  the  ASP+  had  
been  added  to  the  cells  added,  10  µμL  of  the  KOPr  agonist  (U50,488H,  Sal  A  and  DS-­‐‑3-­‐‑
240),  or  vehicle  control  was  carefully  added  to  the  glass  bottom  dish  containing  the  
visualized  cells.  Figures  3.4  and  3.5  illustrate  this  protocol  and  the  time  intervals  at  0  
s  (Fig.  3.4  C  and  3.5  C),  1  min  (Fig.  3.4  D  and  3.5  D),  5  min  (Fig.  3.4  E  and  3.5  E)  and  
10   min   (Fig.   3.4   F   and   3.5   F)   have   been   chosen   to   illustrate   the   increasing   red  








Fig.  3.5.  Time  course  of  ASP+  uptake  in  HEK-­‐‑293  cells  transiently  transfected  with  eGFP-­‐‑hSERT  and  myc-­‐‑rKOPr.  Transiently  transfected  cells  were  visualised  by  
the  confocal  microscope  to  focus  on  cells  expressing  eGFP-­‐‑  hSERT  (A)  cells  that  consisted  of  a  DIC  image  (B)  of  an  appropriate  monolayer  of  cells.  The  ASP+  uptake  at  0  s  (C),  






Fig.  3.6.  Time  course  of  ASP+  uptake  in  HEK-­‐‑293  cells  transiently  transfected  with  eGFP-­‐‑hSERT  and  myc-­‐‑rKOPr.  Transiently  transfected  cells  were  visualised  by  
the  confocal  microscope  to  focus  on  cells  expressing  eGFP-­‐‑  hSERT  (A)  cells  that  consisted  of  a  DIC  image  (B)  of  an  appropriate  monolayer  of  cells.  The  ASP+  uptake  at  0  s  (C),  
1  min  (D),  5  mins  (E)  and  10  mins  (F).  The  pink  arrow  indicated  a  non-­‐‑transfected  cell,  and  the  red  arrow  inducates  a  transfected  cell
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3.4     Discussion  
The  aim  of  this  chapter  was  to  use  confocal  microscopy  to  measure  ASP+  uptake  
in   HEK-­‐‑293   cells   co-­‐‑expressing   eGFP-­‐‑hSERT   and   myc-­‐‑rKOPr   to   elucidate   if   KOPr  
activation  modulates  SERT  function.    
  
3.4.1     ASP+  Uptake  Method  Validation       
Preliminary   ASP+   uptake   experiments   were   performed   to   confirm   the  
sensitivity  of   the  ASP+  uptake  assay.  From   these  preliminary  experiments  we   found  
ASP+   uptake   AFU   at   300   s   versus   eGFP-­‐‑hSERT   AFU   at   0   s   resulted   in   an   overall  
positive  correlation  (r2=0.58).  This  illustrates  that  as  eGFP-­‐‑hSERT  expression  increases  
ASP+   uptake   also   increases,   which   indicates   ASP+   uptake   occurs   through   by   SERT  
mediated  mechanism.  The  difference  in  ASP+  accumulation  between  eGFP-­‐‑hSERT  and  
myc-­‐‑rKOPr  transiently  transfected  HEK-­‐‑293  cells  compared  to  non-­‐‑transfected  HEK-­‐‑
293   cells   and   also   eGFP   of   less   than   200,000   AFU   (Figure   3.3)   was   statistically  
significant   (***p<0.001).  This  suggests   that   the  successful   transfection  of  eGFP-­‐‑hSERT  
is   required   for  any  ASP+  AFU.  Again,   this   illustrates   that  as  eGFP-­‐‑hSERT  expression  
increases   ASP+   uptake   also   increases.   Furthermore,   co-­‐‑expressing   cells   were  
preincubation   for   5   min   with   fluoxitene   (1.5   mM;   *p<0.05)   which   significantly  
decreased  SERT  function  and  ASP+  AFU.  Lastly,   there  was  a  significant  difference   in  
the   fluoxitene   pre-­‐‑treated   condition   when   compared   against   non-­‐‑transfected   or  
classified   non-­‐‑transfected   HEK-­‐‑293   cells   (**p<0.01).   Collectively,   these   findings  
illustrate   the  eGFP-­‐‑tagged  hSERT  proteins  are  functional,  and  this  ASP+  uptake  real-­‐‑
time  live  cell  assay  is  working  appropriately,  which  means  we  can  continue  with  the  
main  experiment.  
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3.4.2     Effect  of  Acute  KOPr  Agonist  on  SERT  Function    
This   confocal   microscopy   experiment   illustrates   that   the   KOPr   compounds  
tested   did   not  modulate   SERT   function   in  HEK-­‐‑293   cells   co-­‐‑expressing  myc-­‐‑rKOPr  
and  eGFP-­‐‑tagged  SERT.  Thus,  acute  (5  mins)  KOPr  agonists  (10µμM;  U50,488H,  Sal  A  
and   DS-­‐‑3-­‐‑240)   exposure   compared   to   the   DMSO   vehicle   matched   control   (p<0.099)  
had  no  effect  on  SERT   function.  To  confirm   the  absense  of  a  KOPr  agonist  effect  on  
SERT   function  we   illustrated   that   SERT  was   functional.   This  was   achieved  with   the  
inhibition  of  SERT  by  the  SERT  inhibitor,  fluoxitene  (5  min  preincubation  of  1.5  mM),  
which   significantly   decreased   SERT   function   as   analysed   by   a   one   way   ANOVA  
followed  with  a  Tukey  post  test  (***p<0.001).  In  conclusion,  the  KOPr  agonists  (10  µμM;  
U50,488H,  Sal  A  and  DS-­‐‑3-­‐‑240)  do  not  modulate  SERT  function  in  HEK-­‐‑293  cells  co-­‐‑
expressing  myc-­‐‑rKOPr  and  eGFP-­‐‑tagged  SERT.  
  
These   findings   are   difficult   to   compare   and   contrast   with   the   avaliable  
research   because   there   is   currently   no   published   literature   on   the   effect   of   KOPr  
agonists   on   SERT   function   in   HEK-­‐‑293   cells   co-­‐‑expressing   myc-­‐‑rKOPr   and   eGFP-­‐‑
tagged   SERT   by   confocal   microscopy.   However,   these   results   found   here   with  
confocal   microscopy   were   replicated   with   RDEV   (see   Chapter   3).   Interestingly,  
previous   studies   from   our   laboratory   by   Morani   (unpublished   data)   suggest   a  
difference   in   SERT   function   in   HEK-­‐‑293   cell   model   co-­‐‑expressing   myc-­‐‑rKOPr   and  
eGFP-­‐‑tagged   SERT   (not   inhibited   by  D-­‐‑22)  when   incubated  with   the  KOPr   agonists  
U50,488H  (10  µμM)  but  not  Sal  A  (10  µμM)  for  30  minutes.  Perhaps  this  discrepancy  in  
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SERT  function  reflects  experimental  differences  between  the  two  studies.  Differences  
such  as  incubation  time  5  min  vs.  30  min.    
  
The  current  study  investigates  the  KOPr  agonist  pre-­‐‑treatment  time  of  5  min,  
whereas  Morani  (unpublished  data)  investigates  a  pre-­‐‑treatment  of  time  of  30  min.  If  
both   studies  hold   true  and  SERT   function   is  modified  with  a  KOPr  agonists   30  min  
pre-­‐‑treatment,  but  not  5  min,  then  KOPr  activation  decreases  SERT  uptake  by  either,  
different  pathways  being   activated   (one   at   5  min   that  does  not  modulate   SERT  and  
one  at  15-­‐‑30  min  which  modulates  SERT)  or  a  biphasic  activation  of  one  pathway  (one  
phase  at  5  min  that  does  not  modulate  SERT  and  one  at  15-­‐‑30  min  which  modulates  
SERT).   These   hypotheses   are   discussed   in   more   depth   in   chapter   6,   but   briefly   it  
suggeststhat    perhaps  different  pathways,  as  hypothesised  by  Bruchas  and  Chavkin’s  
(2010;  figure  1.3).  For  example,  PKC  and  ERK1/2  pathways  transduce  with  shortterm  
KOPr  activation,  whereas  p38  and  ERK1/2  pathways  transduce  with   longterm  KOPr  
activation.   Or   perhaps   one   single   pathway   activates   a   shortterm   (acute)   and   a  
longterm   (chronic)   effect   where   only   the   latter   modulates   SERT   function.   When  
activated  this  one  pathway  has  a  biphasic  signal  transduction  process  where  the  first  
signal  transduction  occurs  at  5  min  (acute)  and  the  second  phase  other  at  30  min,  such  
as   PKC   or   ERK1/2.   It   is   also   entirely   possible   that   both   of   these   explanations   are  
correct  if  ERK1/2  is  involved  in  decreasing  SERT  function.    
  
Thus,  the  absense  of  an  effect  between  acute  (5  min)  KOPr  activation  and  SERT  
function  in  this  experiment  does  not  mean  that  this  interaction  does  not  exist.  Rather,  
it  simply  implies  that  the  relationship  may  be  more  complex  than  previously  thought  
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and   may   require   additional   research.   Collectively,   these   findings   suggest   either   a  
more   complex   cell   model   is   required,   such   as   primary   cell   cultures   that   has  
endogenous  systems  present,  or  that  there  simply  is  no  KOPr  and  SERT  relationship  
in  the  acute  (5  min)  model.    
  
From   this   first   experiment   a   particularly   interesting   observation   was  
discovered.  It  was  observed  that  ASP+  uptake  occurs  in  non-­‐‑transfected  cells  and  cells  
classified   as   non-­‐‑transfected   (Figure   3.3).   This   uptake   reflects   the   presence   of   low  
affinity   monoamine   transporters,   such   as   extraneuronal   monoamine   transporter  
(EMT),   the   plasmalemmal   monoamine   transporter   (PMAT),   and   the   organic   cation  
transporters  -­‐‑OCT1,  OCT2,  and  OCT3  in  this  model.  These  proteins  are  known  to  take  
up   small   amounts   of   monoamine   neurotransmitters,   yet   they   remain   relatively  
unstudied  (Hagen  et  al.,  2011),  although  it  was  recently  shown  by  Mayer  et  al.  (2012)  
that  OCT3   is   present   in  HEK-­‐‑293   cells   as   shown   by   real-­‐‑time   uptake   of   fluorescent  
ASP+.  Perhaps  our  findings  that  low  affinity  transporters,  perhaps  just  OCT3,  take  up  
ASP+   (and   thus   5-­‐‑HT)   highlights   the   overlap   of   5-­‐‑HT   and   other  monoamine  uptake  
into  neurons  by  alternative   low  affinity   transporter  proteins.  These   findings   suggest  
not   only   that   low   affinity  monoamine   transporters   are   likely   to   be   involved   in   the  
same  diseases  and  disorders  that  other  monoamine  transporters  are  implicated  in,  but  
also  that  further  experimental  analysis  in  the  future  should  also  investigate  the  effect  
of   these   low  affinity   transporters  by  using   their   respective   inhibitors   to  conclusively  
suggest  a  new  hypothesis.  Collectively,  these  findings  highlights  how  important  these  
less  understood  low  affinity  transporters  are  in  modulating  the  overall  signalling  of  5-­‐‑
HT  and  other  monoamines.    
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Chapter   4:   The   Effect   of   Acute   (5   min)   KOPr   Agonist  
Exposure   on   Modulating   SERT   Function   in   HEK-­‐‑293  
Cells  using  Rotating  Disc  Electrode  Voltammetry    
  
4.1     Introduction  
   Rotating   disc   electrode   voltammetry   (RDEV)   is   recently   developed  
electrochemical   technique   to   investigate   SERT   function   (Earles   and   Schenk,   1998).  
RDEV  is  an  experimental  technique  that  measures  the  monoamine  transporter  kinetic  
parameters,  Vmax  to  reflect  transporter  uptake  and  Km  to  reflect  transporter  release,  in  
different  biological  models,   such  as   tissue   samples   and  overexpressing   cell   cultures.  
This   technique   was   originally   developed   to   measure   the   uptake   and   release   of   the  
norepinephrine  transporter  (NET)  in  cell  and  tissue  models  (Burnette  et  al.,  1996;  Chen  
et   al.,   1999;  Earles  and  Schenk,  1998).  More  recently   it  has  been  used   to  measure   the  
real-­‐‑time   uptake   and   release   of   5-­‐‑HT   in   tissue   samples,   such   as   rat   brain  
synaptosomes  (Hagan  et  al.,  2010;  Hagan  et  al.,  2011b).    
  
   RDEV  (Figure  4.1)  measures  transporter  uptake  and  release  through  a  rotating  
submerged   glassy   carbon   rotating   electrode.   This   electrode   draws   the  
neurotransmitter  molecules  towards  its  electrode  surface  where  a  constant  voltage  is  
maintained   and   all   of   the  monoamines   present   in   the   chamber   oxidise   and   release  
electrons  that  produce  current,  which  is  measured  (Earles  and  Schenk,  1998;  Hagan  et  
al.,   2010).   The   magnitude   of   this   electron   current   is   directly   proportional   to   the  
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amount   of   free  monoamine  molecules   in   the   sample.   Therefore,   as   free  monoamine  
molecules  in  the  solution  are  transported  into  cells  through  a  monoamine  transporter  
the  current  changes  accordingly,  because  there  is  a  decrease  in  oxidising  monoamine  
molecules   in   the   surrounding   sample   solution   (Earles   and   Schenk,   1998).   The  
measured   current   is   then   calculated   to   provide   the   monoamine   transporter   uptake  




Fig.   4.1.   A   systematic   diagram   of   RDEV.   RDEV   consists   of   a   rotating   glassy   carbon  
electrode   connected   to   a   high-­‐‑precision   rotator   set   and   maintained   to   a   constant   2000   rpm  
using  a  digital  lazer  tachometer.  The  sample  of  interest  sits  in  a  chamber  that  has  an  Ag/AgCl  
reference   electrode   and  a  platinum  auxiliary   electrode   submerged   into   the   sample.  Voltage   is  
applied  to  oxidise  the  monoamine  molecules  and  the  resulting  current  is  recorded  and  used  to  





The  magnitude  of  current  measured  at  the  elecrode  surface  can  be  defined  by  
the  Levich  equation:  
  
IL  =  0.62nFACD2/3v  -­‐‑1/6ω  ½  
  
Where  IL  is  the  limiting  current,  n  is  the  number  of  electrons  transferred  per  mole,  F  is  
Faraday’s   constant   (96,485   coulombs/equivalent   of   electrons),   A   is   the   area   of   the  
electrode  in  cm2,  D  is  the  diffusion  coefficient  of  the  electroactive  species  in  cm2/sec,  C  
is   the   concentration  of   the   electroactive   species   in   the  bulk   solution   in  mM,  v   is   the  
kinematic  viscosity  of  the  solution  in  cm2/sec,  ω   is  the  angular  velocity  of  rotation  in  
rad/sec,   where  ω   =   2πN,   and  N   is   the   number   of   rotations   per   second   (Earles   and  
Schenk,  1998).  This  equation  defines  the  current  that  is  measured  at  the  solid  electrode  
surface.    
  
RDEV   is  a   simple,   cost  effective   technique   to  establish  and  provides  detailed  
information  about  Michaelis-­‐‑Menten  kinetics   (Earles   and  Schenk,   1998),  drug  effects  
(Earles   and   Schenk,   1999;   Thompson   et   al.,   2000),   ion   dependency   of   transporters  
(Bjorklund   et   al.,   2007;  Chen   et   al.,   1999),   and  binding   information   (Chen   et   al.,   1999;  
Earles   and   Schenk,   1999).   Two   methods   of   RDEV   can   determine   the   kinetic  
parameters   of  monoamine   transporters.   The   first  method   is   known   as   the   zero   trans  
model  and  involves  the  single  addition  of  the  monoamine  neurotransmitter  added  to  
a   single   tissue   or   cell   sample.   This   is   repeated   over   increasing   neurotransmitter  
concentrations,  with  each  new  concentration  added  to  a  fresh  sample  preparation.  The  
second  RDEV  method  is  the  low  to  infinite  trans  model,  which  involves  the  increasing  
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neurotransmitter  concentrations  to  be  sequentially  added,  from  lowest  to  the  highest,  
to   one   sample  within   the   chamber   and   allowing   the   nA   to   reach   baseline   between  
each   new   concentration   addition.   This   method   gives   comparable   results   to   single  
addition   studies   (Povlock   and   Schenk,   1997),   without   having   to   use   numberous  
samples.    
  
   Currently,   there   is   insufficient   RDEV   literature   measuring   SERT   function  
(Hagan   et   al.,   2010;   2011a;   2012;   Holley,   unpublished   data;   Simonson,   unpublished  
data).     Hagan  et  al.   (2010)  were  the  first   to  publish  peer-­‐‑reviewed  literature  showing  
that  RDEV  can  sensitively  measure  SERT  kinetics  in  tissue  samples.  Hagan  et  al.  (2010)  
observed  a  difference  in  5-­‐‑HT  uptake  between  three  different  5-­‐‑HTTLPR  genotypes  in  
mice   that   was   not   found   with   less   sensitive   5-­‐‑HT   uptake   techniques,   such   as  
radioactive  uptake  (Bengel  et  al.,  1998).  Using  whole  brain  synaptosomes  Hagen  et  al.  
(2010)   are   the   first   to   illustrate   that   it   is   possible   to   measure   SERT   kinetics   using  
RDEV.   They   observed   that   wild   type   mice   have   an   increased   5-­‐‑HT   uptake   when  
compared  to  heterozygous  or  homozygous  SERT  knockout  mice  and  this  increase  was  
attenuated   with   the   SSRI,   paroxetine   hydrochloride   (Hagan   et   al.,   2010).   Recently,  
Hagen   et   al.   (2012)   further   highlight   the   critical   use   of   the   low   affinity  monoamine  
transporter   inhibitor,   D-­‐‑22   (1.5   mM),   when   investigating   monoamine   transporter  
function  because   these   transporters   are   endogenously   expressed   in   cells   and  uptake  
monoamine   transmitters   at   high   concentrations.   Thus,   experimentation   without  
inhibiting   the   low   affinity   transporters   could   result   in   confounding   (Hagen   et   al.,  
2012).  At  present  there  is  limited  peer-­‐‑reviewed  literature  investigating  SERT  function  
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in  cultured  cells  as  measured  by  RDEV  and  therefore,  much  of  this  protocol  is  based  
on   a   recently   published   PhD   thesis   completed   in   our   laboratory   (Simonson,  
unpublished   data),   past   literature   (Hagan   et   al.,   2010;   2011a;   2012;   Holley,  
unpublished  data)  and  experimental  development  in  this  study  within  the  confinds  of  
these  previous  studies.    
  
4.1.1     Aim  
   In  this  chapter  we  aim  to  use  RDEV  to  measure  transporter  uptake  (Vmax)  and  
release   (Km)   in   HEK-­‐‑293   cells   transiently   transfected   with   eGFP-­‐‑hSERT   and   myc-­‐‑
rKOPr  to  determine  if  KOPr  activation  modulates  SERT  function.    
  
4.2     Methods  
4.2.1     Experimental  Procedure    
   RDEV  consists  of  a  rotating  glassy  carbon  electrode  (Pine  Instruments,  special  
order  AFMDO3GC,  Pennsylvania)   that   is  connected   to  a  high-­‐‑precision  MSR  rotator  
(Pine   Instruments)  and  set   to  2000   rpm  using  a  digital   lazer   tachometer.  The   rate  of  
rotation   is   maintained   and   recorded   to   keep   the   sample   or   buffer   in   the   chamber  
mixing  at  a  custom  speed   that  gives  continuous  and  consistent   readings   throughout  
the  experiment.  The  sample   is  mixed   in   the  chamber  with  a   constant  air   flow  of  5%  
CO2/95%   with   O2   gently   and   constantly   flowing   across   the   sample   solution,   while  
simultaneously  being  heated   to   37˚C.  The   chamber  also  has   two  electrodes  attached  
and  submerged   into   the   sample.  An  Ag/AgCl   reference  electrode   is  used   to  apply  a  
+450  mV  potential  (relative  to  the  electrode)  by  an  eDAQ  potentiostat  EA161  (eDAQ,  
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NSW,  Australia)  and  a  piece  of  platinum  is  used  as  an  auxiliary  electrode.  Voltage  is  
applied  and  resulting  current  was  recorded  by  an  eDAQ  recorder  2010  (eDAQ)  and  a  
PC   computer   with   Chart   software   (eDAQ)   was   used   to   collect   and   interpret   the  
recordings.  
  
4.2.2     Standard  Curve  
A   standard   concentration   curve   was   created   at   the   beginning   of   each  
experimental  session.  5-­‐‑HT  HCl  was  dissolved  and  and  diluted  in  1x  PBS  (pH  7.2)  to  
decrease   oxidation   (Chen   et   al.,   1999).   A   linear   regression  was   calculated   using   the  
increase  in  current  (nA)  at  each  5-­‐‑HT  concentration  (0.125,  0.25,  0.5,  0.75,  1.0  and  1.25  
µμM).  These  5-­‐‑HT  concentrations  were  chosen  because   the  current   literature  suggests  
they  are   the  most  reliable   to  use  when  measuring  SERT  function  (Hagan  et  al.,  2010;  
2011a;   2012;   Holley,   unpublished   data;   Simonson,   unpublished   data).   Specifically,  
Hagen   et   al.   (2010)   highlight   that   concentrations   above   1.0   µμM   cause   5-­‐‑HT   to  
spontaneously   oxidise  without   the   addition   of   a   voltage   to   oxidise   it.   In   this   study,  
this  finding  was  also  seen  in  RDEV  experiments  as  the  linear  line  (see  Fig.  A3.1)  after  
1.0   µμM.   This   linear   line   reflects   spontaneous   oxidation   of   the   5-­‐‑HT   increase   rather  
than  a  linear  SERT  function  increase.  The  purpose  of  a  standard  curve  of  increasing  5-­‐‑
HT   concentration   allows   data   collected   from   the   experimental   cell   samples   to   be  
transformed  into  µμM,  based  on  the  measured  nA  values  and  their  corresponding  µμM    
value   from   the   standard   curve   as   established   by   other   protocols   (Chefer   and  
Shippenberg,  2002;  Chen  et  al.,  1999).  Each  5-­‐‑HT  HCl  solution  was  made  fresh  for  each  
71	  	  
experimental   session   and   used   within   2   hours   of   preparation   to   prevent   oxidation  
confounding  effects  (Meiergerd  and  Schenk,  1995).  
  
4.2.3     Cell  Preparation  
HEK-­‐‑293  cells  were  cultured  and  transiently  transfected  with  myc-­‐‑rKOPr  and  
eGFP-­‐‑hSERT   plasmids   (as   described   in   Chapter   2)   and   used   48   hours   after  
transfection  when  the  cells  were  70-­‐‑90%  confluent.  In  RDEV  optimisation  experiments  
100  mm  plastic  bottom  dishes  with  3.5  x  106  cells  in  7  mL  were  used  but  the  increase  in  
cell  incubation  time  with  D-­‐‑22  in  the  chamber  meant  that  fewer  cells  were  required  at  
any   one   time.   So   to  minimise   consumables   60  mm  plastic   bottom  dishes  were  used  
with  1.5  x  106  cells  in  3  mL  instead.  Additional  cells  were  seeded  in  parallel  for  each  
transfection   onto   a   glass   bottom   plate   to   allow   the   percentage   of   transfection   to   be  
determined  by  eGFP-­‐‑hSERT  expression  using  confocal  microscopy.    
  
For   RDEV   cells   were   rinsed   twice  with   37˚C   saline   (138  mM  NaCl,   4.1  mM  
KCl,  5.0  mM  KH2PO4,  2%  w/v  D-­‐‑glucose,  pH  7.3)  (Appendix  1)  and  then  harvested  by  
mechanical   agitation   with   37˚C   KREBS   buffer   saturated   with   5%   CO2/95%   O2.   Cell  
suspensions  were  then  centrifuged  at  300  g  for  5  min,  re-­‐‑suspended  in  1  mL  of  37˚C  
KREBS  buffer  saturated  with  5%  CO2/95%  O2,  and  stored  in  an  incubator  at  37˚C  until  
needed  but  for  no  longer  than  30  min.    
  
For   5-­‐‑HT  cell  uptake  assays,   294  µμL  of   the   cell   suspension  was  added   to   the  
RDEV  chamber,  the  rotator  lowered  and  turned  on,  and  the  cells  were  incubated  until  
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a  constant  baseline  was  reached.  The  low  affinity  monoamine  transporter  inhibitor  D-­‐‑
22  (1.5  mM)  was  then  added  for  a  total  of  9  min  before  any  5-­‐‑HT  addition.  In  the  KOPr  
agonist   pre-­‐‑treatment   condition   KOPr   agonists   (500   nM)   were   incubated   for   5   min  
before  5-­‐‑HT  addition.  Control  experiments  were  carried  out  as  above  instead  either  a  
vehicle  (DMSO)  matched  solution  or  fluoxitene  (1.5  mM)  pre-­‐‑treatment  was  added  5  
min  before  5-­‐‑HT  addition.  After  each  experiment  the  a  live  count  was  determined  30  
sec  5-­‐‑HT  addition,  with  the  addition  of  0.4%  trypan  blue  and  manually  counted  on  a  
microscope  using  a  haemocytometer.    
  
4.2.4     Data  Analysis  
To   measure   the   initial   SERT   uptake   of   the   cells   30   seconds   of   uptake   data   was  
collected   after   the   addition   of   the   5-­‐‑HT   concentration.  Using  Microsoft  Office   Excel  
linear   regression  was   calculated   from   this   data.   Any   linear   regression  with   r2   <0.95  
was  not  used  because   this  suggested  SERT  function  was  not   representative  of   linear  
uptake   and   therefore,   not   comparable.   The   concentration   curve   plotted   before   each  
experiment  was  used  to  convert  the  measured  charge  in  nA  into  µμM/s,  and  this  value  
was   adjusted   or   normalised   to   the   number   of   alive   cells   counted.   The   final  
measurement  of  SERT  function  was  expressed  as  pmol/s/1x106  cells.  For  this  zero  trans  
model   the   values   were   then   entered   into   GraphPad   5   software,   and   a   Michaelis-­‐‑
Menten   curve   was   fitted.   The   Michaelis-­‐‑Menten   curve   was   used   because   the  
Lineweaver-­‐‑Burk   (LWB)   plot   was   widely   used   to   determine   important   terms   in  
enzyme   kinetics,   such   as   Vmax   and   Km,   before   the   wide   availability   of   powerful  
computers   and   non-­‐‑linear   regression   software.   Unfortunatly,   the   double   reciprocal  
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plot  (LWB)  distorts  the  error  structure  of  the  data,  and  it  is  therefore  unreliable  for  the  
determination   of   enzyme   kinetic   parameters   (Serap   et   al.,   2006).   Although   it   is   still  
used   for   representation   of   kinetic   data   (Serap   et   al.,   2006)   because   the   y-­‐‑intercept   is  
equivalent   to   the   inverse  of  Vmax,   and   the  x-­‐‑intercept  of   the  graph   represents   -­‐‑1/  Km.  
This  also  gives  a  quick,  visual  impression  of  the  different  forms  of  enzyme  inhibition,  
such   as   competitive   or   non-­‐‑competitive   (Lineweaver   and  Burk,   1934)   but   is   of   little  
use   when   simply   measuring   presise   kinetic   parameters   of   one   protein   with   no  
enzymatic  activity.  However,  non-­‐‑linear  regression  or  alternative   linear   forms  of   the  
Michaelis-­‐‑Menten   equation   are   generally   used   for   the   calculation   of   precise  
parameters,  such  as  Vmax  and  Km  (Greco  and  Hakala,  1979). The  Vmax  and  Km  of  each  
individual  sample  was  calculated  and  the  average  and  SEM  of   these  was  computed.  
Student’s   t-­‐‑tests  were  performed   for  each   treatment  group  on  Vmax  and  Km  values   to  
determine  whether  significant  differences  were  attained.  Significance  was  defined  as  
p<0.05 
4.3     Results    
RDEV   experiments   were   conducted   using   transiently   transfected   HEK-­‐‑293  
cells   that   co-­‐‑express   eGFP-­‐‑hSERT   and   myc-­‐‑rKOPr   in   HEK-­‐‑293   cells   shown   with   a  
Cy5-­‐‑myc-­‐‑rKOPr  antibody  (Simonson,  unpublished  data).  
  
4.3.1     Preliminary  Experimental  Procedure    
   Preliminary   experiments   highlight   the   need   for   the   low   affinity   5-­‐‑HT  
transporter,  D-­‐‑22,  for  experimental  samples  to  reach  kinetic  saturation  (Figure  4.2  and  
Table  4.1).   In  addition,  D-­‐‑22   incubation   time   increased   from  5  mins  as   suggested  by  
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(Hagan  et  al.,  2010)  to  9  min  because  this  is  when  saturation  was  seen  (Figure  4.3  and  
Table  4.2).    
  
  
Fig.   4.2.   The   effect   of   acute   (5   min)   KOPr   agonists   on   5-­‐‑HT   uptake   by   SERT   in  
transiently   transfected   HEK-­‐‑293   cells   in   the   absence   of   D-­‐‑22   preincubation.  
Transiently  transfected  cells  were  pre-­‐‑treated  with  the  classic  KOPr  agonists  U50  488H,  Sal  
A,  the  novel  KOPr  agonist  DS-­‐‑3-­‐‑240,  the  vehicle  (DMSO)  for  5  min,  in  the  absence  of  D-­‐‑22.  
A   total   of  9  min  D-­‐‑22  preincubation  was  also  used  as  a   comparison.  Data  points   shown  are  
average  ±  SEM  (n  =  8-­‐‑12).  
  
Table  4.1.  D-­‐‑22  inhibition.  
Treatment  
Vmax  (pmol/s/106  
cells)     Vmax  SEM   Km   Km  SEM  
D-­‐‑22   10.80   5.20   0.71   0.53  
U50   1.49  x  1023    ***   1.32  x  1013    ***   2.10  x  1022  ***       1.86  x  1012  ***    
Sal  A   2.21  x  1023    ***   1.86  x  1012    ***   3.33  x  1022  ***   3.49  x  1012  ***    
DS-­‐‑3-­‐‑240   1.81  x  1024    ***   2.92  x  1013    ***   2.18  x  1022  ***   3.52  x  1012  ***    
Fluoxitene     1.87  x  1026      ***   5.50  x  1016    ***   4.01  x  1025  ***   1.18  x  1016  ***  
DMSO   1.13  x  1025    ***   4.55  x  1014    ***   2.21  x  1024  ***   8.89  x  1013  ***    




Fig.   4.3.  The   effect  of  different  D-­‐‑22   incubation  periods  on  5-­‐‑HT  uptake  by  SERT   in  
transiently  transfected  HEK-­‐‑293  cells.  Transiently  transfected  cells  were  pre-­‐‑treated  D-­‐‑22  
for  5  min,  7  min  and  9  min.  Data  points  shown  are  average  ±  SEM  (n  =  4-­‐‑6).  
  
  
Table  4.2.  Uptake  kinetics  of  SERT  in  transiently  transfected  HEK-­‐‑293  cells  with  with  
different  D-­‐‑22  preincubation  increments.  
Treatment  
Vmax  (pmol/s/106  
cells)   Vmax  SEM   Km   Km  SEM  
D-­‐‑22  (5  min)   4.9  x  1024  ***   2.29  x  1014  ***   1.2  x  1024  ***   5.56  x  1013  ***  
D-­‐‑22  (7  min)   524.3   108.2   108.8   21.45  
D-­‐‑22  (9  min)   14.58   0.77   2.48   0.27  
***p<0.001  compared  to  control  Vmax  and  Km  
  
  
4.3.2     Effect  of  Acute  KOPr  Agonist  on  SERT  Function  
   To   investigate   the   effect   of   KOPr   agonists   on   modulating   SERT   it   was  
necessary  to  incubate  cell  suspensions  with  the  low  affinity  transporter  inhibitor,  D-­‐‑22  
(1.5  mM),  for  4  min  to  block  any  low  affinity  transporters  endogenously  expressed  in  
HEK-­‐‑293   cells.   The   cell   suspension   was   then   incubated   with   a   test   KOPr   agonist  
compound  (500  nM)  for  5  min  before  5-­‐‑HT  addition  at  the  appropriate  concentration.  
Results  showed  (Figure  4.4  and  Table  4.3)  that  none  of  the  KOPr  agonists  investigated  

















had  an  acute  (5  min)  effect  on  SERT  function  when  compared  with  the  DMSO  vehicle  
matched  control.  These  results  was  statistically  analysed  using  a  Student  t-­‐‑test  and  the  
Vmax  values  were  U50,488H  (p<0.4665),  Sal  A  (p<0.3054),  and  DS-­‐‑3-­‐‑240   (p<0.1242)  and  
the   Km   values  were  U50,488H   (p<0.8525),   Sal   A   (p<0.7467),   and  DS-­‐‑3-­‐‑240   (p<0.1346).  
The   selective   5-­‐‑HT   reuptake   inhibitor,   fluoxitene,   significantly   decreased   SERT  
uptake,   Vmax,   (***p<0.001)   and   binding   affinity,   Km,   (***p<0.001).   This   finding   was  
confirmation   that   SERT   is   functional.   Thus,   we   can   conclusively   say   that   SERT   is  
functional  and  the  absense  of  an  observed  effect  by  KOPr  agonists  on  SERT  function  
cannot  be  because  of  a  dysfunctional  SERT  protein.  
  
Fig.   4.4.   The   effect   of   acute   (5  min)  KOPr  agonists   on  SERT   function   in   transiently  
transfected   HEK-­‐‑293   cells   in   with   9   min   D-­‐‑22   preincubation.   Transiently   transfected  
cells  were  preincubated  with  D-­‐‑22  (9  min)  and  then  pre-­‐‑treated  with  the  classic  KOPr  agonists  
U50,488H,  Sal  A,   the  novel  KOPr   agonist  DS-­‐‑3-­‐‑240,   or   the   vehicle   (DMSO)   for   4  min,   as  
well  as  the  fluoxitene  pre-­‐‑treatment  (5  min).  All  cells  were  pre-­‐‑incubated  with  D-­‐‑22  for  a  total  
of  9  min.  Data  points  shown  are  average  ±  SEM  (n  =  8-­‐‑12).  
  
  



























Table   4.3.   Uptake   kinetics   of   SERT   in   transiently   transfected   HEK-­‐‑293   cells   with  
acute  (5  min)  exposure  to  KOPr  agonists  and  a  total  of  9  min  D-­‐‑22  preincubation.  
Treatment  
Vmax  (pmol/s/106  
cells)     Vmax  SEM   Km   Km  SEM  
D-­‐‑22   14.47   1.89   0.81   0.21  
D-­‐‑22  +  U50   24.14   12.33   2.068   1.526  
D-­‐‑22  +  Sal  A   27.12   17.14   2.318   2.051  
D-­‐‑22  +  DS-­‐‑3-­‐‑240   18.71   7.285   1.131   0.7504  
D-­‐‑22  +  DMSO   15.85   2.875   0.8143   0.2942  
D-­‐‑22  +  
Fluoxitene     5.45  x  1035  ***   1.09  x  1024  ***   8.52  x  1034  ***   1.71  x  1023  ***  
***p<0.001  compared  to  control  Vmax  and  Km  
  
The   control   samples,   D-­‐‑22   and   the   DMSO   vehicle   matched   control,   show   a  
significant  difference  between  the  two  (Figure  4.5  and  Table  4.4),  Vmax  (***p<0.001)  and  
Km   (***p<0.001).   This   confirms   that   D-­‐‑22   has   the   ability   to   block   other   5-­‐‑HT   uptake  
transporters   in   these  HEK-­‐‑293   cells.  The   inhibition  of   low  affinity  5-­‐‑HT   transporters  
means  only  5-­‐‑HT  is  taken  up  by  SERT  at  a  rate  that  fits  the  Michaelis-­‐‑Menten  enzyme  
kinetics,   up   to   1.25  µM  where   saturation   is   observed   (Figure   4.5).   The   5-­‐‑HT  uptake  
saturation  provides  a  Vmax  and  Km.  The  linear  line  of  the  DMSO  vehicle  control  reflects  





Fig.   4.5   The   effect   of   9  min  D-­‐‑22   preincubation   versus  DMSO  matched   controls   on  
SERT   function   in   HEK-­‐‑293   cells.   Transiently   transfected   cells   were   either   pre-­‐‑incubated  
with  D-­‐‑22  or  the  vehicle  (DMSO)  for  9  min.  Data  points  shown  are  average  ±  SEM  (n  =  8-­‐‑
12).  
  
Table   4.4.   Uptake   kinetics   of   SERT   in   HEK-­‐‑293   cells   in   9   min   D-­‐‑22   preincubation  
versus  DMSO  matched  controls.  
Treatment  
Vmax  (pmol/s/106  
cells)   Vmax  SEM   Km   Km  SEM  
D-­‐‑22   14.47   1.89   0.81   0.21  
DMSO     3.91  x  1032  ***   7.76  x  1023  ***   4.32  x  1031  ***   8.57  x  1022  ***  
***p<0.001  compared  to  control  Vmax  and  Km  
Simultaneous   inhibition  of  both  SERT  with   the  SSRI,   fluoxitene,  and   the   low  
affinity  SERT  transporters,  by  D-­‐‑22,  resulted  in  a  much  higher  Vmax  (***p<0.001)  and  Km  
(***p<0.001)  than  with  just  D-­‐‑22  or  fluoxitene  alone  (Figure  4.6  and  Table  4.5).  Again,  
when   the  D-­‐‑22   alone   or  D-­‐‑22   +  DMSO   condition   values   are   compared  with  DMSO,  
DMSO   (D-­‐‑22)   +   DMSO   (Fluox),   D-­‐‑22   +   Fluox,   or   Fluox   condition   values   the   Vmax  
(***p<0.001)  and  Km  (***p<0.001)  are  significantly  different.  Again,   this  highlights   the  






























Fig.  4.6.  The  effect  of  matched  controls  on  SERT  function  in  transiently  transfected  
HEK-­‐‑293  cells.  Transiently  transfected  cells  were  pre-­‐‑incubated  with  either  D-­‐‑22  (9  min),  the  
matched  vehicle  (DMSO)  control  or  fluoxitene  for  5  min.  All  cells  were  treated  with  their  
control  for  the  respective  time  and  cells  from  all  the  groups  were  in  the  chamber  for  a  total  of  9  
min  before  5-­‐‑HT  was  added.  Data  points  shown  are  average  ±  SEM  (n  =  8-­‐‑12).  
  
Table  4.5.  Uptake  kinetics  of  SERT  in  transiently  transfected  HEK-­‐‑293  cells  in  D-­‐‑22  (9  





Vmax  SEM   Km   Km  SEM  
D-­‐‑22   14.47   1.89   0.81   0.21  
DMSO     3.91  x  1032  ***   7.76  x  1023  ***   4.32  x  1031  ***   8.57  x  1022  ***  
D-­‐‑22  +  Fluoxitene   5.45  x  1035  ***   1.09  x  1024  ***   8.52  x  1024  ***  
1.71  x  1022  
***  
D-­‐‑22  +  DMSO     15.85   2.875   0.8143   0.2942  
DMSO  (D-­‐‑22)  +  
DMSO  (Fluox)  
3.36  x  1026***   2.93  x  1016  ***   3.76  x  1025  ***   3.28  x  10
15  
***  
Fluoxitene   2.44  x  1029  ***   1.09  x  1024  ***   1.09  x  1028  ***   4.56  x  10
23  
***    
***p<0.001  compared  to  control  Vmax  and  Km  
  





























4.4     Discussion  
   The  aim  of  this  chapter  was  to  use  RDEV  to  measure  5-­‐‑HT  transporter  uptake  
(Vmax)  and  binding  affinity  (Km)  in  HEK-­‐‑293  cells  co-­‐‑expressing  eGFP-­‐‑hSERT  and  myc-­‐‑
rKOPr  to  determine  if  KOPr  activation  modulates  SERT  function.    
  
4.4.1     Preliminary  Experimental  Procedure    
   The   initial   experimental   results   illustrate   that   it   is   impossible   to  obtain  SERT  
transporter   saturation  without   the  presence  of   the   low  affinity   transporter   inhibitor,  
D-­‐‑22  (1.5  mM;  Figure  4.2  and  Table  4.1).  Also,  it  was  found  that  in  this  overexpressing  
cell  model  the  incubation  time  of  D-­‐‑22  needs  to  be  increased  from  5  min,  as  suggested  
by  Hagan  et  al.  (2010;  2011),  to  9  min  because  this  is  when  SERT  saturation  occurs  and  
thus,   this   is  when   the   low   affinity   transporters   are   completely   inhibited   (Figure   4.3  
and  Table  4.2).  This  increase  in  D-­‐‑22  incubation  time  suggests  that  HEK-­‐‑293  cells  have  
more   low  affinity   transporters  present   than   in   the  rat  synaptosome  model   (Hagan  et  
al.,  2010).  The  D-­‐‑22  concentration  (1.5  mM)  was  not  adjusted  because  it  was  desired  to  
have   compable   results   with  Hagen   et   al.   (2011)   because   no   other   RDEV  model   has  
used  D-­‐‑22,   let   alone   a   cell  model,   and   adjusting   the   concentration  would   add  more  
variables  to  compare  in  the  results.  
  
4.4.2     Effect  of  KOPr  Agonists  on  SERT  Function  
In  this  HEK-­‐‑293  cell  model  co-­‐‑expressing  myc-­‐‑rKOPr  and  eGFP-­‐‑tagged  SERT,  
we   found   none   of   the   KOPr   compounds   tested   had   a   modulatory   effect   on   SERT  
function   as   measured   with   RDEV.   SERT   function   as   indicated   by   the   kinetic  
parameters,  Vmax   (transporter  uptake)   and  Km   (transporter  binding  affinity),  was  not  
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modulated  with  acute  (5  min)  KOPr  agonist  exposure  when  compared  to  the  DMSO  
matched  control,  Vmax  (U50,488H  (p<0.4665),  Sal  A  (p<0.3054),  and  DS-­‐‑3-­‐‑240  (p<0.1242))  
and   Km   (U50,488H   (p<0.8525),   Sal   A   (p<0.7467),   and   DS-­‐‑3-­‐‑240   (p<0.1346))   were   non-­‐‑
significant.  The  absense  of   a  KOPr  agonist  modulatory   effect  on  SERT   function  was  
reassured  to  be  correct  by  further  experiments  to  identify  that  SERT  was  functioning  
correctly.   SERT   function   was   investigated   with   the   preincubation   of   transiently  
transfected  HEK-­‐‑293  cells  with  the  SSRI,  fluoxitene  (1.5  mM),  for  5  min.  Results  show  
a  significant  decrease  in  SERT  Vmax  (***p<0.001)  and  Km  (***p<0.001)  with  a  fluoxitene  
(1.5   mM)   pre-­‐‑treatment   of   5   min   when   compared   to   the   vehicle   matched   control  
DMSO.  These  RDEV  findings  suggest   that   in   this  HEK-­‐‑293  cell  model  co-­‐‑expressing  
myc-­‐‑rKOPr  and  eGFP-­‐‑tagged  SERT  we  found  no  presence  of  an  acute  (5  min)  KOPr  
activation   effect   by   the   KOPr   agonists   (U50,488H,   Sal   A,   and   DS-­‐‑3-­‐‑240)   on   SERT  
function  as  indicated  by  the  RDEV  kinetic  parameters,  Vmax  and  Km.    
	  
These  findings  are  difficult  to  compare  and  contrast  with  the  current  literature  
because  research  into  the  effect  of  KOPr  agonists  on  SERT  function  in  HEK-­‐‑293  cells  
co-­‐‑expressing  myc-­‐‑rKOPr  and  eGFP-­‐‑tagged  SERT   inhibited  with  D-­‐‑22  by  RDEV  has  
never   been   published.   In   addition,   an   incubation   time   of   5   min   has   never   been  
investigated   by   our   laboratory   either.   However,   the   results   found   here  with   RDEV  
was  replicated  by  confocal  microscopy  (see  Chapter  3).  Interestingly,  previous  studies  
from   our   laboratory   by   Simonson   (unpublished   data)   suggest   a   difference   in   SERT  
function   in   HEK-­‐‑293   cell   model   co-­‐‑expressing   myc-­‐‑rKOPr   and   eGFP-­‐‑tagged   SERT  
(not   inhibited  by  D-­‐‑22)  when  incubated  with  the  KOPr  agonists  U50,488H  (500  nM),  
Sal  A   (500   nM)   (and  DS-­‐‑1-­‐‑216,   500   nM)   for   15  minutes.   Perhaps   the   discrepancy   in  
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SERT  function  reflects  experimental  differences  between  the  two  studies.  Differences  
such   as   incubation   time   5   min   vs.   15   min,   D-­‐‑22   present   vs.   no   D-­‐‑22,   HEK-­‐‑293   co-­‐‑
expressing  cells  vs.  rat  striatal   issue  a,  or  maximum  5-­‐‑HT  concentrations  for  enzyme  
kinetics,  1.25  µμM  vs  3  µμM.    	  
The  current  study  investigates  the  KOPr  agonist  pre-­‐‑treatment  time  of  5  min,  
whereas  Simonson  (unpublished  data)  investigated  a  pre-­‐‑treatment  of  time  of  15  min.  
Interestingly,   Simonson   also   did   not   find   a   SERT   decrease   by   the   KOPr   agonists  
U50,488H  (500  nM),  Sal  A  (500  nM)  and  DS-­‐‑1-­‐‑216  (500  nM)  at  the  time  intervals  of  4  or  
10  min,  but  there  was  a  decrease  at  15  min.  If  both  studies  are  factual  (irrespective  of  if  
Simonson   had   used   D-­‐‑22)   and   SERT   function   is   modified   by   KOPr   agonists  
somewhere  between  5  min  and  15  min  exposure  time  it  is  possible  this  is  due  to  either  
different   pathways   being   activated,   or   a   biphasic   activation   of   one   pathway.  These  
hypotheses   are   discussed   in   more   depth   in   chapter   6,   but   briefly   it   suggests   that  
Bruchas  and  Chavkin’s   (2010;   figure  1.3)  hypothesis  of  different  KOPr  pathways  are  
activated   depending   on   time,   and   thus   intensity.   This   means   that   one   pathway   is  
activated   at   5   min   (acute),   which   involves   ERK1/2   and   PKC,   the   other   at   15   min  
(chronic),  which   involves  ERK1/2  and  p38.  Another  explanation  for   the  difference   in  
results   found   between   5  min   and   15  min   pre-­‐‑treatment   could   be   because   the  main  
pathway  responsible  is  biphasic,  such  as  is  the  case  with  PKC.  It  is  also  possible  that  
both   of   these   explanations   are   correct   because   both   p38   and   PKC   are   known   to  
decrease  SERT  function  (Ramamoorthy  et  al.,  2011).    
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Another   interesting   variable   between   the   two   studies   investigating   KOPr  
function  on  SERT  function  measured  with  RDEV  is  that  Simonson  (unpublished  data)  
did   not   use   the   low   affinity   transporter   inhibitor,   D-­‐‑22.   This   is   important   to   note  
because   in   the   current   study   it   was   impossible   to   obtain   realistic   (if   any)   SERT  
transporter   function   enzyme   kinetic   data   without   D-­‐‑22   preincubation.   Hagen   et   al.  
(2010;   2011)   also   state   the   importance   of   using   a   low   affinity   transporter   inhibitor  
when  measuring   SERT   transporter   function.   Simonson   (unpublished)   also   failed   to  
show  any  decreases  of  SERT  function  by  KOPr  activation  at  4  min  and  10  min  and  it  is  
possible  that  thee  results  may  also  complement  the  current  study.  However,  because  
D-­‐‑22   was   not   used   in   the   comparison   study,   any   real   differences   between   the   two  
studies  should  be  made  with  caution.    
  
Different   preclinical   models   also   offer   another   another   explanation   for  
discrepancies  between  the  current  study  and  Simonson’s  (unpublished)  study.  In  the  
current   study   we   used   cultured   cells   and   Simonson   (unpublished)   used   4-­‐‑5   rat  
striatial  tissue  samples.  Or  perhaps  a  possible  reason  for  the  difference  is  simply  that  
the   cell   model   lacks   the   additional   endogenous   biochemical   pathways   that   are  
necessary  for  KOPr  activation  to  modulate  SERT  function.    
  
  Lastly,  it  has  been  suggested  that    the  use  of  5-­‐‑HT  concentrations  above  1  µμM  
are  too  high  for  use  in  RDEV  to  measure  SERT  function  (Hagan  et  al.,  2010).  Hagen  et  
al.  (2010)  state  that  5-­‐‑HT  is  unstable  at  concentrations  above  1  µμM  because  it  oxidises  
in   solution   so   rapidly,  which  makes  measuring   free   5-­‐‑HT  difficult   and   inconsistent.  
This  makes  5-­‐‑HT  oxidation  difficult   to  differentiate  between  an  modulation   in  SERT  
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function  or  just  the  oxidation  of  5-­‐‑HT  in  solution  because  of  high  5-­‐‑HT  concentrations.  
In   this   study,   it   was   found   that   a   maximum   5-­‐‑HT   concentration   of   1.25   µμM   was  
necessary  to  saturate  SERT  because  1  µμM  did  not  show  kinetic  saturation  as  measured  
by  the  kinetic  parameters  Vmax  and  Km.  A  5-­‐‑HT  concentration  higher  than  1.25  µμM,  in  
the   optimisation   experiments,   resulted   in   the   SERT   function   saturation   increasing  
again   and   produce   the   same   linear   increase   of   5-­‐‑HT   uptake   that   is   illustrated   by  
Hagan   et   al.   (2010;   Appendix   3).   This   was   suggested   by   Hagan   et   al.,   (2010)   to   be  
indicative  of  5-­‐‑HT  oxidation,  rather  than  uptake  and  this  explanation  is  accepted  here  
as  a  possible  reason  into  why  Simonson’s  data  (unpublished  data)  differed  from  our  
finding.  Collectively,  It  would  have  been  interesting  to  have  investigated  the  effect  of  
a  KOPr  agonist  preincubation  time  of  15  min  to  definitively  justify  these  explanations  
for  result  differences.    
  
However,  these  findings  and  possible  suggestions  should  be  interpreted  with  
caution  because  this  experiment  is  one  cell  model  of  many  possible  preclinical  models.  
Thus,  it  would  be  interesting  to  further  investigate  additional  cellular  models,  such  as  
primary   cell   cultures,   which   endogenously   express   other   neurotransmitter   systems  
that  may   act   in   a   synergistic  manner   to   facilitate   the   KOPr   and   SERT   relationship.  
Animal  models  and  different  brain   regions  would  also  be  very   interesting   to  add   to  
this  literature.  Finally,  additional  studies  by  RDEV  will  also  help  to  further  elucidate  






Chapter   5:   Developing   a   Potential   High-­‐‑Throughput  
Screening  Protocol  to  Elucidate  the  Effect  of  Chronic  (30  
min)   KOPr   Agonist   Exposure   on   Modifying   SERT  
Function    
  
5.1     Introduction    
   Neurotransmitter   transporters,   such   as   SERT,   DAT   and   NET,   represent  
established   pharmaceutical   targets   because   they   play   an   essential   role   in   regulating  
monoamines   that   play   a   role   in   many   neurological   diseases   and   disorders.  
Specifically,   SERT   has   been   implicated   in   the   role   of   brain   development,   neural  
plasticity,   synaptogenesis,   cell   proliferation,   and   emotional   disorders   such   as  
depression  (Owens  and  Nemeroff,  1994),  anxiety  (Suranyi-­‐‑Cadotte  et  al.,  1990),  bipolar  
disorder   (Bellivier   et   al.,   1997)   and   addiction   to   psychostimulants   (Baumann   and  
Rothman,   1998;   Heinz   et   al.,   2001).   Thus,   the   ability   to   monitor   neurotransmitter  
uptake  is  key  to  a  better  understanding  of  these  diseases.    
  
   Currently,   researchers   remain   relatively   limited  with   transporter   assays   that  
provide   cost   effective,   rapid   and   reliable   data.  An   assay  with   these   qualities  would  
allow   for   high-­‐‑throughput   screening   for   potential   SERT   modifying   compounds,  
particularly   those   that   modulate   mood,   stress,   learning   and   memory.   Recent  
introduction   of   novel   transporter   assay   kits   provide   researchers   with   the   tools   to  
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screen   live-­‐‑cell   kinetic   uptake   for   key   neurotransmitters   in   a   homogeneous,  
fluorescence-­‐‑based,  and  high-­‐‑throughput  format.  This  means  that  temporally  limited  
techniques,   such   as   radioactive   labeled   compounds,   are   being   replaced  with   kinetic  
assays   suitable   for   mechanistic   studies,   or   as   a   high   throughput   screening   with  
readable  endpoints.  This  is  possible  because  these  neurotransmitter  transporter  assay  
kits  use   fluorescent   substrates   that  mimic   the  biogenic   amine  neurotransmitters   and  
when   taken   into   the   cell   through   the   transporter   it   results   in   an   increase   of  
intracellular  fluorescence  intensity  that  can  be  monitored  in  real-­‐‑time  using  a  bottom-­‐‑
reading  microplate  reader.  In  this  convenient  procedure,  cells  can  be  incubated  with  a  
compound   of   interest   and   transferred   into   the   plate   reader   for   evaluation   with   a  
fluorescent  reagent.    
  
   A   high-­‐‑throughput   screening   assay   to   identify   SERT   modifying   compounds,  
such   as   this,   requires   a   uniform   cell   population   for   consistent   replication   across  
relatively   similar   samples.   The   development   of   stable   cell   lines   can   be   a   difficult  
procedure   to  perform  given   that   there  are   so  many  potential  variables.  This  process  
requires   transfection   with   the   transporter   plasmid   of   interest   and   then   growth   in  
media  substituted  with  an  antibiotic  to  render  any  cell  with  the  plasmid  immune  from  
the  appropriate  antibiotic  (Schwartz  et  al.,  2005).  Immune  cells  are  assumed  to  contain  
the  plasmid  of  interest,  then  they  are  isolated  to  a  single  cell  in  the  hope  that  this  cell  
will  divide  to  produce  an  identical  population.  This  constant  population  is  the  sample  
population   to  screen   the  potential  SERT  modifying  compounds,  as   is  presumed   that  
each   cell   has   similar   SERT   cell   surface   expression.   The   development   of   a   high-­‐‑
throughput  assay  to  monitor  SERT  function  is  required  for  the  prompt  development  
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of  SERT  modifying  pharmacotherapeutics.  
  
5.1.1     Aims  
The   aim   of   this   chapter   is   to   develop   a   high-­‐‑throughput   screening   assay   to  
investigate  the  effects  of  chronic  (30  min)  KOPr  agonist  exposure  on  SERT  function  in  
HEK-­‐‑293  cells  transiently  expressing  myc-­‐‑rKOPr  and  eGFP-­‐‑tagged  hSERT.    
  
5.2     Methods  
5.2.1   Cell  Preparation  
To  investigate  the  chronic  (30  min)  effect  of  KOPr  agonists  on  SERT  function,  
HEK-­‐‑293  cells  were  cultured  and  transiently  transfected  with  myc-­‐‑rKOPr  and  eGFP-­‐‑
hSERT  plasmids  as  described  in  the  general  methods  section  (Chapter  2)  and  used  48  
hours   after   transfection   when   the   cells   were   70-­‐‑90%   confluent.   Preliminary  
experiments  required  cells  to  be  plated  onto  100  mm  plastic  bottom  dishes  with  3.5  x  
106   cells   in   7   mL,   but   for   the   final   experimental   procedure,   60   mm   plastic   bottom  
dishes  were  used  instead  with  1.5  x  106  cells  in  3  mL.  
    
5.2.2       Experimental  Procedure    
Cells  were  rinsed  twice  with  37˚C  saline  (138  mM  NaCl,  4.1  mM  KCl,  5.0  mM  
KH2PO4,  2%  w/v  D-­‐‑glucose,  pH  7.3)  (Appendix  1)  and  then  harvested  by  mechanical  
agitation  with  37˚C  KREBS  buffer  saturated  with  5%  CO2/95%  O2.  The  cell  suspension  
cell  count  was  then  determined  with  the  addition  of  0.4%  trypan  blue  and  manually  
counted   using   a   haemocytometer.   Cells   were   subsequently   diluted   to   the   required  
concentration,  2  x  105  cells/mL,  with  37˚C  5%  CO2/95%  O2  saturated  KREBS  buffer.  200  
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µμL  of  this  cell  solution  was  placed  into  each  well  of  a  96-­‐‑well  plate  (Invitrogen)  using  
a  multipipettor  with   10   µμM  of   the  KOPr   agonist   pre-­‐‑treatment   and   loaded   into   the  
plate   reader   at   37˚C.   After   30  min,   ASP+   (3   µμM)  was   added   and   re-­‐‑loaded   into   the  
plate  reader  and  fluorescence  was  read  after  5  min.  Control  experiments  were  carried  
out  using  a  vehicle  (DMSO)  matched  solution,  fluoxitene  (1.5  mM)  pre-­‐‑treatment  and  
cells   transiently   transfected   with   myc-­‐‑rKOPr   and   eYFP-­‐‑hDAT   plasmids.   Non-­‐‑
expressing  HEK-­‐‑293  cells  served  as  a  negative  control  to  determine  non-­‐‑specific  ASP+  
uptake  by  non-­‐‑SERT  mediated  mechanisms.  Each  condition,  along  side   the  negative  
controls,  was  measured  on  at  least  2  plates  across  at  least  3  separate  transfections.    
  
Table  5.1.  eYFP-­‐‑hDAT  Plasmid  information  
Gene     Vector     Resistance     Provided  by    
eYFP-­‐‑hDAT     pciHyg     Ampicillin  (100  
µμg/mL)    
J.  Javitch  (Scholze  
et  al.,  2000)  
  
5.2.3     Establishing  a  Stable  Cell  Line  Expressing  eGFP-­‐‑tagged  hSERT  
   HEK-­‐‑293   cells   were   cultured   and   transfected   as   described   in   the   general  
methods   section   (Chapter   2),   however   these   cells   were   transfected   with   1.0   µl/mL  
eGFP-­‐‑   hSERT   plasmid   and   then   grown   in   PS   free   DMEM   media   substituted   with  
Geneticin  (G418)  antibiotic  as  in  (Schwartz  et  al.,  2005).  Transfected  cells  were  selected  
at   400   µμg/mL   G418   and   maintained   at   300   µμg/mL   so   only   transfected   cells   were  
grown.  The  reason  a  stable  cell  line  was  produced  but  not  used  in  any  of  the  previous  
experiments   is   because   this   stable   cell   line   was   developed   at   the   same   time   as   the  
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experiments  were  performed  in  the  previous  chapters.  More  time  would  be  necessary  
for  a  stable  transiently  transfected  cell  line  to  be  used  in  the  earlier  experiments.    
  
Those   that  survived   the  selection  process  were  subcultured   in  a  maintenance  
process   for  eight  weeks.   Individual  cell   lines  were  cloned  by   limiting  the  dilution  of  
cells.   Briefly,   selected   and   maintained   cells   were   diluted   to   a   concentration   of   2.5  
cells/mL   and   then  plated   out   in   a   96-­‐‑well   plate.   Immediately   following   cell   seeding  
each   well   was   visualised   under   a   fluorescent   microscope   to   find   each   well   with   a  
single   fluorescent   cell.   When   these   cells   became   70-­‐‑80%   confluent   they   were  
mechanically   removed   and  placed   into   a   24-­‐‑well   plate   and   the   growth   process  was  
continued.  This  process  was  repeated  into  a  12-­‐‑well  plate  and  then  into  a  6-­‐‑well  plate.  
Cells  were  then  grown  in  a  small  30  cm2  flask  and  then  a  75cm2  flask.  At  each  passage  
step   cells   were   visualised   for   eGFP   expression   using   the   confocal   microscope   to  
ensure   they   still   contained   the   eGFP-­‐‑   hSERT   plasmid.   Cell   lines   that   had   even   cell  
surface  expression  in  90%  or  more  of  the  cells  were  deemed  acceptable  and  allowed  to  
continue  growth.  When   cells   became  70-­‐‑90%  confluent   in   the   75cm2   flask   they  were  
passaged  and  frozen  as  in  the  general  methods  section  for  future  use.    
  
5.2.4     Data  Analysis  for  Chronic  ASP+  Uptake  Studies    
  Data  was  exported  from  the  plate  reader  to  analyse.  Values  were  entered  onto  
an   Excel   spreadsheet   and   the   average   AFU  was   calculated   for   each   condition.   The  
average   for   each   condition   was   then   normalised   to   the   average   of   the   vehicle  
condition   (ASP+   +   Cells   +   Vehicle)   and   expressed   as   a   percentage   of   change.   This  
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percentage  of  change  was  then  entered  into  GraphPad  Prism  and  a  repeated  measures  
ANOVA  followed  by  a  Tukeys  post  test  was  performed.    
     
5.3     Results  
5.3.1     Fluorescence-­‐‑Based  SERT  Activity  Measurement    
Fluorescence   is   when   light   is   absorbed   at   one   wavelength   and   emitted   at   a  
different,   and   longer,   wavelength   and   thus,   it   was   necessary   to   use   fluorescence  
spectroscopy   to  optimise   the  excitation  and  emission  wavelengths  of  ASP+   to  ensure  
that  only  ASP+  uptake  was  being  measured  by  the  the  96-­‐‑well  plate  reader  (EnSpire®  
Multimode   Plate   Readerm   2300-­‐‑001M,   PerkinElmer,   USA).   It   was   found   that   ASP+  
was  excited  at  447  nm  and  emitted  at  600  nm  by  plate  reader.  In  order  to  validate  the  
novel   fluorescence-­‐‑based   SERT   assay   a   series   of   preliminary   experiments   using   the  
plate  reader  were  performed.  The  plate  reader  can  read  a  96-­‐‑well  plate  simultaneously  
across   a   time  period.   This   allows   for   fluorescence   over   time   to   assess   the  uptake   of  
ASP+.   Figure   5.1   represents   the   change   in   fluorescence   for   eGFP-­‐‑hSERT   transfected  
HEK-­‐‑293   cells   versus   non-­‐‑transfected   HEK-­‐‑293   cells   for   a   total   of   30   min   at   60   s  
intervals  as  inducated  by  ∆RFU  (relative  fluorescent  units).  From  this  graph  is  can  be  
observed   that   eGFP-­‐‑hSERT   transfected   HEK-­‐‑293   cells   uptake   ASP+   at   a   rate   that   is  
significantly   different   (**p<0.01)   from   the   control  matched   conditions   of   no   cells,   no  
ASP+,   and   fluoxitene   (1.5   mM)   pretreated.   This   is   indicative   that   eGFP-­‐‑hSERT   is  
working  as  it  should  in  this  experiment  and  that  the  ASP+  fluorescent  wavelengths  are  
correct   as   only   ASP+   uptake   is   being   measured.   Although   parental   HEK-­‐‑293   cells  
display   some   ASP+   uptake   the   transfected   cells   have   a   significantly   higher  
accumulation   of   ASP+,   demonstrating   that  ASP+   uptake   is   highly   specific   over   time  
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compared   to   non-­‐‑transfected   cells,   yet,   ASP+   is   taken   up   by   non-­‐‑SERT   mediated  
mechanisms.  Also,   the  substrate  uptake  appears   to  be  at  a   linear  rate  constant   for  at  
least  30  min.  
  
  
Fig.  5.1.  Time  dependent  uptake  of  ASP+  fluorescence  in  transiently  transfected  HEK-­‐‑
293  cells  versus  controls.  eGFP-­‐‑hSERT  and  myc-­‐‑rKOPr  co-­‐‑expressing  cells  uptake  ASP+  at  
a  linear  rate  for  a  total  of  30  min  at  60  s  intervals  that  is  significantly  different  (***p<0.001)  
from  the  controls.  Monoamine  transporter  activity  (i.e  uptake  of  the  fluorescent  substrate)  is  
depicted  as  relative  fluorescence  unit  changes  (∆RFU).  Data  points  are  presented  as  mean  ±  
SEM.  
  
5.3.2     Uptake  Inhibition  by  Re-­‐‑uptake  Inhibitors  
   To   further   investigate   the  use  of  ASP+  as  a   fluorescent   substrate   in   this  high-­‐‑
thoroughput  assay,  preliminary  experiments  were  performed  to  ensure  SERT  function  
was   being   measured.   To   determine   this   uptake   was   inhibited   by   the   re-­‐‑uptake  
inhibitor,   fluoxitene.   As   seen   in   Figure   5.2   it   was   illustrated   that   fluoxitene  
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5.3.3     Effect  of  Chronic  (30  min)  KOPr  Agonist  on  SERT  Function    
In  addition  to  other  preliminary  experiments,  a  transiently  transfected  positive  
control   was   also   performed.   Chronic   (30   min)   KOPr   agonist   experiments   were  
conducted  in  transiently  transfected  HEK-­‐‑293  cells  that  have  previously  shown  to  co-­‐‑
express   eGFP-­‐‑hSERT   and   myc-­‐‑rKOPr   in   HEK-­‐‑293   cells   using   a   Cy5-­‐‑myc-­‐‑rKOPr  
antibody  (Simonson,  unpublished  data).  
  
  
Fig.  5.2.  Percentage  changes  of  ASP+  uptake  by  eGFP-­‐‑hSERT  after  chronic  (30  
mins)  KOPr  agonist  exposure  (10  µμM),  DMSO  and  fluoxitene  pre-­‐‑treatment  (5  
min).  There  is  a  significant  difference  in  percentage  change  of  ASP+  uptake  between  the  
DMSO  and  U50,488H  (***p<0.001)  but  not  between  DMSO  and  Sal  A  (***p<0.001).  
Fluoxitene  was  statistically  different  from  vehicle  (***p<0.001)  and  from  U50,488H  (**p<0.01)  
but  not  from  Sal  A  (p<0.743).  As  shown  by  a  repeated  measured  ANOVA  followed  with  a  







































Fig.  5.3.  Percentage  changes  of  ASP+  uptake  by  eYFP-­‐‑hDAT  after  chronic  (30  
mins)  KOPr  agonist  exposure  (3  µμM),  and  DMSO.  There  is  a  significant  difference  in  
percentage  change  of  ASP+  uptake  (3  µμM)  between  the  DMSO  and  U50,488H  (***p<0.001)  as  
well  as  between  DMSO  and  Sal  A  (***p<0.001).  As  shown  by  a  repeated  measured  ANOVA  
followed  with  a  Tukey  post  test.  
  
5.3.4     Establishing  a  Stable  Cell  Line  Expressing  eGFP-­‐‑tagged  hSERT     
The   procedure   was   repeated   twice,   in   the   first   attempt   no   cells   had   eGFP-­‐‑
hSERT   expression.   In   the   second   attempt   two   subcultures   expressed   eGFP-­‐‑hSERT.  
These   were   visualised   under   the   confocal   microscope   and   are   referred   to   as   ‘high  
eGFP-­‐‑hSERT  concentration’  (Figure  5.4)  and  ‘low  eGFP-­‐‑hSERT  concentration’  (Figure  
5.5).  This   cell   line  was   frozen,  unfrozen  and   then  grown   to  assess   the   integrity  each  
week  for  a  total  of  5  weeks  and  illustrated  acceptable  consistent  integrity  (Figure  5.6)  
































Fig.   5.4.   Stable   SERT   HEK-­‐‑293   cell   line   with   high   eGFP-­‐‑hSERT   expression   viewed  
using   confocal  microscopy.  Different   views   after   selection   and  8  weeks   of  maintenance   in  






Fig.   5.5.   Stable   SERT   HEK-­‐‑293   cell   line   with   low   eGFP-­‐‑hSERT   expression   viewed  
using   confocal  microscopy.  Different   views   after   selection   and  8  weeks   of  maintenance   in  
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Fig.   5.6.   5  weeks   of   growth   of   the   stable   SERT  HEK-­‐‑293   cell   line  with   high   eGFP-­‐‑
hSERT   expression   viewed   using   confocal   microscopy.     After   freezing,   unfreezing   and  
growing  for  a  total  of  6  weeks.  (A)  at  week  1,  (B)  at  week  2,  (C)  at  week  3,  (D)  at  week  4,  and  







5.4     Discussion    
The  aim  in  this  chapter  was  to  develop  a  high-­‐‑throughput  screening  assay  to  
investigate  the  effects  of  chronic  (30  min)  KOPr  agonist  exposure  on  modulating  SERT  
function  in  HEK-­‐‑293  cells  transiently  expressing  myc-­‐‑rKOPr  and  eGFP-­‐‑tagged  hSERT.  
It   was   found   that   chronic   (30   min)   KOPr   activation   can   directly   modulate   SERT  
function   using   this   cell  model   and  novel   technique.   This   novel   protocol   provided   a  
readily   avaliable   screening   tool   for   potential   SERT  modifying   compounds.  A   stable  
SERT   cell   line   was   also   developed   to   facilitate   further   screening   of   SERT  modifing  
componds  using  a  uniform  cell  population.  
  
5.4.1     Effect  of  Chronic  (30  min)  KOPr  Agonist  on  SERT  Function  
Preliminary   experiments   provided   excitation   and   emission   wavelengths   to  
provide   data   only   indicitive   of   ASP+   uptake   as   measured   by   arbituary   fluorescent  
units   (AFU).   This   ASP+   fluorescence   reflects   SERT   uptake,   so   any   changes   in   ASP+  
uptake   (Figure  5.2)  suggest  SERT  function  differences.  These   findings  reveal  chronic  
(30   min)   exposure   to   the   KOPr   agonists,   U50,488H   (10   µμM)   and   Sal   A   (10   µμM),  
significantly   decrease   SERT   function   (**p<0.01)   as   measured   by   ASP+   uptake   assay  
using  a  96-­‐‑well  plate  reader.  SERT  functional  integrity  was  confirmed  with  the  5  min  
exposure  to  the  SSRI,  fluoxitene  (**p<0.01)  to  produce  a  significant  reduction  in  SERT  
function.  In  addition,  it  was  found  in  HEK-­‐‑293  cells  transiently  expressing  myc-­‐‑rKOPr  
and  eYFP-­‐‑tagged  hDAT  with  chronic  (30  min)  exposure  of  U50,488H  (10  µμM)  and  Sal  
A   (10   µμM)   significantly   increased   DAT   function   (**p<0.01).   DAT   function   increases  
have  been  illustrated  before  by  our  laboratory  (Simonson,  unpublished  data)  when  it  
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was  illustrated  that  DAT  function  increases  by  5%  for  U50,488H  (1  µμM),  3%  for  Sal  A  
(1   µμM),   12%   for   U50,488H   (5   µμM),   and   20%   for   Sal   A   (5   µμM)   as   well   as   20%   for  
U50,488H   (10   µμM)   and   45%   for   Sal   A   (10   µμM).   Therefore,   based   on   Simonson’s  
(unpublished)  findings,  the  findings  in  the  current  study  that  DAT  function  increases  
by  9%   for  both  U50,488H   (3  µμM)  and  Sal  A   (3  µμM)  appears   to  be   in   line  with  other  
research.   Our   has   laboratory   also   illustrated   that   chronic   (30   min)   exposure   of  
U50,488H  (10  µμM)  decreased  SERT  function  by  about  7%  using  confocal  microscopy  
(Morani,  unpublished  data).  Because  the  DAT  findings  are  in  line  with  past  findings  
within  our   laboratory  and  because  SERT   is  performing   in   line  with  past   findings   in  
our   laboratory,   it   can   be   strongly   suggested   that   SERT   function   decreases  
significantly,   by   about   8%,   with   chronic   (30   min)   exposure   to   the   KOPr   agonists  
U50,488H   (10  µμM)   and   Sal  A   (10  µμM)   in  HEK-­‐‑293   cells   transiently   expressing  myc-­‐‑
rKOPr  and  eGFP-­‐‑tagged  hSERT  as  measured  with  a  96-­‐‑well  plate  reader.    
  
Our   findings   are   very   interesting   because   SERT   function  was  not  modulated   by  
acute  (5  min)  KOPr  agonist  exposure  but   it  was  significantly  decreased  with  chronic  
(30  min)  KOPr  agonist  exposure.  Unfortunately,  at  the  time  of  publishing  there  is  no  
published   literature,   other   than   from   our   laboratory,   investigating   the   effects   of  
chronic   (30   min)   KOPr   agonist   exposure   on   modulating   SERT   function   in  
immortalised   cells.   Therefore,   these   findings   are   difficult   to   compare   and   contrast  
with  the  current  literature.    
  
Interestingly,   previous   studies   from   our   laboratory   by  Morani   (unpublished  
data)  suggest  a  difference  in  SERT  function  in  HEK-­‐‑293  cell  model  co-­‐‑expressing  myc-­‐‑
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rKOPr   and   eGFP-­‐‑tagged   SERT   (not   inhibited   by   D-­‐‑22)   when   incubated   for   30   min  
with  the  KOPr  agonist  U50,488H  (10  µμM)  but  not  Sal  A  (10  µμM)  measured  by  confocal  
microscopy.   This   discrepancy   in   SERT   function   results   may   reflect   experimental  
differences   between   the   two   studies   or   the   difference   may   exhist   because   of  
experimentor   error.   Measuring   SERT   function   after   KOPr   agonist   exposure   in  
repeated  experiments  might  help  to  clarify  if  experimentor  error  is  the  reason.  	  
Another   interesting   variable   between   the   two   studies   investigating   KOPr  
function  on  SERT   function  measured  with  RDEV   is   that  Morani   (unpublished  data)  
did   not   use   the   low   affinity   transporter   inhibitor,   D-­‐‑22.   This   is   important   to   note  
because   studies  using  other  biological   techniques   (Hagen   et   al.,   2010;   2011)   insist  on  
the   importance   of   using   a   low   affinity   transporter   inhibitor   when  measuring   SERT  
transporter   function.   Because  D-­‐‑22  was   not   used   in   the   comparison   study,   any   real  
differences  between  the  two  studies  should  be  made  with  caution.  	  
Additionally,   the   discrepancy   between   acute   (5   min)   KOPr   exposure   and  
chronic   (30   min)   exposure   on   SERT   function   may   reflect   the   signal   transduction  
pathways  that  are  being  activated.  The  potential  pathways  are  discussed  further  in  the  
final   discussion   (chapter   6).   Further   experiments   need   to   investigate   different   time  
points  to  look  at  to  see  if  the  KOPr  agonist  concentration  increases  can  act  to  decrease  
SERT  function  and  if  the  time  points  have  an  effect  on  SERT  function.  This  could  help  
to  explain  signal  pathways  activation  over  time.  It  would  also  be  interesting  to  look  at  
different  KOPr  agonists  such  as  DS-­‐‑3-­‐‑240  and  U69,593  to  elucidate  if  SERT  functional  
changes  discrimate   against  different  KOPr   agonists.  Collectively,   the   above   findings  
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reveal  that  chronic  (30  min)  exposure  to  the  KOPr  agonists,  U50,488H  (10  µμM)  and  Sal  
A   (10   µμM),   significantly   decrease   SERT   function   (**p<0.01)   as   measured   by   ASP+  
uptake  assay  using  a  96-­‐‑well  plate  reader.  
  
5.4.2     Establishment  of  a  Stable  Cell  Line  Expressing  eGFP-­‐‑tagged  hSERT  
Here,  two  stable  cell  lines  expressing  eGFP-­‐‑tagged  hSERT,  the  high  expression,  
(Figure  5.4)  and  the  low  expression  (Figure  5.5)  were  developed.  The  high  expression  
cell   line  was   frozen,  unfrozen  and  grown   for  6  weeks   (Figure  5.6)   to   investigate   the  
integrity   of   this   cell   line   after   being   frozen   for   future   experimental   use.   The   cells  
appeared   to   grow   after   being   thawed   without   compromising   their   integrity.   These  
cells  were  intended  to  be  used  in  the  above  experiment  with  transfected  myc-­‐‑rKOPr,  
however,  due  to  time  constraints  co-­‐‑transfection  of  myc-­‐‑rKOPr  in  the  stable  SERT  cell  
line  was  not  performed.   In   addition,   it  was   also   anticipated   that   the   findings   above  
could   be   confirmed   using   confocal   microscopy,   however   time   constraints   also  
prevented   this   from   occuring.   Together   this   chapter   illustrates   that   SERT   is  
functioning   correctly,   and   that   this   novel   highthrough   put      assay   has   the   ability   to  
show  5-­‐‑HT  transporter  changes  with  pharmacologcal  agents.  
  
The  finding  that  chronic  (30  min)  KOPr  activation  modifies  SERT  would  be  of  
particular   interest   as   a   pharmaceutical   target   given   its   intrinsic   role   in   addiction,  
mood  and   stress.  Any   future   research   in   our   laboratory   investigating   the   SERT  and  
KOPr   relationship  would   be   far  more   economically   feasible   now  because   this   SERT  
stable   cell   line   could   be   transfected   with   just   the   myc-­‐‑rKOPr   plasmid,   minimizing  
101	  	  
expensive  consumables.  Initially,  this  would  require  co-­‐‑localisation  of  KOPr  but  using  
a  more  uniform  SERT  expressing  population  would  produce  more  consistent  results  
across  different  experimental  procedures.  This  SERT  function  (uptake)  assay  provides  
a  fast,  simple,  and  reliable  fluorescence-­‐‑based  assay  for  the  detection  of  SERT  activity  















Chapter  6:  General  Discussion    
SERT   is   an   important   protein   essential   for   normal   brain   function   and   SERT  
dysfunction   is  heavily   involved  in   the  etiology  of  brain  disorders.  Specifically,  SERT  
dysfunction  occurs  because  of  environmental  stressors,  such  as  drugs  of  abuse  or  life  
adversity.  Environmental  stressors  can  modify  the  SERT  gene,  such  as  the  5-­‐‑HTTLPR,  
and   the   SERT   protein   through   epigenetic   modifications.   These   modifications  
contribute  to  the  aetiology  of  SERT  related  brain  diseases  and  disorders  such  as  drug  
addiction,   affective   disorders,   stress   homeostasis   and   pain.   Many   of   these   SERT  
related   diseases   and   disorders   are   also   correlated   with   KOPr   dysfunction.   This  
overlap   of   SERT   and   KOPr   diseases   and   disorders   suggests   that   SERT   and   KOPr  
pathways   are   similar   and/or   they   overlap,   which   indicates   some   sort   of   direct   or  
indirect   relationship.  Recently,   the   co-­‐‑localisation  of  both  KOPr  and  SERT   in   the   rat  
DRN   (Land   et   al.,   2009)   highlights   that   there   is   a   relationship   between   these   two  
proteins.  
  
The   KOPr   and   SERT   relationship  was   first   proposed   by   Schenk   et   al.   (2000)  
when   it   was   observed   that   the   DAT   inhibitor,   RTI-­‐‑55,   produces   cocaine-­‐‑seeking   in  
rats,  which  was  subsequently  attenuated  with   the   traditional  KOPr  agonist  U69,593.  
In  other  words,  when  the  DAT  inhibitor,  RTI-­‐‑55,  increases  DA  levels  cocaine-­‐‑seeking  
increases   in  rats   the  subsequent  administration  of  U69,593  shortly  after   reduced   this  
cocaine-­‐‑seeking   behaviour.   Schenk   et   al.   (2000)   suggest   this   inhibition   of   cocaine-­‐‑
seeking  by  U69,593  occurs  because  cocaine  and  κ-­‐‑opioids  interact  at  a  common  site  on  
the  SERT  protein.  Furthermore,  Ramamoorthy  et  al.  (2002)  consolidate  this  hypothesis  
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by   showing   that   U69,593   decreases   5-­‐‑HT   re-­‐‑uptake   by   SERT   in   rat   striatal  
synaptosomes.  Zakharova  et  al.  (2008)  also  indicate  KOPr  modulates  SERT  function  by  
illustrating  a  decrease  in  rat  KOPr  activity  when  SERT  levels  are  reduced.  In  line  with  
this   proposed   KOPr   and   SERT   relationship,   our   laboratory   show   KOPr   activation  
decreases  SERT  function  with  acute  (15  min)  exposure  to  U50,488H  (500  nM),  and  Sal  
A   (500  nM)  as  measured  with  RDEV  on   rat   striatum   tissue   (Simonson,  unpublished  
data)  and  with  chronic  (30  min)  exposure  to  U50,488H  (10  µμM)  in  co-­‐‑expressing  myc-­‐‑
rKOPr   and   eGFP-­‐‑hSERT   HEK-­‐‑293   cells   using   confocal   microscopy   (Morani,  
unpublished  data).  In  the  current  study  we  also  found  chronic  (30  min)  but  not  acute  
(5  min)   KOPr   activation   by  U50,488H   (10   µμM),   and   Sal   A   (10   µμM)   decreases   SERT  
function  as  measured  with  a  novel  high  throughput  assay.  
  
The  aim  of  this  current  study  is  to  investigate  the  effect  of  KOPr  activation  on  
SERT   function   in   HEK-­‐‑293   cells   co-­‐‑expressing   myc-­‐‑rKOPr   and   eGFP-­‐‑hSERT.   We  
found   that  acute   (5  min)  exposure  by   the  KOPr  agonist  U50,488H   (500  nM)  and   the  
novel  KOPr  agonists,  Sal  A  (500  nM),  and  DS-­‐‑3-­‐‑240  (500  nM)  had  no  effect  on  SERT  
function   in   transiently   transfected   (myc-­‐‑rKOPr   and   eGFP-­‐‑hSERT)   HEK-­‐‑293   cells   as  
measured  with  RDEV  as  well  as  measured  by  confocal  microscopy  (U50,488H,  10  µμM;  
Sal   A,   10   µμM;   &   DS-­‐‑3-­‐‑240,   10   µμM).   However,   it   was   found   that   chronic   (30   min)  
exposure   to   U50,488H   (10   µμM),      and   Sal   A   (10   µμM),   significantly   decreases   SERT  
function   in   transiently   transfected   (myc-­‐‑rKOPr   and   eGFP-­‐‑hSERT)   HEK-­‐‑293   cells  





Table  6.1:  Summary  of  KOPr  agonist  effects  on  SERT  function.  Acute  (5  min)  exposure  
to  the  KOPr  agonists  U50,488H  (500  nM)  and  the  novel  KOPr  agonists,  Sal  A  (500  nM),  and  
DS-­‐‑3-­‐‑240  (500  nM)  had  no  effect  on  SERT  function  in  transiently  transfected  (myc-­‐‑rKOPr  
and  eGFP-­‐‑hSERT)  HEK-­‐‑293  cells  as  measured  with  RDEV  as  well  as  measured  by  confocal  
microscopy  (U50,488H,  10  µμM;  Sal  A,  10  µμM;  &  DS-­‐‑3-­‐‑240,  10  µμM).  However,  KOPr  
activation  decreases  SERT  function  with  acute  (15  min)  exposure  to  U50,488H  (500  nM),  and  
Sal  A  (500  nM),  as  measured  with  RDEV  on  rat  striatum  tissue  (Simonson,  unpublished  
data),  as  well  as  chronic  (30  min)  exposure  to  U50,488H  (10  µμM)  in  co-­‐‑expressing  HEK-­‐‑293  
cells  using  confocal  microscopy  (Morani,  unpublished  data).  In  this  study  chronic  (30  min)  
exposure  to  U50,488H  (10  µμM),    and  Sal  A  (10  µμM)  significantly  decreases  SERT  function  in  
transiently  transfected  (myc-­‐‑rKOPr  and  eGFP-­‐‑hSERT)  HEK-­‐‑293  cells  measured  with  a  novel  
high-­‐‑throughput  assay.    
  
  
Interpretation  of   these   results   should  be  made  with   caution  because   this   cell  
model,  along  with  any  preclinical  model,  it  has  its  limitations.  This  co-­‐‑expressing  cell  
model  is  an  oversimplified  preclinical  model  that  serves  the  purpose  to  investigate  a  
direct   relationship   between   two   proteins   by   overexpressing   them   both.   Thus,   our  
observation  of    no  effect  by  acute  (5  min)  KOPr  activation  on  SERT  function  suggests  
that  there  is  no  KOPr  activation  effect  on  SERT  function,  but  this  may  only  be  present  
in   this   cell   model.   Perhaps,   acute   (5   min)   KOPr   activation   of   SERT   function   may  
involve   additional  molecular   systems,   as   has   been   suggested   by  Collins   et   al.   (2001;  
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Further  experiments  to  clarify  if  an  acute  (5  min)  KOPr  and  SERT  relationship  
exhists   is   necessary.   For   example,   a   preclinical   model   that   better   resembles   the  
neuron,  such  as  a  primary  cell  culture,  may  provide  more  insight  into  the  acute  KOPr  
and   SERT   relationship.   Primary   neuronal   cultures   have   endogenously   expressing  
monoamine  transporter  systems  that  may  be  required  for  an  acute  (5  min)  KOPr  and  
SERT   relationship.   Overexpressing   KOPr   and   SERT   in   a   primary   cell   culture   and  
measuring  the  acute  (5  min)  effect  of  KOPr  agonists  on  SERT  function  would  provide  
a   mechanism   to   further   clarify   if   an   acute   KOPr   and   SERT   relationship   requires  
monoamine   transporter   synergy.   However,   like   all   preclinical   models   primary   cell  
cultures  have   their   limitations   too.  For  example,  protein  expression  can  change  over  
time  in  these  cultures  and  the  absence  of  supporting  glial  cells,  that  may  interact  with  
primary   neurons   in   a   whole   brain,   presents   additional   confounding   variables.  
Nevertheless,  utilisation  of  additional  monoamine  neurotransmitter  systems  in  other  
preclinical  models  will   elucidate   if   other   systems   are   synergistically   involved   in   an  
acute  (5  min)  KOPr  activation  to  modulate  SERT  function  or  if  an  acute  (5  min)  KOPr  
and  SERT  relationship  exhists  at  all.    
  
It   was   observed   in   this   current   study   that   SERT   function   significantly  
decreases   after   chronic   (30   min)   exposure   to   the   KOPr   agonists   U50,488H   (10   µμM)    
and   Sal   A   (10   µμM).   This   finding   suggests   a   direct   relationship   between   KOPr   and  
SERT.   Further   additional   experiments   to   test   these   KOPr   agonists   in   confocal  
microscopy,   with   the   low   affinity   monoamine   transporter   inhibitor   D-­‐‑22,   would  
conclusively  confirm  that  chronic  (30  min)  KOPr  activation  decreases  SERT  function.    
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To  summarise,  the  KOPr  and  SERT  relationship  appears  to  be  absent  at  5  min  
because  no  SERT  function  differences  were  measured  in  transiently  transfected  (myc-­‐‑
rKOPr  and  eGFP-­‐‑hSERT)  HEK-­‐‑293  cells  with  confocal  microsopy  and  RDEV  (current  
study).   However,   it   appears   a   long   term   (chronic)   KOPr   and   SERT   relationship   is  
present   that   is  being  activated  somewhere  between  5  min  and  30  min.     A  KOPr  and  
SERT   relationship   is   present   at   30   min   because   KOPr   activation   decreased   SERT  
function  as  measured  in  transiently  transfected  (myc-­‐‑rKOPr  and  eGFP-­‐‑hSERT)  HEK-­‐‑
293   cells   with   confocal   microcopy   (Morani,   unpublished)   and   a   novel   high-­‐‑
throughput   assay   (current   study).   But   it   is   likely   that   this   is   occuring   at   15   min  
because   KOPr   activation   for   15   min   decreased   SERT   function   as   measured   in   rat  
striatum  tissue  with  RDEV  (Simonson,  unpublished).    
  
The   molecular   pathway   responsible   for   this   decrease   in   SERT   function  
between  5   and  15-­‐‑30  min  KOPr   activation   remains   to  be   fully   elucidated.  However,  
SERT   function   is   known   to   rapidly   decrease   in   response   to   acute   depletion   of  
intracellular   Ca2+,   inhibition   of   calmodulin,   Ca
2+
  /calmodulin-­‐‑dependent   protein  
kinases   II   (CaMKII),   Src-­‐‑kinase,   p38-­‐‑Mitogen   activated   protein   kinase   (p38  MAPK)  
and   activation   of   PKC   (Ramamoorthy   et   al.,   2011).   Additionally,   data   also   suggests  
that  cytokines  can  affect  SERT  activity  through  p38  MAPK-­‐‑dependent  mechanisms  in  
some   cell   lines   and   mice   neurons   (Zhu   et   al.,   2006).   Conversely,   SERT   function   is  
increased  by  an  increase  in  intracellular  Ca2+  as  well  as  activation  of  NOS/cGMP  and  
MAPK   pathways   (PKA).   However,   the   three   major   protein   kinases   that   are  
responsible   for   SERT’s   phosphorylation   state   and   SERT   membrane   expression   are  
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PKC   (Qian   et   al.,   1997)   and   p38  MAPK   (Samuvel   et   al.,   2005)  which   decrease   SERT  
function,   and   PKA   (Ramamoorthy   et   al.,   1997)   which   increases   SERT   function.  
Currently,   there   are   two   major   protein   kinases   responsible   for   decreasing   SERT  
function,   the   inhibition  of  p38  MAPK  (Samuvel   et  al.,  2005)  and  also   the  presence  of  
PKC   (Qian   et   al.,   1997),   and   each   pathway   is   discussed   below.   In   addition,   to   the  
known   pathways   that   modulate   SERT   function,   known   KOPr   pathways   are   also  
discussed   as   proposed   by   Bruchas   and   Chavkin   (2011).   Suggested   KOPr   pathways  
(Bruchas  and  Chavkin,  2011)  for  acute  (short  term)  KOPr  activation  involve  PKC  and  
PKC   dependent   ERK1/2   and   chronic   (long   term)  KOPr   activation   involves   p38   and  
independent   ERK1/2   (see   Fig.   1.3)   KOPr   signal   transduction.   Therefore,   given   the  
collective  pathways  above  the  p38,  ERK1/2  and  PKC  pathways  are  all  possibilities  for  
the  observed  KOPr  activation  and  subsequent  SERT  function  decrease.  
  
The   mitogen-­‐‑activated   protein   kinases   (MAPK’s)   activate   SERT   in   midbrain  
synaptosomes  and  heterologous  cell  models,  whereas  inhibition  of  p38  MAPK  inhibits  
SERT   activity   either   pharmacologically   or   by   specific   siRNAs-­‐‑mediated   knockdown  
(Ramamoorthy   et   al.,   2011).   Furthermore,   activation   of   p38  MAPK   stimulates   SERT  
activity  either  by  overexpressing  a  constitutively  active  form  of  MAP  kinase  kinase  3b,  
an  upstream  kinase  activator  of  p38  MAPK,  exposure   to  aniosmycin,  an  activator  of  
p38  MAPK,   or   adenosine   receptor   (AR3)   activation   (Samuvel   et   al.,   2005;  Zhu   et   al.,  
2005;  Zhu,  Hewlett,  Feoktistov  et  al.,  2004;  Zhu  et  al.,  2007).  The  extent  that  p38  MAPK  
regulates  SERT  surface  expression  remains  controversial  and  requires  further  research  
with   evidence   supporting   both   trafficking   dependent   and   independent  mechanisms  
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(Ramamoorthy  et  al.,  2011).  Interestingly,  p38  signalling  is  activated  by  KOPr  chronic  
(long   term)   exposure   Bruchas   and   Chavkin   (2010);   however,   Ramamoorthy   et   al.  
(2011)  suggest  an  increase  of  p38  signalling  increases  SERT  function.  Ramamoorthy  et  
al.’s   (2011)   hypothesis   explains   how   stress   can   induce   affective   disorders.   For  
example,  stress  increases  p38  MAPK  to  increase  SERT  function,  which  decreases  5-­‐‑HT  
signalling  and  increases  anxiety  and  depression.  However,  the  observation  that  KOPr  
chronic  signaling  increases  p38,  and   increases  SERT  function  too  does  not  fit  together  
with  our  data,  which  observed  a  decrease  in  SERT.  Nevertheless,  the  brain  is  a  complex  
and   extremely   difficult   organ   to   understand   and   it   is   possible   that   perhaps   p38  
upregulates   SERT   in   some   brain   cell   regions   and   down   regulates   in   other   brain  
regions.  If  p38  increases  (KOPr  chronic  activation)  can  downregulate  SERT  function  in  
some  cells  too,  this  pathway  might  explain  the  findings  observed  in  the  HEK-­‐‑293  cells  
from   this   study.   Further   investigation   into   this   chronic   (30   min   KOPr   agonist  
treatment)   cell   model   is   necessary   to   further   investigate   p38   as   the   pathway  
responsible  for  KOPr  activation  decreasing  SERT  function.    
  
The   biochemical   mechanism   between   KOPr   activation   and   SERT   function  
decrease  remains  unknown.  Another  possible  pathway  to  explain  the  chronic  (30  min)  
relationship   between   KOPr   and   SERT   is   ERK1/2.   The   ERK1/2   pathway   is   the  most  
commonly  studied  MAPK  pathway  activated  by  KOPr;  Yet,  although  ERK1  and  ERK2  
are  two  separate  proteins,   they  are   largely   investigated  as  the  same  pathway  known  
as  ERK1/2  (Assenio  et  al.,  2006).  This  signalling  pathway  is  possible  because  ERK1/2  is  
phosphoryled   and   activated   by   MEK1/2   in   biphasic   stages   with   the   first   stage  
occuring  after  5  minutes  of  exposure,  and  this  biphasic  stage   is  reflected   in  our  data  
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with   no   acute   (5   min)   effect   but   an   effect   is   seen   after   5   min.   Early   phase   ERK1/2  
phosphorylation   is  seen  after  5-­‐‑15  min  and  is  PI3K,  PKC  and  Ca2+  dependent  and  β-­‐‑
arrestin   independent.   Late   phase   ERK1/2   phosphorylation   is   seen   after   2   h   and   is  
GRK3  and  β-­‐‑arrestin  dependent  (Belcheva  et  al.,  2005;  McLennan  et  al.,  2006).  Based  on  
the   current   ERK1/2   phosphorylation   literature   it   appears   that   the   SERT  modulation  
Simonson   (unpublished   data)   observed  with   15  min   KOPr   activation  was   the   early  
phase   ERK1/2   activation,   and   this   was   also   observed   in   the   chronic   (30  min)   SERT  
modulation   seen   in   the   current   study.   This   could   explain  why  we   did   not   see   any  
acute   (5   min)   effects,   because   the   pathway   between   KOPr   and   SERT   takes   5-­‐‑15  
minutes   to   occur,   which   is   why   Simonson   (unpublished)   and   the   current   study  
observes   SERT   function   decreases   at   15   and   30   min.   If   the   ERK1/2   early   phase  
pathway   is   involved   in  SERT  modulation   then   it  would  be   interesting   to   investigate  
further  to  see  if  inhibiting  or  modifying  this  pathway  can  attenuate  the  KOPr  decrease  
on  SERT  function.  This  would  confirm  if  ERK1/2  is  responsible  in  this  cell  model  for  
the  chronic  (30  min)  KOPr  activation,  by  U50,488H  or  Sal  A,  and  subsequent  decrease  
of   SERT   function.   However,   because   this   pathway   is   abundent   within   the   cell   this  
could  prove  difficult  to  achieve.  Prasad  et  al.  (2005)  showed  that  p38  MAPK  activation  
modulates  function  of  the  SERT,  but  because  KOPr  activation  of  ERK1/2  activation  is  
in   line  with   the  observed  SERT  modulation  at  15  and  30  min,  ERK1/2  appears  more  
likely  to  be  the  pathway  responsible.  Future  experiments  are  necessary  to  investigate  
the  role  of  ERK1/2    in  KOPr  agonist  induced  SERT  function  decreases.  Co-­‐‑expressing  
HEK-­‐‑293  cells    and  performing  a  Western  blot  with  a  pERK1/2  antibody  is  required  to  
investigate   ERK1/2   activation   at   5   and   15  min   time   points.   If   ERK1/2   appears   to   be  
responsible,   then   differentiating   ERK1   from   ERK2  would   be   required   to   see   which  
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protein   was   specifically   responsible.   If   ERK1/2   concentrations   do   not   show   any  
changes  at  the  5,  15  and  30  min  time  points  then  it  would  make  sense  to  look  further  
into  p38  or  PKC.    
  
In   contrast   to   p38   and   ERK1/2,   PKC   is   also   suggested   to   be   a  major   protein  
kinase  responsible  for  decreasing  SERT  function  (Qian  et  al.,  1997).  Because  inhibiting  
extracellular   signal-­‐‑regulated  kinase   (ERK1/2)   or   c-­‐‑Jun  N-­‐‑terminal  Kinase   1   (JNK)   is  
without   effect   on   SERT   (Oz   et   al.,   2010;   Samuvel   et   al.,   2005),   PKC  may   be   a   better  
candidate  to  explain  the  relationship  between  KOPr  activation  and  a  decrease  in  SERT  
function.   Recently,   time   course   studies   observed   a   decrease   in   SERT   surface  
expression   by   SERT   phosphorylation   from   the   PKC-­‐‑dependent   pathway,   which  
triggers  SERT  internalization  and  reduces  5-­‐‑HT  uptake  to  result  in  a  synaptic  increase  
of   5-­‐‑HT   (Ramamoorthy   et   al.,   2011).   Bruchas   and   Chavkin   (2011)   suggest   PKC   and  
PKC   dependent   ERK1/2   to   also   be   involved   in   acute   (short   term)   KOPr   activation.  
PKC  regulates  SERT  in  a  biphasic  manner,  where  the  initial  phase  (1  –  5  min)  of  5-­‐‑HT  
uptake  inhibition  occurs  independently  of  trafficking  but  the  later  phase  (5  –  60  min)  
is  associated  with  enhanced  endocytosis  (Jayanthi  et  al.,  2005).  The  biphasic  inhibition  
of  SERT  is  accompanied  with  sequential  phosphorylation  of  plasma  membrane  SERT  
because  it  was  shown  that  phosphorylation  of  the  serine  (Ser)  residues  precedes  that  
of  the  threonine  (Thr)  residue(s)  (Jayanthi  et  al.,  2005).  It  has  also  been  suggested  that  
the   initial   phosphorylation   on   the   Ser   residues   are   responsible   for   changes   in   the  
intrinsic   properties   and/or   silencing   of   SERT,   and   that   Thr   phosphorylation   may  
trigger  internalization  of  phosphorylated  SERT  (Ramamoorthy  et  al.,  2011).   If  PKC  is  
responsible   for  KOPr  activation  decreasing  SERT   function   it  would  be   interesting   to  
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investigate  the  Ser  and  Thr  phosphorylation  patterns  (Jayanthi  et  al.,  2005)  at  5,  15  and  
30  min  time  points  to  see  if  they  correlate  with  SERT  cell  function  and  expression.  
  
The   recent   finding   that   PKC   activation   increases   SERT   internalization   and  
phosphorylation,   whereas   inhibition   of   p38   MAPK   reduces   basal   SERT  
phosphorylation  and  plasma  membrane  insertion  suggests  that  p38  MAPK  and  PKC  
must  act  at  different  phosphorylation  sites   (Ramamoorthy   et   al.,   2011).  And   if  direct  
phosphorylation  is   involved  in  both  processes,  then  these  kinases  are  likely  to  target  
SERT  at  different  locations  (Ramamoorthy  et  al.,  2011).  Future  efforts  directed  towards  
the   identification   of   the   specific   sites   of   PKC   and   p38   MAPK   mediated  
phosphorylation  will   illuminate   the   cellular   and  molecular  basis  of   SERT   regulation  
by  these  kinases  (Ramamoorthy  et  al.,  2011),  and  perhaps  that  of  KOPr  activation  on  
SERT.  
  
An   interesting   finding   in   the  current   research  worth  mentioning   is   that  ASP+  
uptake  occurs  in  HEK-­‐‑293  cells.  Non-­‐‑transfected  HEK-­‐‑293  cells  and  cells  classified  as  
‘non-­‐‑transfected’   (Figure   3.3),   as   measured   by   confocal   microscopy,   as   well   as  
transfected  HEK-­‐‑293  cells  with  SERT  inhibited  by  fluoxitene,  but  not  D-­‐‑22,  can  uptake  
5-­‐‑HT   (Figure   4.3).   These   findings   reflect   the   abundance   and   significance   of   low  
affinity  monoamine  transporters  in  5-­‐‑HT  uptake,  even  though  SERT  is  thought  to  play  
a   largest   role   in   5-­‐‑HT   uptake.   Low   affinity  monoamine   transporters,   extraneuronal  
monoamine   transporter   (EMT),   the   plasmalemmal  monoamine   transporter   (PMAT),  
and   the   organic   cation   transporters-­‐‑OCT1,  OCT2,   and  OCT3,   are   known   to   take   up  
small  amounts  of  monoamine  neurotransmitters  but  they  remain  relatively  unstudied  
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(Hagen   et   al.,   2011).   Recently,   Baganz   et   al.   (2008)   illustrated   that   OCT3   regulates  
extracellular   5-­‐‑HT   in   SERT-­‐‑deficient   mice.   Furthermore,  Mayer   et   al.   (2012)   proved  
that  OCT3   is   present   in  HEK-­‐‑293   cells   as   shown   by   real-­‐‑time   uptake   of   fluorescent  
ASP+.  Collectively,  these  findings  consolidate  the  data  found  in  the  current  study  that  
these  low  affinity  transporters  clearly  contribute  to  5-­‐‑HT  clearance.  This  highlights  the  
overlap   between   5-­‐‑HT   uptake   and   other   monoamine   uptake   by   these   alternative  
integral   transporter  proteins.  Now   it   is   apparent   that  other  monoamine   transporters  
also   contribute   synergistically   to   monoamine   signalling.   The   low   affinity   5-­‐‑HT  
transporters   are   also   sensitive   to   corticosteroids,  which   increases   their   sensitivity   to  
stressors   and   5-­‐‑HT   uptake   (Daws,   2009).   Thus,   it   is   likely   that   these   low   affinity  
monoamine   transporters   are   involved   in   drug   addiction,   affective   disorders   and  
dysfunctional   stress   homeostasis.   These   findings   highlight   the   importance   of   more  
research  into  these  enigmatic  low  affinity  transporters  and  their  overall  potential  role  
in  monoamine   signalling.   Controlling   for   confounding   variables,   such   as   these   low  
affinity   transporters,   in   clinically   relevant   scenarios   is   important   for   future  
neurobehavioural  research  (Kalueff  and  LaPorte,  2010).  	  
6.2     Significance  
In   the   current   study  we   found   chronic   (30  min)   but   not   acute   (5  min)  KOPr  
activation  decreases  SERT   function.  This  has   enormous   clinical   applications  because  
of  SERT’s  intrinsic  role  in  addiction,  mood,  stress  and  pain.  Currently,  KOPr  agonists  
and   antagonists   are   known   to   attenuate   different   stages   of   the   addiction   cycle   and  
SSRIs   are   used   to   treat   depressive,   anxious   and   stressed   states,   as   well   as   alcohol  
addiction   (ondansetron-­‐‑SSRI).   Given   the   proposed   relationship   between   KOPr   and  
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SERT,  the  overlap  in  targeting  different  systems  in  therapeutic  compounds  for  similar  
disorders   is   one   step   closer   to   being   understood.  Novel   KOPr   agonists   compounds  
also   have   the   potential   to   treat   pain,   cough,   diarrhoea,   stimulant   dependence,   and  
mood   disorders;   unfortunately,   Sal   A   contains   undesirable   side   effects,   such   as  
dysphoria   and   anxiety   (Prisinzano,   2005).   Thus,   it   has   limited   for   therapeutic   use.  
Based  on   this   information   the   relationship  between  KOPr   and  SERT   is   of   particular  
interest   for   therapeutic   targets.   Medicinal   chemistry   efforts   continue   to   explore   the  
structure  and  activity  relationship  of  Sal  A.  To  date  these  have  mainly  focused  on  Sal  
A’s   high   affinity   and   selectivity   for   the   KOPr   with   few   investigators   looking   at  
interactions  with  transporters  or  new  analogues  for  pharmacotherapeutics  with  fewer  
side  effects   (Prisinzano  and  Rothman,  2008).  Several  models  suggest   that  the  affinity  
and  selectivity  of  Sal  A   for  KOPr’s   is   the   result  of   interactions  with  unique   residues  
compared   with   other   KOPr   ligands   (Prisinzano   and   Rothman,   2008).   Further  
experiments  are  required  with  other  KOPr  ligands  to  further   investigate   interactions  
with   unique   residues   compared  with   other   KOPr   ligands.   And   these   findings  may  
unveil   the   KOPr   residue   responsible   for   the   decrease   in   SERT   function.   Further  
elucidating  the  interaction  between  these  two  important  proteins  has  the  potential  to  
unveil  key  targets,  which  will  facilitate  future  therapeutic  research  and  treatment.    
  
6.2     Future  Directions  
To   define   the   KOPr   and   SERT   relationship   further,   investigations   with   a  
multitude   of   different   variables   are   necessary.   Firstly,   it   is   necessary   to   define   the  
effect  of  different  KOPr  agonist  preincubation  times  on  SERT  function  using  real-­‐‑time  
confocal   microscopy   to   definitively   conclude   when   there   is   a   KOPr   and   SERT  
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relationship.  The   next   step   is   to   investigate   varying  KOPr   agonist   concentrations   (1  
µμM   to   10   µμM)   to   provide   insight   into   the   strength   of   KOPr   agonists   necessary   to  
induce   these   SERT   function   changes.   Also   measuring   the   effects   of   different   KOPr  
agonists,   such   as   DS-­‐‑3-­‐‑240   and   U69,593,   at   these   time   points   and   concentrations  
would  clarify  any  KOPr  agonist  differences  in  modulating  SERT  function.  This  would  
enlighten  us  to  specific  KOPr  residues  that  the  KOPr  agonists  tranduces  the  signal  to  
moodify   SERT.  Then   the   signal   transduction  pathways   responsible   for   each   residue  
effect   will   need   to   be   identified.   Additional   variables   to   investigate   in   future  
experiments   also   include   different   preclinical   models   to   elucidate   if   the   same  
biochemical   trends   occur   in   different   clinical   models.   Additionally,   protein   co-­‐‑
immunoprecipitation  of   rat   brain   samples,   and  perhaps   even  human  brain   samples,  
also   need   to   be   further   illustrated   to   identify   the   specific   locations   of   the   co-­‐‑
localisation   of   KOPr   and   SERT   in   the   DRN   in   rats.   Ultimately,   PET   scans   may  
highlight  the  specific  locations  where  KOPr  and  SERT  co-­‐‑localise  in  the  primate  brain.  
This   will   facilitate   extrapolation   of   this   information   to   form   hypotheses   on   human  
brain  and  behaviour  based  on  the  neurobiology  revealed.    
  
Future   experiments   are   necessary   to   elucidate   this   potential   and   exciting  
interaction  between  KOPr  and  SERT.  These  experiments  allow  us  to  be  much  closer  to  
understanding   the   molecular   mechanisms   between   KOPr   and   SERT   and   thus,   the  
underlying  pathways   involved   in  drug   addiction,   affective  disorders,   and   abnormal  






Chapter  2  Solutions  
Krebs  Ringer  Hepes  buffer  (KREBS)  
  
Concentration        g/L  
NaCl           130  mM         7.6  
KCl             1.3  mM         0.10  
CaCl2          2.2mM         0.24  
MgSO4.6H2O     1.2mM         0.27  
KH2PO4        1.2mM           0.16  
HEPES        10mM           2.6  
D-­‐‑Glucose        10mM           1.8  
pH  7.4    
  
10  x  Phosphate  Buffered  Saline  (PBS)    
Concentration        g/L    
NaCl           1.4  M              80    
KCl           26.8  mM           2.0    
Na2HPO4        81.0  mM           26.8    
KH2PO4        14.7  mM           2.4       
pH  7.4    
  
  
1x  PBS  for  cell  culture  
  
Concentration        g/L    
NaCl           137  mM         8  
KCl           2.7  mM         0.2  
Na2HPO4        8.1  mM         2.68  
KH2PO4        1.5  mM           0.24  







1x  PBS  RDEV  5-­‐‑HT  solute  
Concentration        g/L    
NaCl           137  mM         8  
KCl           2.7  mM         0.2  
Na2HPO4        8.1  mM         2.68  
KH2PO4        1.5  mM         0.24  
pH  7.2    
  
LB  Agar           g/L            
NaCl              10    
Yeast  Extract        5.0    
Bactotryptone        10    
Yeast  Agar           10    
  
  
LB  Broth           g/L       
NaCl              10    
Yeast  Extract        5.0    


























Fig  A.3.1.  ASP+  uptake.  Initial  ASP+  studies  were  conducted  to  investigate  when  the  
KOPr  agonists  had  their  maximal  uptake  effect  within  5  min.  To  calculate  this  ASP+  
uptake   60   seconds   before   the   addition   of   the   KOPr   agonist   was   compared   to   ASP+  
uptake   +  60  seconds  after   the  KOPr  agonist  was  added.   It  was   found  that  U50,488H  
(A)   showed   its  maximal   effect   at   210-­‐‑270   s,   Sal  A   (B)   showed   its  maximal   effect   at  
240-­‐‑300  s,  and  DS-­‐‑3-­‐‑240  (C)  showed  its  maximal  effect  at  120-­‐‑180  s.  n  =  43-­‐‑57  cells,  
across   a   minimum   of   2   dishes   in   each   transfection,   over   a   total   of   3   different  
transfection  days.  These  time  points  were  used  to  adjust  all  of  the  following  studies,  in  
case  the  time  of  action  looked  as  if  it  was  trending  to  occur  after  the  5  min  mark.  There  
was   no   statistically   significant   difference   between   the   vehicle   and   any   of   the   KOPr  
agonists  and  ASP+  uptake,  so  this  data  was  not  required.  However,  this  was  performed  









ASP+ uptake after acute KOPr agonist pre-treatment
















Chapter  4:  RDEV  in  Transiently  Transfected  HEK-­‐‑293  Cells  with  
Increasing  Increments  of  5-­‐‑HT  Concentration    
  
  
Fig.   A3.1.   SERT   function   in   transiently   transfected   HEK-­‐‑293   cells   with   increasing  
increments  of  5-­‐‑HT  concentration.  5-­‐‑HT  is  unstable  at  concentrations  above  1  µμM  because  
it   rapidly   oxidises   making   measuring   free   5-­‐‑HT   difficult   because   it   beomes   impossible   to  
differentiate  whether   the   electron   current  measured   is   an   increase   in   oxidation   or   change   in  
SERT  function  at  higher  5-­‐‑HT  concentrations.    
  
Table.  A3.1.   SERT   function   in   transiently   transfected  HEK-­‐‑293   cells  with   increasing  
increments  of  5-­‐‑HT  concentration  
Treatment  
Vmax  (pmol/s/10  6  
cells)     Vmax  SEM   Km   Km  SEM  
U50   1.43  x  1037       8.97  x  1026       1.22  x  1036     7.67x  1025    
Sal  A   2.21  x  1036       7.72  x  1030       3.33  x  1035     9.22  x  1029    
DS-­‐‑3-­‐‑240   1.81  x  1037       2.64  x  1032       2.18  x  1036     2.09x  1031    
DMSO   9.26  x  1023         1.46  x  1013       9.96  x  1022     1.57  x  1012    
Fluoxitene   1.65x  1023       1.41x  1013       2.02  x  1022     1.73  x  1012    
HEK-­‐‑293   1.26  x  1025       2.98  x  1018       1.36  x  1028     3.23x  1017    
  
  
In   this   study,   initial   optimisation   experiments   justify   the   use   of   a   5-­‐‑HT  
concentration   up   to   1.25   µμM   because   1   µμM   did   not   show   kinetic   saturation   and  





























concentrations  higher  than  1.25  µμMresulted  in  the  same  linear  increase  of  5-­‐‑HT  uptake  
that   is   illustrated   in  Hagan   et   al.,   (2010)  which   is   suggested   to  be   indicative  of  5-­‐‑HT  
oxidation,  rather  than  uptake.  Therefore,  the  last  5-­‐‑HT  concentration  before  this  linear  
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